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Aims of the project
The search for an effective anti-inflammatory therapy for treatment of 
debilitating chronic inflammatory diseases was thought to be over when i
glucocorticoid steroids were prescribed for sufferers of rheumatoid |
arthritis. The improvement in the condition of patients was dramatic, but :
the unwanted side-effects have meant the use of glucocorticoids as anti- :
inflammatory agents has been limited.
Stevenson, 1978 described a potential second messenger of the anti­
inflammatory actions of these steroids in his M.D. thesis, secreted by 
cultured monocytes in the presence of steroids.
The main aim of this project was the purification of the factor(s), present 
in the supernatant of these cultured monocytes (STMS), responsible for 
the effect on neutrophil motility described by Chettibi et al., 1993.
In order to fulfil this aim it was necessary to develop the cell tracking 
assay data analysis by utilising the data produced from a program written 
in C by P.D. Lawrence. This required the writing of a procedure in C 
(Appendix 1) that processed raw data from cell tracking experiments and 
calculated the parameters of cell locomotion described by Gail and Boone,
1970, 1972. This assay allowed the comparison of the behaviour of 
neutrophils in response to various stimulators of neutrophil motility.
The unusual way in which STMS-treated cells behave in this tracking assay 
i.e. high diffusion coefficient and persistence in a uniform concentration, 
provided parameters for the identification of active samples during the 
purification protocol. :
xvii
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X V lll
It was also of interest to study the effects of STMS on other neutrophil 
functions, initially to understand the nature of the persistent locomotion 
observed. F-actin content of neutrophils treated with STMS, and a novel j f
n;.tilt assay was utilised for this purpose.
A number of experiments designed to assess the potential anti­
inflammatory actions of the active factor(s) in STMS were also 
performed.
The adhesion of neutrophils to endothelial cells is a crucial step in the 
inflammatory response of these cells, and so their adhesion to bovine aorta 
endothelial cells was assayed under the influence of STMS.
Chemotaxis of neutrophils in response to a gradient of pro-inflammatory 
mediators is also an important stage in the inflammatory response. The 
effect of STMS on neutrophil chemotaxis in response to fMLP was assayed 
using a modified Boyden chamber.
The release of lysophosphatidic acid (LPA) by thrombin-activated platelets 
at physiologically relevant concentrations (Eichholtz et al., 1993) led to 
the assaying of various concentrations of LPA in the neutrophil tracking 
assay. The surprising findings that neutrophils responded to LPA by 
altering shape and increasing motility led to the study of the effect of LPA 
on the fMLP and PMA-induced metabolic burst of neutrophils using 
DNDH-dependent chemiluminescence. The potential role of LPA as a 
modulator of neutrophil function in vivo is discussed.
î,;î
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SUMMARY
A monocyte-derived factor that stimulates the locomotion of human 
neutrophils on an albumin- coated glass surface has been prepared from 
the culture supernatant of dexamethasone-treated human monocytes and 
called STMS (steroid-treated monocyte supernatant). A modified cell 
tracking program has been developed and the parameters of locomotion 
determined by the analysis of Gail and Boone (1970, 1972) for cells 
moving in a persistent random walk. Cells moving in uniform 
concentrations of STMS, interleukin-8 (lL-8) and n-formyl-methionyl- 
leucyl-phenylalanine (fMLP) chosen to give a sub-maximal speed of 
locomotion show persistent, random and constrained random diffusion 
respectively with augmented diffusion coefficients of 0.8 ± 0.1, 0.14 ± 
0.02 and 0.12 ± 0.03 jim^ per second for STMS, lL-8 and fMLP 
respectively. The augmented diffusion coefficient and the underlying 
persistence are therefore sensitive quantitative assay parameters for STMS 
activity and the qualitative characteristics of locomotion allow STMS 
activity to be distinguished from that of all other factors tested. The 
contribution of lowered adhesion to locomotion was examined in a novel 
tilt- assay which demonstrated that cells in the presence of STMS, but not 
other factors, moved down slope with significantly increased speed while 
maintaining contact with the substratum. The results were interpreted in 
terms of the bipolar form of STMS-treated cells, contrasting with 
multipolar forms in response to other agents. This together with low 
adhesiveness plus an inherent tendency of a single locomotor focus to 
continue motion in its original direction has been used to explain the 
difference between response to STMS and other factors. STMS has been 
proposed to prevent directed locomotion of neutrophils to an
XIX
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inflammatory site or to promote dispersive locomotion away from such a 
site, and perhaps to inhibit neutrophil transmigration between endothelial 
cells.
STMS also inhibits adhesion of neutrophils to bovine aorta and human 
endothelial cells by a yet undetermined mechanism. It induces unique 
changes in neutrophil shape with a characteristic monopole of F-actin 
distribution, which may correlate with the dispersive locomotion observed 
in the absence of a concentration gradient. This factor also inhibits n- 
formyl-methionyl-leucyl-phenylalanine-induced chemotaxis of neutrophils 
in a modified Boyden chamber assay. The reduction of adhesion and the 
inhibition of chemotaxis by the factor in vitro indicate a possible in vivo 
anti-inflammatory role.
The dispersive locomotion of neutrophils induced by this factor was 
utilised to monitor the purification of the active molecule, using standard 
chromatography techniques, present in the starting monocyte supernatant. 
The purification procedure identified a derivative of Thymosin |34 with an 
oxidised methionine residue (T(34ox) as the molecule responsible for the 
dispersive locomotion of neutrophils on the cell tracking assay. The shift 
in the elution of thymosin p4 from a reversed-phase chromatography 
column following oxidation by hydrogen peroxide was utilised to confirm 
the activity was in fact associated with Tp4ox and not a contaminant. 
Thymosin p4 was purified from human neutrophils using a reversed-phase 
chromatography column, 50% oxidised with hydrogen peroxide, and re­
applied to the same column. The shift in elution meant that any 
contaminants present in the thymosin p4 would be removed. Assays of this 
sample and the non-oxidised thymosin p4 have confirmed the dispersive 
locomotion of human neutrophils in the cell tracking assay by STMS is 
caused by the presence of Tp4ox.
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Parallel purification of thymosin p4 from control monocyte supernatants 
(CMS) and STMS have indicated that thymosin Tp4ox is present in greater 
quantity in STMS, confirming the steroid-induction of its release into the 
culture supernatant. These results indicate that thymosin P4, with an 
oxidised methionine residue, secreted by monocytes and macrophages, 
could be an important second messenger in the anti-inflammatory actions 
of glucocorticoids.
During the investigation into mediators of neutrophil functions, 
particularly locomotion, lysophosphatidic acid (LPA) was assayed at 
various concentrations in the cell tracking apparatus, and surprisingly 
showed a do se-dependent induction of locomotion and at the optimum 
concentration of 20 p.M, a speed of 11.4 ± 0.9 qm/min, similar to fMLP 
(11.3 ± 1.0 jim/min) and IL-8 (10.7 ± 0.6 pm/min). Polarisation studies 
indicated a strong correlation between shape change and speed of 
locomotion, being detectable at 2 pM LPA and virtually 100% of cells 
polarised at 20 pM LPA. At higher concentrations shape changes and 
motility were diminished, but this decrease was reversed by albumin.
LPA also inhibited the formyl-methionyl-leucyl-phenylalanine (fMLP) 
and Phorbol 12-myristate 13-acetate (PMA)-induced metabolic burst of 
human neutrophils assayed using 7-dimethylamino-naphthalene-1,2- 
dicarbonic acid hydrazide (DNDH)-dependent chemiluminescence. 
Inhibition of the PMA-induced metabolic burst by LPA was not affected 
by pertussis toxin, showing that the effect was not mediated by pertussis 
toxin-sensitive heterotrimeric G protein, and that inhibition of the PMA- 
stimulated metabolic burst by LPA could result from a direct action of 
LPA on the small cytosolic GTP-binding proteins. These results indicate 
that lysophosphatidic acid production by thrombin-activated platelets could 
play a significant role in the regulation of the inflammatory response.
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Introduction
1.1.) General Review
Inflammation can be defined through its four classic symptoms 'Dolor, 
turgor, calor, and rugor', i.e. Pain, swelling, heat and redness. These are 
beneficial responses, but there is another aspect of long term 
inflammation, namely, tissue destruction by activated phagocytes.
Most non-steroidal anti-inflammatory strategies aimed at reducing pain 
do so at the risk of greater or lesser cumulative self-destruction. Most 
aspects of these four attributes of inflammation are controlled by other 
cell types, e.g. mast cells and macrophages, but the effectors of tissue 
damage are primarily the neutrophils. In contrast, administration of 
glucocorticoid steroids reduces the four attributes of inflammation and 
diminishes the tissue destruction, but here too there is a high price to pay. 
Glucocorticoids act globally, affecting the function of many cell types, as 
well as immune cells, and in doing so, cause a whole range of unwanted 
side-effects.
The primary aim of much anti-inflammatory therapy research is to 
discover a second messenger of glucocorticoid action specific to the 
immune system. This will allow the development of a non-steroidal anti­
inflammatory therapy that has the same anti-inflammatory effect as 
glucocorticoids, but with immune system specificity, and none of the 
unwanted side-effects.
In contrast to the adaptive immune response involving specific antibodies 
derived from lymphocytes recognising specific foreign antigens, the 
innate immune response is non-specific response to infectious agents or 
injury. The cells that mediate the innate response are primarily 
phagocytic cells, including monocytes, macrophages, and neutrophils, 
which respond to mediators secreted by other cell types e.g. endothelial,
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mast, or platelet cells, prompting them to leave the circulation 
(neutrophils and monocytes), and migrate towards the site of insult, 
where they bind to, engulf, and kill micro-organisms. These phagocytic 
cells are aided in their role by soluble mediators of immunity, such as, 
complement and acute-phase proteins, which bind to micro-organisms 
(opsonization), promoting their uptake by phagocytes.
The recruitment of leucocytes from the blood stream to extra vascular 
tissue is crucial in host defence against microbial pathogens and in repair 
of tissue damage. This process involves alteration in the microvasculature 
of the post-capillary venules, allowing leakage’ of plasma (Ryan and 
Majno, 1977) and the movement of leucocytes from the bloodstream to 
sites of tissue damage, or microbial infection. Studies have indicated that 
the recruitment of leucocytes from the bloodstream is a multi-step 
process (Carlos and Hanlan, 1994) involving an initial ’rolling' of the 
leucocyte along the vascular endothelium mediated through a group of 
adhesion molecules called selectins (Ley et al., 1991). This is followed by 
stronger adhesion via integrins, a 'switching on' of the leucocytes' 
motility, diapedesis through the endothelium and migration through 
extracellular tissue towards a site of inflammation in response to a 
chemotactic gradient (Carlos and Harlan, 1994) (Fig 1). There are 
numerous chemical mediators involved in the recruitment of leucocytes 
from the bloodstream, termed cytokines and chemokines, acting on many 
cell types including endothelia, epithelia and leucocytes. Most of these 
mediators are soluble, but some are presented on the surface of the cells. 
These include both pro- and anti-inflammatory molecules which act 
together to form an appropriate response to an inflammatory stimulus. 
Inappropriate inflammatory responses can cause a great deal of tissue 
damage, as phagocytic leucocytes release neutral proteases capable of 
destroying tissue at physiological pH and highly active superoxide ions.
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Fig. 1. Schematic diagram of leucocyte recruitment to an 
inflammatory site
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Release of pro-inflammatory mediators by tissue, macrophages, and 
mast cells leads to the activation of the vascular endothelium 
accompanied by an increase in vascular permeability, and strong 
adhesion of rolling leucocytes. This is followed by activation of 
leucocytes, shape change, and locomotion, followed by diapedesis, 
and chemotaxis to the inflammatory site. The diagram shows some 
of the pro-inflammatory mediators involved with this process (after 
Roitt, 1998).
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There are a large number of disease states in humans where these 
inappropriate immune responses can cause acute or chronic illness, e.g. 
rheumatoid arthritis, asthma and inflammatory bowel syndrome.
1.1.1.) Chemical mediators of Inflammation
A normal acute inflammatory response involves changes in the 
microvasculature, the most important change being the flow of plasma 
exudates and leucocytes from the bloodstream to the damaged tissue.
A number of different groups of molecules involved in signalling in 
inflammation are produced by immune and non-immune cells. These 
include, cytokines, which are regulatory, produced by both immune and 
non-immune cells, signalling a responding cell to change it's function; 
lymphokines, referring to lymphocyte source of cytokine; chemokines, 
that includes two families of cytokines that induce chemotaxis, the C-X-C 
and the C-C family; and interleukins, that are mediators, signalling 
between immune cells. The categorisation of interleukins, however, is not 
consistent, for some interleukins are not known as such. e.g. Tumour 
necrosis factor (TNFa), Monocyte chemotactic protein-1 (MCP-1) etc.
whereas IL-1, IL-2  etc. are, despite there not being a difference in
function. There are also many lipid mediators of inflammation, e.g. 
Leukotriene B4 (LTB4 ), which is chemotactic for neutrophils and 
macrophages, complement components, such as C5a, which is also 
chemotactic for neutrophils and macrophages, and bacterial products, like 
the frequently used chemotactic factor, n-formyl-methionyl-leucyl- 
phenylalanine (fMLP), and lipopolysaccharides (LPS).
The signalling that goes on between immune and non-immune cells via 
cytokines is often referred to as a 'network'. The intricacies of this
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network however, are far from being fully understood, and only a few 
pieces of this network have so far been elucidated.
1.1.2.) Chemokines
Chemokines a sub-class of cytokines chemoattractant for immune cells, 
are secreted by many cell types. They are divided into two families, C-X- 
C and C-C, that have different cell targets. The C-C and C-X-C refer to 
the first two cysteines in a conserved motif, and whether they are adjacent 
or not (Schall, 1991). In general, the members of the C-X-C chemokines 
are chemoattractant for neutrophils, but not mononuclear leucocytes or 
other PMN leucocytes (Oppenheim et al., 1991), whilst C-C chemokines 
are chemoattractant for monocytes, basophils, eosinophils and some T- 
cell types, but not neutrophils (Schall, 1991).
a-chemokines (C-X-C) include, IL-8 which is important in neutrophil 
infiltration into inflammatory sites; GRO-a,-p,-y are chemotactic for, 
and prime human neutrophils, making them more receptive to further 
stimulation; melanoma growth-stimulating activity (MGSA), neutrophil 
activating protein (NAP-2), Platelet Factor 4 (PF4), epithelial-derived 
neutrophil activating protein (ENA-78), granulocyte chemotactic protein 
2 (GCP-2), IP-10, and MGSA. IL-8 was the first of the a-chemokines to 
be described, and is the one on which most study has been done. It has 
two membrane-bound receptors (7 span), which couple to G protein 
domains (Kupper et al., 1992), found in large numbers on neutrophils 
(20-90000/cell), with fewer present on monocytes and macrophages 
(1600-8000), and 150-1500 on lymphocytes, so IL-8 is not exclusivity a 
neutrophil activator, as other cell types are able to respond to it. One of 
these receptors binds IL-8 specifically, whilst the other binds several
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other a-chemokines. Most a-chemokines share a conserved N-terminal 
sequence, and contain the tri-peptide sequence Glu-Arg-Leu (ERL) 
(Clark-Lewis et al., 1991). IL-8 is released by many cell types in 
response to agents such as IL-I/, TNFa, or Lipopoly saccharides (LPS) 
(Baggiolini et al., 1989).
p-chem okines (C-C) with a much wider range of target cells, also act 
through G protein-coupled receptors (Sozzani et al., 1993). p-chemokines 
include, RANTES, which is chemotactic for monocytes and T 
lymphocytes (Schall et ak, 1990), monocyte chemotactic protein-1 (MCP- 
l,-2,-3), macrophage inflammatory proteins 1 (MIP-1) and MIP-1.
All of these chemokines are low molecular weight proteins between 7 and 
16 kDa, which elicit functional alterations in their target cells, and prime 
them to respond to other stimuli, as well as inducing release of other 
inflammatory mediators. The specificity of cell targets may help to 
explain the specificity of immune cell types found in different organs of 
the body after an inflammatory insult e.g. eosinophils in the lung in 
asthma (Butcher, 1991). Increased levels of these chemokines have been 
associated with a large number of inflammatory diseases, including 
rheumatoid arthritis, asthma, lung reperfusion injury, and granulomatous 
disease, so they have been the target of anti-inflammatory therapy 
research (review; Howard et ak, 1996).
1.1.3.) Lipid mediators of Inflammation
A wide range of lipid mediators are involved in the inflammatory 
process, some of which have anti-inflammatory effects, others pro- 
inflammatory. The majority of lipid mediators are products of
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arachidonic acid (AA), which is liberated from membrane phospholipids 
by the action of phospholipase A2 .
Eicosanoids, including prostaglandins, leukotrienes and thromboxanes all 
have 20 Carbon atoms, and their name contains a number reference to the 
number of double bonds contained in the molecule. They have diverse 
effects on various cell types and differing effects on the same cell types in 
different organs in the body. The variety of effects can be explained in 
part by the existence of selective receptors for different eicosanoids. 
Elevated levels of eicosanoids are associated with a number of 
inflam matory disorders, e.g. in lung tissue is associated with 
bronchoconstriction in asthma (Wenzel et ak, 1990; Liu et ak, 1990).
1.1.3.1.) Prostaglandins
Prostaglandins (PGs) are produced from AA by the action of cyclo- 
oxygenase enzymes, CoxI and Coxlk PGs named PGA through PGI, are 
short-lived, so act as local mediators, but their role in inflammation is not 
fully understood, as they have been described as having both pro- and 
anti-inflammatory effects. The expression of Cox I and II and their 
activation has been linked to the opposing effects that prostaglandins seem 
to possess, with CoxI being constitutively expressed, and responsible for 
the protective, anti-inflammatory effects, whilst CoxII, the inducible type 
being responsible for the pro-inflammatory role.
In their pro-inflammatory role, PGE, PGE2 , PGI2 cause vasodilation 
(Williams and Peck, 1977), acting in synergy with C5a, LTB4 , and 
histamine to produce edema, mediate fever and myalgia in response to 
IL-1, and in synergy with bradykinin to potentiate pain. They can also 
inhibit the release of vasoconstriction mediators like endothelin-1, by
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inhibiting transcription of mRNA and secretion of protein (Prins et aL, 
1994).
As anti-inflammatory mediators they are able to inhibit leucocyte 
recruitment (Asako et ak, 1992). There is also an increase in the 
symptoms of mucosal inflammation in animal models of colitis when 
animals are treated with inhibitors of prostaglandin synthesis (Wallace et 
ak, 1992). PGE2 is an inhibitor of some pro-inflammatory cytokines, 
namely, TNFa release (Kunkel et ak, 1986) and transcription (Kunkel et 
ak, 1988) as well as IL-1 (Kunkel and Chensue, 1985) from 
macrophages, and also inhibits the release of PAF, histamine and TNFa 
from cultured mast cells (Hogaboam et al., 1993). They have anti­
inflammatory effects on neutrophils, inhibiting release of LTB4 (Ham et 
ak, 1983), IL-8 (Wertheim et ak, 1993), and suppressing superoxide 
release from these cells (Wong and Freund, 1981).
1.1.3.2.) Leukotrienes
Leukotrienes are produced from A A by the action of the enzyme, 5- 
lipoxygenase. There are two main types of leukotrienes, LTB4 , and 
peptido-leukotrienes LTC4 , LTD4 , and LTE4 , that have amino acid 
residues attached. Leucocytes, endothelial, and epithelial cells all produce 
the peptido-leukotrienes, whilst the neutrophil is the main source of 
LTB 4 , although it is also produced by macrophages and monocytes. 
Release of leukotrienes is induced by cytokines, as well as activation 
through adhesion of leucocytes, this induction being reduced by 
antibodies to CD 18 and L-selectin (Brady and Serhan, 1992).
LTB4 is a pro-inflammatory mediator, chemotactic for neutrophils, but 
displays no effect on vascular permeability (Martin et ak, 1989). It
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induces increased adhesion of neutrophils to endothelial cells (Hoover et 
aL, 1984; Palmbald and Lerner, 1992) and stimulates release of 
superoxide ions by neutrophils. Administration of LTB4 in in vivo 
models of inflammation causes increased adhesion and migration of 
leukocytes, as well as increased vascular plasma leakage (Thureson et al., 
1986). Increased levels of LTB4 in inflammatory bowel disease (Sharon 
and Stenson, 1984), and rheumatoid arthritis (Davidson et al., 1983), 
indicate that it is a mediator in these conditions. It also causes the 
proliferation of T lymphocytes through increased production of IL-2, and 
the production of cytokines by monocytes (Rola-Pleszczynski et aL, 1986; 
Rola-Pleszczynski 1992), acting through the transcription factors NFkB 
(Brach et al., 1992) and AP-1 (Stankova and Rola-Pleszczynski, 1992) 
Peptido-leukotrienes display no chemotactic activity but stimulate smooth 
muscle contraction (Samuelsson et aL, 1987), increase vascular 
permeability (Peck et aL, 1981; Joris et aL, 1987), can induce increased 
P-selectin expression on endothelial cells (Kanwar et aL, 1995), LTD4 
induces IL-1 expression by monocytes, INFy secretion by T lymphocytes 
(Johnson et aL, 1986), and increased expression of these lipids has also 
been implicated in inflammatory bowel disorders (Peskar et ai., 1986) 
and asthma (Wenzel et ak, 1990).
1.1.3.3.) Thromboxanes
Thromboxanes also produced via cyclo-oxygenase enzyme pathway, are 
primarily released by platelets, however, neutrophils also release them 
(Higgs et ak, 1983). Thromboxane is a potent vasoconstrictor and 
stimulator of platelet aggregation. It can also induce LTB4 release and so 
has a role in the recruitment of leucocytes to an inflammatory site.
8
Introduction
1.1.3.4.) Lipoxins
Lipoxins are a group of lipids produced via lipoxygenase enzyme activity 
on AA, via 15-HETE, which is a product of the aspirin-acetylated CoxII 
enzyme. Lipoxin A4 has some anti-inflammatory effects in in vivo animal 
models of inflammation, eliciting vasodilation and increase in blood flow, 
without plasma exudation or leukocyte adherence (Dahlen et aL, 1987), so 
some of the anti-inflammatory effects of aspirin could be ascribed to the 
diversion of A A metabolism to the lipoxin pathway via 15-HETE.
1.1 .3 .5 .)P hospholip ids
1.1.3.5.1.) Lysophosphatidic Acid
Lysophosphatidic acid (LPA), l-acyl-5'n-glycerol 3-phosphate (Fig 2), 
mainly C l6:0 and C l8:0 is released from thrombin-activated platelets as a 
mixture of 1-palmitoyl and 1-stearoyl derivatives (Eichholtz et aL, 1993), 
It can be produced by the action of phospholipase A2 (PLA2 ) on 
phosphatidic acid (PA), which itself can be produced by phospholipase D 
action on phosphatidylcholine (PC) or phosphatidylethanolamine (PE) 
(Fig. 2). Platelets are known to have a PA-specific PLA2 (Billah et aL, 
1981). LPA has a variety of biological effects when exogenously applied 
to various cell types. These include, stimulation of DNA synthesis, cell 
proliferation (van Corven et aL, 1989), calcium mobilisation, platelet 
aggregation and adenyl cyclase (Moolenaar, 1991), inhibition of cAMP- 
induced stellation (Edwards et aL, 1993), neurite retraction (Jalink et aL,
1993), stimulation of focal adhesion and actin stress fibres through 
activation of ras-related GTP-binding protein rho (Ridley and Hall,
Fig. 2. Schematic diagram showing the actions of PLA2 and PLD 
on phospholipids producing lysophosphatidic acid
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1992), and activation of Phospholipase C (Moolenaar, 1991; van Corven 
et aL, 1991; Pelvin et aL, 1991; Naccache et aL, 1991). A 55 kDa putative 
receptor for LPA has been described (van DerBond et aL, 1992) and it 
appears to be an intrinsic membrane protein (7 span) characteristic of the 
type that binds trimeric G-proteins. LPA has been reported to affect cell 
functions through a family of membrane-bound G-proteins, only some of 
which show sensitivity to pertussis toxin (van Corven et aL, 1993). LPA 
is rapidly released from thrombin-activated platelets and is found in 
serum bound to serum albumin at biologically active concentrations, and 
so has been implicated in the proliferation of cells and the control of 
inflammation in response to injury.
Engleberger et aL, 1987, assessed the effect on the metabolic burst of 
polymorphonuclear leucocytes(PMNs) of a number of lipid species 
including lysophosphatidylcholine (LC), platelet activating factor (PAF), 
and its precursor lyso-PAF and found that they enhanced the release of 
superoxide ions, when stimulated by 4-0-Phorbol-12-myristate-13-acetate 
(PMA). They postulated that these lipids might be important in the 
activation of PMNs during tissue injury or in the inflammatory response. 
However, they did not study the effect of LPA on the metabolic burst of 
PMNs. No receptor has been found on human neutrophils until now, and 
it has been shown that there is no change in intracellular calcium levels in 
neutrophils when LPA was applied extracellularly at concentrations that 
cause an increase in cultured fibroblasts (Jalink et aL, 1990). Since LPA 
is found at biologically active concentrations at sites of inflammation and 
tissue injury, it may have an important role in the regeneration of tissue, 
since it promotes fibroblast cell proliferation (van Corven et aL, 1989), 
and it is possible that it will have an effect on the functions of immune 
cells at these sites in vivo.
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1.1.3.5.2.) Platelet Activating Factor
Platelet activating factor (PAF), I -0 -alkyl-2 -acetyl-5/i-glycerO"3 ~ 
phosphocholine was originally named through its ability to cause 
aggregation and degranulation in platelets (Benveniste et ak, 1972), 
however, since then it has been shown to have many other biological 
functions, acting on, and being released by many cells involved with the 
inflammatory response. It causes activation of neutrophils through 
increasing their adhesion to endothelium (Kubes et ak, 1990) by 
increasing expression of p2 -integrins (Sun et ak, 1996), and indeed has 
been shown to act as an adhesion molecule itself through surface 
expression of PAF on endothelial cells (Zimmerman et ak, 1990) and 
priming them for superoxide release (Engleberger et ak, 1987).
1.1.4 .) A dhesion  m olecules and cytokines involved  in 
recruitment of leucocytes to a site of inflammation.
Adhesion between immune cells and cells of the microvasculature plays 
an important role in the inflammatory response. The first step in immune 
cell activation is through adhesive interactions. Many adhesion molecules 
are involved in this process, some of which are constitutively expressed 
on both immune and endothelial cells, whilst others are expressed only 
following activation by an inflammatory signal. The expression and 
activation state of these adhesion molecules is controlled by both pro- 
inflammatory factors to evoke an inflammatory response, and must be 
regulated by anti-inflammatory mediators to prevent undesirable 
inflammation in tissue. This appears to be the most attractive stage to 
block inflammation and has been the subject of a great deal of
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investigation. The importance of adhesion between leucocytes and the 
endothelium can be demonstrated in diseases such as leucocyte adhesion 
deficiencies (LAD), where the patients suffer persistent and life- 
threatening infections (Anderson and Springer, 1987).
There are a large number of adhesive interactions between immune and 
non-immune cells during inflammation, involving a number of different 
groups of adhesion molecules and ligands.
1.1.4.1.) Selectins
The first stage in the recruitment of leucocytes to an inflammatory site 
involves weak interactions between the endothelium and the leucocyte via 
a group of cell adhesion molecules called selectins (Carlos and Hanlan, 
1994). There are three main family members involved in this process. 
They are named after the cells on which they were first identified; L- 
from Leucocytes, P- from Platelets, and E- from Endothelial cells, but 
are also expressed on other cell types. At any time in the body a large 
number of leucocytes are interacting with the vascular endothelium via 
selectins. These cells are referred to as the marginating pool. As the name 
suggests each of the three selectin family members contains a lectin 
domain, that is responsible for their interaction with ligand. The ligands 
for selectins were shown by inhibition studies to be carbohydrate in 
nature (Stoolman and Rosen, 1983). Further studies have indicated that 
particular moieties found at the termini of oligosaccharide chains were 
important to the binding of selectins, including sialylates and fucosylates, 
the most prominent of these being the Sialyl Lewis X moiety (Walz et al, 
1990; Zhou et al., 1991). In patients with leucocyte adhesion deficiency 
type II (LAD II), where there is a deficiency in fucose metabolism, there
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is a reduction in the migration of neutrophils into tissue (Price et aL,
1994), with a susceptibility to repeated infection, although not as severe 
as that for LAD I defect; section 1.1.4.2. Studies have shown that LAD II 
neutrophils were only able to adhere to vascular endothelial cells under 
low flow conditions, whereas LAD-1 neutrophils were able to roll on the 
endothelial cells, but were unable to adhere strongly (von Adrian et al.,
1993). These findings support the rolling, adhesion followed by 
migration model of leucocyte migration from the bloodstream. Calcium 
is also important for ligand binding as shown by inhibition of adhesion by 
EGTA (Bevilacqua and Nelson, 1993).
1.1.4.1.1.) E-selectin
E-selectin (CD62E, ELAM-1) is a 110 kDa selectin adhesion molecule, 
expressed only on endothelial cells where it is synthesised following 
stimulation by cytokines TNFa, IL-1 or LPS (Bevilacqua et al., 1987, 
1989). It is stimulated at the level of transcription, as inhibitors of 
transcription and translation prevent its expression following stimulus 
(Bevilacqua et al., 1989). Expression of E-selectin on a cultured 
endothelial monolayer is transient peaking at 3 to 6 hours following 
stimulation, and decreasing to basal levels after about 24 hours even in 
the continued presence of the stimulus. Induction of E-selectin expression, 
like many other genes involved with the inflammatory response, is via 
NFkB (Collins et aL, 1995). Other factors may influence the expression 
of E-selectin. Treatment of the endothelium with interferon-gamma 
(IFNy), and either TNFa or LPS, prolongs the expression of E-selectin. 
Treatment with glucocorticoids decreases the thrombin and LPS induction
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of E-selectin expression (Cronstein et al., 1992), and may explain some of 
the anti-inflammatory actions of glucocorticoids.
1.1.4.1.2.) L-selectin
L-selectin (CD62L, Lam-1, LECAM-1) is a 70-90 kDa transmembrane 
protein. It is constitutively expressed on the surface of leucocytes (Jutila 
et ak, 1989) and differs from E- and P-selectin in that it is down- 
regulated upon activation of the leucocyte by cytokines like IL-8 , through 
shedding of the extracellular component of the molecule (Kishimoto et 
ak, 1989). It is expressed on all circulating leucocytes except a sub- 
population of lymphocytes.
The interaction of leucocytes with the endothelium via selectins is 
normally referred to as rolling, since the leucocytes maintain movement, 
at a reduced velocity. L-selectin, as well as P-selectin, are required for 
leucocyte rolling as shown in in vivo studies using antibodies to the two 
molecules (Ley et ak, 1991; Jutila et ak, 1989; Bosse and Vestweber,
1994).
1.1.4.1.3.) P-selectin
P-selectin is a 110 kDa selectin adhesion molecule. The gene for P- 
selectin is constitutively expressed in platelets and endothelial cells, 
however, the protein is stored within alpha granules in platelets and 
Weibel-Palade bodies in endothelial cells (McEver et al., 1989). The 
protein is only expressed on the surface of the cell following exposure to 
an appropriate pro-inflammatory agent such as leukotriene C4 /D 4
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(Kanwar et aL, 1995), histamine, thrombin, or oxygen radicals, which 
cause fusion of the granules with the plasma membrane, with maximum 
expression seen after only 10 minutes (Hattori et al, 1989). This surface 
expression is transient however, and the protein is internalised rapidly 
(McEver et aL, 1989), or shed like L-selectin. TNFa, LPS or IL-1 induce 
increased P-selectin gene expression without the rapid surface expression, 
with peak expression 2 to 4 hours later (Gotsch et ak, 1994). These two 
levels of control of P-selectin functional expression on the surface of 
endothelium leads to fine control possibilities over leucocyte adhesion, 
which has been shown to be at least partly involved with the initial rolling 
interaction between leucocytes and the endothelium during an 
inflammatory response (Bosse and Vestweber, 1994). Upregulation of P- 
selectin is concurrent with an upregulation and secretion of PAF, which 
induces GDI 1/CD 18 expression in leucocytes (Zimmerman et ak, 1990).
1.1.4.2.) p2-in teg r in s
Activation of vascular endothelium by pro-inflammatory mediators, such 
as TNFa, IL-1 or LPS emanating from an inflammatory site, causes an 
increase in surface expression of endothelial adhesion molecules (Pober et 
ak, 1986) and the release of further pro-inflammatory both soluble and 
presented on the endothelial cell surface, such as IL-8 (Rot, 1992) cause 
the activation of the 'rolling' leucocyte and their adhesion is increased by 
the activation of a group of adhesion molecules called p2 integrins (Lo et 
ak, 1991; Diamond and Springer, 1994). This is followed by an activation 
of cell motility and shape change (Carlos and Hanlan, 1994).
There are two main p2 -integrins responsible for the strong adhesion of 
activated neutrophils to vascular endothelium, namely, LFA-1,
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(CD 11 a/CD 18) (Marlin and Springer, 1987) and Mac-1 (CDllb/CD18) 
(Diamond et aL, 1990).
LFA-1 is expressed on hematopoietic cells, lymphocytes, monocytes, 
macrophages, neutrophils and eosinophils. It is a heterodimer, made up of 
the 180 kDa CD 11a subunit non-covalently associated with the 95 kDa 
CD 18 subunit. Mac-1 is expressed on monocytes, macrophages, natural 
killer (NK) cells and neutrophils. It is a heterodimer, made up of the 170 
kDa CD 11b subunit and is also non-covalently associated with the 95 kDa 
C d l8 subunit.
Their primary ligand is the endothelial intercellular adhesion molecule-1 
(ICAM-1) (Diamond et aL, 1991). CDlla/CD18 and CD 1 lb/CD 18 were 
shown using antibodies in vitro, each to contribute 50% of adhesion of 
neutrophils to inactivated endothelium (Lo et aL, 1989; Smith et al., 
1989). CD 11 a/CD 18, however, was shown to be responsible for almost 
all adhesion to activated endothelium. Antibodies against ICAM-1 reduce 
neutrophil adhesion by 50% in both cases (Smith et el., 1988), implying 
that 50% of CD 11 a/CD 18 and CD 1 lb/CD 18 mediated adhesion is through 
other ligands than ICAM-1,
In unstimulated cells these molecules are in an inactive form, and require 
stimulation to increase their avidity of binding to ligand. Control of this 
activation is thought also to be crucial in controlling the timing and 
duration of an inflammatory response, as the strong adhesion of activated 
neutrophils to the vascular endothelium is a very important step in the 
migration of the cells to an inflammatory site. This can be shown most 
clearly in disease states where function of these adhesion molecules is 
deficient. Leucocyte adhesion deficiency (LAD-1) is a disease associated 
with the absence of p2 integrin function. This disease causes recurrent 
and potentially life-threatening bacterial infections in sufferers (Anderson 
and Springer, 1987). There is, however, a CD 18-independent pathway to
16
Introduction
neutrophil adhesion and migration into tissue, as seen in post-mortem 
examinations of LAD-1 patients where neutrophils are found in lung 
alveolar spaces (Hawkins et ak, 1992).
1.1.4.3.) Intercellular adhesion molecules
Intercellular adhesion molecule-1 (ICAM-1) is a 90 kDa cell surface 
Glycoprotein, with five Immunoglobulin-like domains, that is 
constitutively expressed on a number of cell types including epithelial 
(Wegner et ak, 1990) and endothelial cells, dendritic cells, monocytes, B 
cells, T cells, and fibroblasts. Endothelial cell expression of ICAM-1 is 
increased after stimulation with cytokines such as TNFa, IL-1, IL-8 or 
Lipopoly saccharide (LPS), over a 24-hour period. This induction causes 
de novo synthesis of ICAM-1 through an increase in gene expression. 
There is also a much more rapid response in the induction of ICAM-1 
following stimulation by thrombin and hydrogen peroxide, assayed by an 
increase in neutrophil adhesion, which is thought to occur through an 
alteration in the function of constitutively expressed ICAM-1, as no 
protein synthesis is required. ICAM-1 is responsible for strong leucocyte 
adhesion to endothelium during an inflammatory response (Rothlein et 
ak, 1986), and is the main ligand for the P2 '"ii i^Ggrins CD 11 a/CD 18 and 
CD 1 lb/CD 18 (Diamond et ak, 1991), which are expressed on all 
leucocytes, although they have been shown to interact with two other 
ICAM family members; ICAM-2 and ICAM-3. The expression of ICAM- 
1 is reduced by glucocorticoid treatment in in vitro studies (Cronstein et 
ak, 1992).
ICAM -2 is a 55 kDa integral membrane protein with two 
immunoglobulin-like domains that are similar to the two N-terminal
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domains of ICAM-1, but only binds CD 11 a/CD 18 and not CDllb/CD18 
(Staunton et aL, 1989). It is expressed on endothelial cells, lymphocytes, 
monocytes, NK cells and platelets. ICAM-2 is likely to be responsible for 
ICAM-1 independent leucocyte adhesion, as shown by studies using 
monoclonal antibodies to CD 11/CD 18 but not ICAM-1, completely 
inhibited the homotypic aggregation of lymphocytes (Rothlein et ak, 
1986).
ICAM-3 has similarity of structure to ICAM-1, is not expressed on 
vascular endothelium, but is constitutively expressed on inactivated 
leucocytes (Fawcett et ak, 1992).
1.1.4.4.) Platelet-endothelial cell adhesion molecule
Platelet-endothelial cell adhesion molecule (PECAM-1) (EndoCAM, 
CD31) is a cell adhesion molecule first discovered on platelets (Metzelaar 
et ak, 1991) and endothelial cells (Albelda et ak, 1990), but has since 
been shown to be expressed on many other cell types, including 
monocytes, neutrophils, NK cells, and about 50% of all lymphocytes 
(Watt et ak, 1995). It is involved in homotypic adhesion of endothelial 
cells (Albelda et ak, 1991), and the adhesion of platelets to myeloid cells 
(Muller et ak, 1992). Binding of PECAM-1 to ligand has also been 
implicated in activation of leucocytes, as antibody binding to PECAM-1 
induced the respiratory burst in monocytes, but notably, not in 
neutrophils (Stockinger et ak, 1990).
Antibody studies both in vitro (Muller et ak, 1993), and in vivo 
(Vaporciyan et ak, 1993) have shown that it is required for leucocyte 
transmigration across the endothelium. p2 -integrins have also been 
implicated as a requirement for transmigration. A hypothesis is that
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ICAM-1 molecules are distributed in such a way on endothelial cells that 
they guide the leucocytes towards the junctions between endothelial cells, 
where the majority of PECAM-1 is expressed (Muller et aL, 1989), and 
leucocyte PECAM-1 interactions are responsible for the movement of 
leucocytes through the endothelium.
1.1.4.5.) Vascular cell adhesion molecule-1 (VCAM-1)
Vascular cell adhesion molecule-1 (VCAM-1, CD 106) is a 110 kDa 
transmembrane adhesion molecule, found on endothelium only after 
cytokine activation. Its ligand is primarily the P i-in tegrin , VLA-4, 
expressed on most circulating leucocytes. Antibody studies have indicated 
that it has a role in the tr ans endothelial migration of monocytes and 
eosinophils (Hakkert et aL, 1991), and is also responsible for interactions 
between endothelium and lymphocytes (Rice et al., 1990; Oppenheim et 
al., 1991). Although there is a marked reduction in the infiltration of 
neutrophils into tissue in leucocyte adhesion deficiency diseases where 
there is dysfunction of CD 18 adhesion molecules, there is infiltration of 
eosinophils, lymphocytes, and some monocytes (Anderson et aL, 1985). 
VCAM-1 has been implicated as the CD 18-independent pathway of 
leucocyte adhesion and transendothelial migration. The lack of expression 
on some cell types and selective expression of ligands for such adhesion 
molecules, may explain the selective targeting of cell types in the immune 
system into particular tissues.
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1.1.5.) Anti-inflammatory mediators
There are a number of proposed anti-inflammatory mediators that act in 
conjunction with the pro-inflammatory mediators to control the extent of, 
and 'switch off, the inflammatory process. The definition of a molecule 
as being either pro- or anti-inflammatory can be a difficult exercise as 
many factors display characteristics of both, depending on the assay 
conditions, levels of expression, cells studied, and parameters being 
measured.
1.1.5.1.) L ipocortin-l
Lipocortin-1 (LC-1), a 37kDa (343 amino acid) protein is a member of 
the annexin family of proteins that show calcium and phospholipid 
binding properties. Each member of the Annexin family contains a core 
of 4 or 8 repeated 70 amino acid domains (Crompton et ak, 1988), and 
within each is a 17 amino acid consensus sequence motif, which is 
involved with calcium and phospholipid binding (Geisow et al., 1986). 
LC-1 has a unique N-terminus sequence conferring specific structural and 
functional properties. It was first identified in 1979 in Guinea-pig model 
of inflammation, and was described as a potential mediator of the anti­
inflammatory effects of glucocorticoids (Flower and Blackwell, 1979). 
The Lipocortin-l gene was first cloned in 1986 (Wallner et aL, 1986), 
and contains 13 exons, the first being non-coding. The promoter region 
contains TATA and CCA AT sequence as well as having a glucocorticoid 
response element (GRE) in the region. Gene expression has been shown 
to be restricted to specific cell types such as, ductal/airway epithelia, 
macrophages and polymorphonuclear leucocytes (Fava et aL, 1989) and is
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inducible by glucocorticoids. The anti-inflammatory role of LC-1 has 
been debated for a number of years, with contradictory evidence being 
presented by various groups. The anti-inflammatory role of LC-1 is 
described further in section 1.1.9.
1.1.5.2.) Anti-inflammatory peptides
There are a growing number of peptides that have apparent anti­
inflammatory effects in in vivo models of inflammation (review, Wei and 
Thomas, 1993). These include Corticotropin-releasing factors (CRTs) and 
related peptides that are able to inhibit edema formation in animal models 
of inflammation. These peptides are so called for their ability to affect the 
synthesis and release of corticosteroids from the adrenal glands. 
However, the effect they have on edema is not through the release of 
corticosteroids, as shown by their ability to reduce edema in 
adrenalectomized or hypophysectomized rats, implying a more localised 
effect on vascular permeability. The di-peptide sequence K-R (Lys-Arg) 
appear to be important for activity of these peptides.
Neurotensin and similar peptides (NTs) e.g. Xenopsin, that have the Lys- 
Arg sequence present are also able to inhibit edema formation in animal 
models of inflammation. NT was first discovered and described as a pro- 
inflammatory mediator, increasing vascular permeability, hypotension 
and cyanosis in the rat. However, local administration causes an inhibition 
of histamine release. The apparent anti- and pro-inflammatory roles of 
these molecules depends primarily on their mode of administration.
Both these sets of peptides, CRTs and NTs induce transient hypotension, 
but this does not appear to be the cause of their anti-inflammatory effects
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as sodium nitroprusside administration also induces this hypotension 
without affecting edema formation.
Other anti-inflammatory peptides include, vasoactive intestinal peptide 
(VIP) that inhibits bronchoconstriction and vasoconstriction induced by 
pro-inflammatory mediators, as well as reducing lung injury induced by 
hydrochloric acid, oxidants and FAF, and reduction of edema in lung 
assays; and antiinflammins 1 and 2 which are referred to in section 1.1.9, 
as they are fragments of Lipocortin-1, thought to have anti-inflammatory 
properties similar to the native protein.
1.1.5.3.) Adenosine
Adenosine has two receptors, A l and A2 (van Calker et al., 1979), both 
of which are found on the majority of cells in the body. They effect cell 
functions through a pertussis toxin sensitive membrane-bound G-protein 
receptor (Dolphin and Prestwich, 1985). Binding of receptor increases 
levels of intracellular cAMP, and inhibits cells responding to other 
stimuli (van Calker et al., 1979; Londos et al., 1980). The anti­
inflammatory role of adenosine is not fully understood, but several in 
vitro and in vivo studies have implicated it as a potent anti-inflammatory 
mediator (review; Cronstein, 1994). It inhibits superoxide generation by 
activated leucocytes and reduces adhesion of leucocytes to activated 
endothelial cells in vitro, and accumulation of leucocytes in inflammatory 
models in vivo.
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1.1.5.4.) Nitric Oxide
The role of Nitric oxide (NO) as a cellular signalling molecule first came 
to light in a study of blood vessel relaxation, and indeed is known in that 
system as endothelium-derived relaxing factor (EDRF). As the name 
suggests, it is synthesised by endothelium, and causes relaxation of blood 
vessels allowing increased blood flow. However, NO has been found to 
influence the function of virtually every organ and cell in the human 
body, and indeed, every cell in humans appears capable of producing NO 
given the correct stimulation (review, Harald et al., 1994). It has been 
implicated in many cellular systems including, as a neurotransmitter, 
hormonal functions in the heart, lungs kidney, pancreas gut and the 
immune system.
Within the immune system NO appears to have a ‘split personality’, it has 
apparent pro- and anti-inflammatory functions, depending on the cells 
being effected and the timing of this effect.
There are three separate gene products producing nitric oxide synthetases 
(NOS), all of which are calmodulin dependent, but only one of which is 
independent of increases in intracellular calcium, referred to as inducible 
nitric oxide synthetase (iNOS), and is induced by agonists such as 
cytokines and bacterial lipopolysaccharides. Induction of iNOS confers on 
the cell the ability to produce NO over extended periods. This enzyme is 
primarily implicated in the immune functions of NO. It confers anti­
microbial activity on the host cells, but the cost of this is potential damage 
to self by NO derived reactive molecules, such as peroxynitrite, produced 
by the reaction of NO with superoxide ions (Szabo, 1996).
NO inhibits platelet aggregation and adhesion of platelets by raising levels 
of platelet cGMP in synergy with PGI2 (Radomski et al., 1987), and also 
inhibits histamine release by mast cells (Salvemini et al., 1991)
23
Introduction
1.1.6.) Cells of Inflammation
There are a large number of cell types involved in an inflammatory 
response. Interactions between these cell types via direct interaction, or 
through soluble mediators are extensive, and mediated by a whole range 
of both pro- and anti-inflammatory signals. Figure 3 shows the 
development of the hematopoietic cells primarily involved in the innate 
immune response.
1.1.6.1.) Polymorphonuclear Leucocytes
The most numerous of all immune cells in the circulation are the 
Polymorphonuclear leucocytes (PMNs), which are made up of three cell 
types, namely neutrophils, basophils, and eosinophils.
1.1.6.1.1.) Neutrophils
Neutrophils make up more than 90% of PMNs and are the first cells 
detected at a site of inflammation/infection, where they are thought to be 
very efficient ‘killers’ of a wide variety of microbial pathogens. The 
importance of these cells as the ‘first-line’ of defence against infection can 
be seen in individuals where there is neutrophil dysfunction These 
individuals suffer repeated bacterial and fungal infections, particularly in 
skin and mucous membrane, areas of the body freely accessible to 
microbial infection. Neutrophil dysfunction has two main causes; either a 
lack of the cells in the blood circulation due to arrest of 
development/maturation; neutropenia, or a dysfunction preventing the
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Fig 3. Haematopoesis. Differentiation of granulocytes, platelets, mast 
cells, and erythrocytes(After Roitt).
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cells getting from the circulation into an infected site, or unable to deal 
effectively with the microbes when they do, due to a defect in cell 
function. The outcome of these two dysfunctions is similar, in that the 
individual has recurrent infections; however, they differ in the 
complications arising from initial infection. In individuals who have 
neutropenia, the initial localised infection often develops into septicaemia, 
as the infectious organism is able to escape from the soft-tissue into the 
blood stream; this is not so prevalent in the latter group (Howard et al., 
1977; Anderson et al., 1985).
1.1.6.1.2.) Eosinophils
Eosinophils have been associated with allergic asthma, and are found in 
relatively large numbers in the lungs of sufferers. Eosinophils, like other 
leucocytes must adhere to vascular endothelial cells before infiltration 
into tissue. Unlike neutrophils they express the membrane adhesion 
molecule VLA-4, which may provide a mechanism for the specificity of 
their migration into tissue (Butcher, 1991); section 1.1.4.5.
1.1.6.1.3.) Basophils
Basophils found in very small numbers in the bloodstream, are 
functionally similar to mast cells. They are primed by exposure to IL-3 
or IL-5 to respond to stimuli, such as, GM-CSF, MCP-1 or IL-8 , 
releasing granules containing primarily histamine and leukotrienes by 
exocytosis ( Baggiolini and Dahinden, 1994; Dahinden et al., 1989).
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1.1.6.2.) Mast cells
Mast cells are important mediators of the inflammatory response, as 
many of them are found proximal to the vascular-endothelium in all 
tissues, and they are capable of secreting a large number of pro- 
inflammatory mediators that will cause the activation of the endothelium 
and so the recruitment of blood leucocytes to a site of inflammation. They 
are also sensitive to many of the stimuli found at a site of infection or 
injury, namely IgE, complement component C5a, neuropeptides, 
superoxide ions, several lipid mediators, including PAF, LTB4 and 
PGD2 , bacterial toxins, histamine and bradykinin. They are also sensitive 
to physical stress. The presence of mast cells near to the vascular 
endothelium, makes them suited to amplify the initial inflammatory 
signal, be it an infectious agent, or a physical injury, by activating the 
endothelium, increasing vascular permeability, and attracting blood 
leukocyte invasion of the inflammatory site (review, Kubes and Granger, 
1996)
1.1.6.3.) Monocytes and Macrophages
Monocytes and Macrophages were first identified by Metchnikoff, 1893. 
The bone marrow progenitors of these cells develop over a period of 6 
days into blood monocytes. Monocytes have a half-life of approximately 3 
days. Some of them migrate into tissue and develop into tissue 
macrophage, where their life-span can be from days to many months. The 
mononuclear phagocyte system plays an important regulatory role in 
inflammation, borne out by the fact that they are capable of secreting 
around one hundred different products (Nathan, 1987). They interact
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with all other immune cells, modulating their responses in two main 
ways. Firstly, they process and present antigen to Lymphocytes, which 
recognise these antigens when bound to Major Histocompatibility complex 
molecules on the cell surface. Secondly, and more importantly for the 
purpose of this study, they secrete many important immunoregulatory 
molecules both pro- and anti-inflammatory, that alter the behaviour of 
other immune cells. Glucocorticoid administration inhibits monocyte 
development in vivo.( Shezen et al., 1985).
1.1.6.4.) Endothelial cells
For many years the vascular endothelium was seen as nothing more than a 
barrier, preventing blood cells and plasma proteins from entering body 
tissues. More recently the role of the endothelium in the control of 
inflammation has been realised. Endothelial cells are capable of secreting 
many pro- and anti-inflammatory mediators, can activate leucocyte 
adherence by alteration of surface expression of adhesion molecules, and 
alter the extent of homotypic adhesion to increase/decrease vascular 
permeability. They are also able to present leucocytes with pro- 
inflammatory molecules bound on their surface, e.g. PAF, which 
activates CDlla&b/CD18 (Zimmerman et al., 1990). They are involved 
in the first stage of the activation and movement of leucocytes from the 
bloodstream to a site of inflammation, so are an obvious target for anti­
inflammatory therapy, and indeed some of the actions of anti­
inflammatory steroids affect endothelial cell functions. Glucocorticoid 
administration causes a decrease in vascular permeability, and a decrease 
in the expression of adhesion molecules ELAM-1 and ICAM -1 on 
endothelial cells (Cronstein et al., 1992). Preventing the initial interaction
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of leucocytes with the endothelium would appear to be the most 
promising approach to therapy for inflammatory diseases.
1.1.6.5.) Platelets
Platelets are another cell type whose role in inflammation was overlooked 
for many years. Their role in blood clotting is well recognised, but the 
arsenal of inflammatory mediators that they are able to secrete has only 
recently been realised. They secrete LPA in response to thrombin 
(1.1.3.5.1), and constitutively express the P-selectin gene and store the 
gene product in alpha granules, only transporting it to the surface upon 
stimulation (1.1.4.1.3.). An important role in the inflammatory response 
by platelets is to aggregate and bind endothelial cells at a site of vascular 
damage. They then secrete thromboxanes, seratonin and fibrinogen, 
which act to increase vascular permeability, and activate complement, 
which in turn induces the recruitment of leucocytes to the site via the 
chemoattractant complement factor C5a.
1.1.7.) The release of active oxygen species by human  
neutrophils
The release of superoxide ions by leucocytes is a major part of the arsenal 
of anti-microbial weapons that these cells possess. However, much of the 
self-tissue damage caused by granulocytes in chronic inflammatory 
disorders is thought to be due to the release of these highly reactive and 
destructive oxygen metabolites. However, on the other hand, if there is a 
defect in the production of these oxygen species, as in a group of diseases
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known as, chronic granulomatous disease in childhood, the outcome is 
frequent microbial infections (Tauber et al., 1983).
In recent years many pro-inflammatory mediators have been reported 
either to activate neutrophils directly or else prime their responses to 
known stimulators such as fMLP and PMA. The activation of neutrophils 
by fMLP and PMA is determined by two interrelated cellular signalling 
pathways; fMLP acts by binding to specific plasma membrane receptors, 
that are coupled to pertussis toxin-sensitive G proteins and which in turn 
activate phospholipase C. Activation of this enzyme elevates cytosolic free 
calcium by means of inositol 1,4,5-triphosphate pathway and also 
activates protein kinase C (PKC) via the diacylglycerol pathway that 
phosphorylates several key components of the oxidase system (Thomas et 
al., 1990) leading to the assembly of the NADPH oxidase complex, which 
is made up of several protein subunits, and release of superoxide ions. 
PMA acts as an analogue of diacylglycerol by directly binding to the 
calcium/phospholipid dependent PKC (Tauber, 1987; Garland, 1992)
1.1.8 .) Inappropriate acute and chronic inflam m ation: 
Treatment with anti-inflammatory mediators.
It is apparent from the above text that the reaction of the immune system 
to injury or infection is an intricate and highly controlled reaction 
involving the interaction of many cell types with one another, via the 
expression and secretion of a large number of soluble mediators as well 
as by direct contact through adhesion molecules. The body is continually 
under threat from fungal and bacterial infection, and so the first line of 
defence, namely the phagocytic leucocytes, have to be constantly on duty. 
It is not surprising, when the number of cells involved and the sensitivity
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of the cellular mediated immune system is considered, that sometimes the 
system of control breaks down, leading to an inappropriate or 
exaggerated response and resulting self-damage by overactive phagocytic 
cells secreting neutral proteases, and reactive oxygen species, in diseases 
such as, rheumatoid arthritis, where joints become inflamed without any 
apparent insult or injury. The system too, can become oversensitive to 
stimuli, in diseases such as asthma, where an allergic reaction results 
from hypersensitivity to an allergen, causing inflammation of lung tissue. 
The cause of these types of diseases are not known, but many types of 
drug have been developed to reduce the symptoms. The most widely used 
anti-inflammatory treatment is administration of glucocorticoid type 
steroids, which are highly effective in reducing the inflammation by 
reducing the number of immune cells at the site of inflammation, and 
therefore reducing tissue-damage. This benefit has to be weighed against 
the side-effects of this therapy. Non-steroidal anti-inflammatory drugs, 
tend to alleviate only the obvious symptoms of the inflammation, namely 
swelling and pain, but do not reduce the number of inflammatory cells at 
the inflammatory site, so do not prevent the tissue damage caused by these 
cells, and in the long term the consequences of this inflammation become 
worse.
1.1.8.1.) G lucocorticoids
Glucocorticoids, and four other major classes of steroid hormones, 
progestagens, m ineralocorticoid, androgens, and estrogens, are 
synthesised from a common precursor molecule; cholesterol. 
Glucocorticoids, synthesised in the adrenal cortex, promote the formation 
of glycogen and enhance the degradation of fat and protein in vivo, as
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well as their anti-inflammatory functions. Figure 4 shows a diagram of 
their pre-cursor molecule; cholesterol, and some glucocorticoids 
commonly used as anti-inflammatory therapeutic agents. As discussed 
below, they also have a major effect on the development and function of 
cells involved in the inflammatory response and most of their effects are 
in down-regulating the inflammatory response, through effects on the 
development and distribution of leucocytes, inhibiting the release of pro- 
inflammatory mediators, and reduction of adhesion through down- 
regulation of adhesion molecules on vascular endothelial cells. Some 
cytokines, for example IL-6 induce the release of glucocorticoids from 
the adrenal cortex, as a way of balancing the pro- and anti-inflammatory 
mediators to promote a measured inflammatory response.
1.1.8.1.1.) G lucocorticoids as anti-inflam m atory therapeutic 
agents
Glucocorticoids were first used as an anti-inflammatory treatment in 
1948 , when cortisone was observed to have a very powerful therapeutic 
effect on patients suffering from arthritis (Hench et al., 1949). However 
it was soon discovered that there were unwanted side effects from 
glucocorticoids. This setback however, has not prevented the use of anti­
inflam m atory steroids for the treatm ent of many debilitating 
inflammatory disorders, such as rheumatoid arthritis or osteoarthritis. 
These disabling conditions mean that the adverse side-effects of steroid 
administration have to be weighed against the improvement to the quality 
of life of the patient. “To move freely without restriction due to pain, 
disability, or weakness is among the most basic of human rights. Any 
disorder that impairs mobility; limits the capacity to touch, embrace or
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Fig. 4. Anti-inflammatory glucocorticoids and their common pre­
cursor; cholesterol
Glucocorticoids, synthesised in the adrenal cortex exert their influences 
globally, and as well as their anti-inflammatory effects, alter glucose 
metabolism, enhancing glycogen production, and enhance the degradation fat 
and protein.
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protect; and interferes with personal hygiene, physical labor, or 
recreation threatens a person’s sense of dignity and self worth” (Sobel and 
Klein, 1989).
1.1.8.1.2.) Side effects of glucocorticoid administration
Glucocorticoid receptors are found in most cells of the body (Norman 
and Litwack, 1987), so it is hardly unexpected that there should be side- 
effects from glucocorticoid treatment, and indeed since they have been 
used as an anti-inflammatory drug adverse side-effects have been 
described affecting most organs of the body. Cardiovascular: treatment of 
preterm infants with pulmonary dysplasia with glucocorticoids has led to 
hypertension (Fauser et al., 1993) and hypertrophic obstructive 
cardiomyopathy (Brand et ah, 1993); Psychiatric syndromes: Although 
not common cases have been described of steroid-induced psychotic 
episodes (Klein, 1992; Mullen and Romans-Clarkson, 1993) Neurological 
syndromes: including encephalopathy (Durmus et al., 1991), Endocrine 
and metabolic: adrenal suppression has been described frequently, even 
with inhaled forms, and may continue after withdrawal of treatment 
(Zwaan et al., 1992); eyes: ocular hypertension and cataract development 
(Kaye et al., 1993); Bones and joints: Reduction in bone density(Garton 
and Reid, 1993), although this appears to be reversed after steroid 
therapy is withdrawn (Laan et al., 1993); muscle and tendons: reducing 
the efficiency of respiratory muscle function (Weiner et al., 1993); 
growth: there has been shown to be a reduction in the rate of growth of 
children on steroid therapy (Volovitz et al., 1993); and immune defence 
and infection: Because glucocorticoids, used as anti-inflammatory 
therapy, suppress the immune system, it follows that the patient under
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steroid therapy will be more prone to infection. Adverse side effects have 
limited steroids use as anti-inflammatory therapeutic agents, however, a 
great deal of study is going on to determine the ideal strength and time of 
dosage, to reduce these side-effects, whilst gaining maximum efficacy of 
treatment.
1.1.8.1.3.) M olecular m echanism of the anti-inflam m atory  
actions of glucocorticoids
The glucocorticoid receptor (GR) is almost ubiquitous in the cells of the 
body. The GR is a protein is made up of three domains, the steroid 
binding domain, the DNA binding domain and the modulatory domain 
(Meisfield, 1989, 1990; Gieguere et al., 1986), In the absence of ligand, 
the receptor is bound to a heat-shock protein 90 (HSP90) in the cytosol 
(Howard and Distelhorst, 1988; Rexin et al., 1988). When steroid binds 
the GR, the receptor dissociates from the HSP90 protein and translocates 
to the cell nucleus, where it effects gene expression by binding, as a 
dimer, to a regulatory sequence known as the Glucocorticoid Receptor 
Element (GRE) (Scheidereit et al, 1983), which have the consensus 
sequence d(TGTTCT) (Scheidereit et al, 1986). The binding of receptor 
to the GRE usually produces a suppression of gene expression (Cairns et 
al, 1993) of some pro-inflammatory cytokines (section 1.1.8.1.4.), and 
increased expression of anti-inflammatory mediators like Lipocortin-1 
(Flower and Blackwell, 1979). There may be several GREs for a single 
gene, and these may have differing binding strengths for the receptor 
dependent on their sequence (Miesfeld, 1989), providing different levels 
of control of gene expression. A model has been proposed, that genes on 
which there are more GREs with stronger binding are quickest to be
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affected by glucocorticoid treatment, and the later affected genes have 
less numerous and/or lower binding affinity GREs (Chalepakis et ah, 
1988). The interaction of GR with transcription factors and the alteration 
of chromatin structure may also have an influence on GR control of gene 
expression (Adler et al., 1992; Hayes and Wolffe, 1992; Pearce and 
Yamamoto, 1993; Ptashne, 1988).
There are two subtypes of cellular receptors which bind glucocorticoids; 
Type I receptors, known as mineralocorticoid receptors, and type II 
receptors, known as glucocorticoid receptors. Type I receptors have a 
higher affinity for naturally occurring adrenal steroids, such as cortisol, 
than type II receptors, and are therefore occupied and activated at lower 
concentrations of endogenous hormone (Reul and Kloet, 1985; Spencer et 
al, 1990).
Many of the cytokines, whose expression is inhibited by glucocorticoids 
do not have a GRE in their promoter region and therefore the mode of 
repression must be through another mechanism. The transcription factor 
NFkB, an important transcription factor of cytokine gene expression, is 
functionally inhibited by glucocorticoids by direct interaction of the GR 
with subunits of NFkB (Scheinman et al., 1995). This transcription factor 
is localised in the cytoplasm bound to an inhibitor IkB, which prevents its 
translocation to the nucleus. Activation of the cell by e.g. cytokines, EPS, 
reactive oxygen species, or viral infection causes rapid dissociation, 
phosphorylation and degradation of IkB, and translocation of NFkB to the 
nucleus (Beg et al., 1993), where it associates with other transcription 
factors e.g. AP I, SPl and C/EBPb to initiate transcription of many 
different gene products.
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induction of many other cytokines, and induction of neutrophils to the
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1.1.8.1.4.) Anti-inflammatory mechanism of glucocorticoids
.The primary anti-inflammatory action of glucocorticoids still remains a 
hotly debated subject, despite around fifty years of intense study. A 
number of different models have been proposed to explain the anti­
inflammatory effect of glucocorticoids, primarily because they affect 
many different cell types in different ways (Whelan et al., 1995).
Administration of glucocorticoids to a patient causes a transient decrease #'in the circulating lymphocyte population, by redistributing the cells into
body compartments (Cohen, 1972; Fauci 1975; Beardsley and Cohen,
1978), predominantly T-lymphocytes (Fauci and dale, 1974; Yu et al.,
1974), and only in the recirculating portion of the intravascular
lymphocytes (Fauci and dale, 1975). There is, by contrast, an increase in
number of circulating polymorphonuclear leucocytes (Athens et al.,
1961), reaching maximum concentration after 5 hours (Bishop et al.,
1968) along with an increase in the release of neutrophils from
.marginated granulocyte pool, and prolonging of neutrophil half-life in l |
I
the circulation (Craddock et al., 1960; Dale et al., 1974; Fauci et al., il1976). Glucocorticoids also enhance neutrophil development from
precursor cells and inhibit monocyte development ( Shezen et al., 1985), 
as well as inhibiting the adhesion of neutrophils to IL-1 activated 
endothelial cells in vitro, which could be explained by the reduction of i |
expression of E-selectin and ICAM-1 on glucocorticoid-treated 
endothelial cells (Cronstein et al., 1992), which is thought to be part of 
the reason for the increase in the number of circulating neutrophils in the
bloodstream.
Glucocorticoids also inhibit many pro-inflammatory cytokines, such as,
■■I'IL-1, an important mediator of the inflammatory response, involved with
■
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inflammatory site. Production of IL-1 by monocytes is inhibited in vitro 
(Snyder and Unanue, 1982), at both transcription and post-transcriptional 
levels (Knusden et al., 1987). The in vivo serum concentration of IL-1 is 
also reduced by glucocorticoid administration (Staruch and Wood, 1985); 
Expression of TNFa (Bentier et al., 1986; Bentier and Cerami, 1988), 
another cytokine with a central role in inflammation; The transcription of 
IN Fy (Arya et al., 1984; Gessani et al., 1988), that activates both 
macrophages and neutrophils, enhancing their anti-microbial activity; 
GM-CSF (Churchill et al., 1992), that prolongs the survival of 
macrophages, neutrophils, and eosinophils, and causes an increase in 
expression of adhesion molecules on these cells (Lopez et aL., 1986). 
There are also an increasing number of other interleukins shown to be 
inhibited at either transcriptional or post-transcriptional levels by 
glucocorticoids. These include, IL-2 (Arya et al., 1984), a growth factor 
for T and B lymphocytes (Mingari et al., 1984), and its receptor mRNA 
levels (Grabstein et al., 1986); IL-3 (Culpepper and Lee., 1985), involved 
with immune cell development and differentiation; IL-4 (Wu et al., 1991) 
activator of B cells and T cell differentiation; IL-5 (Whelan, 1996) 
responsible for the development of, and chemotactic for eosinophils; IL-6 
(Waage et al., 1993) involved with development of B and T cells, 
production of acute-phase proteins, and induces glucocorticoid release 
from adrenal cortex; and IL-8 (Kwon et al., 1993).
Biosynthesis of many of the eicosanoid lipid mediators is also inhibited by 
glucocorticoids (Kantrowitz et al., 1975; Lewis and Piper, 1975), perhaps 
due to the inhibition of cyclooxygenase enzymes, as shown with the 
inhibition of IL-1 induction of these enzymes in endothelial cells 
(Szczepanski et al., 1994). This inhibition is now thought to be via the 
inhibition of PLA2 by the glucocorticoid-induced lipocortin-1 (Flower, 
1988). The list of inflammatory mediators affected by glucocorticoids is
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extensive, and growing as more mediators of inflammation are being 
discovered, and the effect of glucocorticoids on their expression and 
function assessed.
1.1.8.2.) Non-steroidal anti-inflammatory drugs
Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs), 
including methotrexate, all reduce PMN adhesion to endothelium at the 
site of inflammation and subsequent accumulation at these sites. 
Methotrexate and similar compounds are thought to act through the 
induction of adenosine from activated endothelial cells and fibroblasts at 
sites of inflammation, which reduces the adhesion of leukocytes, in vivo 
(Asako et al., 1992), and in vitro (Cronstein et al., 1992). Addition of 
adenosine deaminase reduces this inhibition. Adenosine also inhibits 
TN Fa production (Parmely et al., 1993). It has also been shown to inhibit 
the superoxide generation of leucocytes in vitro and superoxide 
generation of activated leucocytes, and so may help diminish tissue 
damage caused by activated leucocytes at inflammatory sites.
Aspirin (Vane, 1971), and over 40 other NSAIDs in use, inhibit the 
synthesis of prostaglandins. Aspirin inhibition of prostaglandin is through 
the acétylation of CoxII, which diverts the metabolism of AA to the 15- 
lipoxygenase pathway producing 15 HETE which is metabolised to 
14,15diHETE, a potent inhibitor of metabolic burst.
Paracetomol (non-acetylated salicylate) inhibits prostaglandin biosynthesis 
and reduces platelet aggregation but is not anti-inflammatory although it 
does reduce pain and fever.
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1.1.9.) Inhibition of pro-inflammatory mediators vs. induction 
of anti-inflammatory mediators by glucocorticoids
Whether the main anti-inflammatory effect of glucocorticoids is to inhibit 
pro-inflammatory cytokines, or the induction of anti-inflammatory 
molecules such as lipocortin-I is a matter for much debate. It has been 
proposed that an important anti-inflammatory effect of glucocorticoid is 
the induction of the expression of anti-inflammatory mediators. A very 
prominent proposed anti-inflammatory mediator that is induced by 
glucocorticoids is Lipocortin-1 (Flower, 1988).
The anti-inflammatory role of LC-1 has been debated for some time with 
contradictory evidence being presented by different research groups. 
Initial results indicated that LC-1 was an inhibitor of PLA2 , an enzyme 
that catalyses the formation of Arachidonic acid, a precursor of pro- 
inflammatory prostaglandins and Leukotrienes. It was shown that LC-I 
inhibited the release of AA from rabbit neutrophil membranes (Hirata et 
al., 1980), or cultured rat renomedullary cells (Russo-Marie and Duval, 
1982) but Davidson et al., 1988 indicated that lipocortin inhibited PLA2 
by binding the substrate, thus physically blocking the enzyme. This 
inhibition could be overcome by increasing the substrate concentration. 
However, it has also been shown in vitro to inhibit the release of lyso- 
PAF from rat leukocytes, the precursor of the pro-inflammatory 
mediator, PAF (Parente and Flower, 1985).
The possibility that Lipocortin-1 may be a second messenger in the anti­
inflammatory mechanism of glucocorticoids has led to speculation that it 
may be used as an anti-inflammatory therapy for many of the disease 
states presently treated with steroids. However, the scarcity of cellular 
product and the instability of the recombinant protein, which 
spontaneously denatures in vitro, has meant that the approach has been to
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study peptide fragments of LC-1 that have the same anti-inflammatory 
effects as the native protein. However, the three peptides tested for anti­
inflammatory activity in in vivo models Ac2-26, 1-188 and antinflammin 
2(246-254) have shown similar activity to the native protein, but at much 
greater concentrations (Perretti et al., 1993; Wei and Thomas, 1993).
1.2.) Polymorph migration stimulator. A peptide mediator of 
glucocorticoid effects on polymorphonuclear leucocytes
1.2.1.) Characterisation of a novel mediator of the anti­
inflammatory effects of glucocorticoids
In 1974, Stevenson described a factor produced by mixed mononuclear 
leucocytes (MML) in response to glucocorticoids that stimulated 
migration of Polymorphonuclear leucocytes in a capillary tube migration 
assay (Fig 5). The factor(s) described by Stevenson, 1973, 1974, 1978 is 
the basis for this study, and a summary of his findings is below.
1.2.2.) Production of m igration stim ulating activity  by 
hydrocortisone-treated mixed mononuclear leucocytes
In the capillary-tube migration assay, hydrocortisone-treated culture 
supernatants stimulated migration of polymorphonuclear leucocytes by a 
mean of 56 % compared with untreated culture supernatants and control 
medium with hydrocortisone (MEM-S). This activity was referred to as 
polymorph migration stimulator (PMS) However, it was noted that 
MEM-S did have some stimulatory effect on migration but shown in
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further experiments that this was mainly due to the stimulation of 
contaminating mononuclear leucocytes by hydrocortisone, causing them 
to release the stimulatory factor during the assay. Later experiments 
indicated that glass-adherent monocytes were the cells responsible for the 
majority of the migration-stimulating activity, and showed that tissue 
macrophages also produce the activity. All other cell types including 
PMNs, platelets and lymphocytes tested did not produce significant 
stimulatory activity.
1.2.3.) Effect of Hydrocortisone concentration
Significant migration was shown with supernatants from mixed 
m ononuclear leucocytes (MMLs) cultured with hydrocortisone 
concentrations of 0.1 pg and above. An optimal concentration of 10 
pg/ml was chosen for the majority of experiments, as the ethanol, in 
which the steroid was dissolved inhibited the activity at higher 
concentrations. It was also shown that the anti-inflammatory efficacy of a 
steroid directly related to its migratory stimulating capacity.
The stimulatory effect was shown with steroid at concentrations 
comparable to pharmacological levels in humans.
1.2.4.) Effect of MML concentration and culture duration
The stimulatory effect was not seen when MML concentration was below 
10^ cells/ml, and no significant increase in stimulatory activity was seen 
at MML concentrations above 2.5 x 10^ cells/ml. There was an increase
40
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in stimulatory activity over a 24-hour period, after which no significant 
increase was seen.
1.2.5.) Production of migration stimulating factor by other 
cell types
Other cell types cultured in the presence of steroid were PMNs, platelets, 
lymphocytes and tissue macrophage from the spleen. The only cell type 
tested that produced the steroid-induced migration stimulating activity 
were tissue macrophages.
1.2.6.) Dose-response of steroid-treated culture supernatants
There was a fairly rapid reduction in the migration stimulating activity, 
coming close to that of control supernatants at a 1:8 dilution.
1.2 .7 .) P hysical properties of the active factor from  
hydrocortisone-treated culture supernatants
The migration stimulating active molecule was soluble, destroyed at 
90^C, and with low and high pH. Size exclusion chromatography 
indicated that it co-eluted with Cytochrome C, molecular weight 12400 
Da. The production was inhibited by Cycloheximide, which indicated that 
protein synthesis was required, and the activity was destroyed by 
protease, further indicating the peptide nature of the active factor.
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1.2.8.) Conclusions reached by R.D. Stevenson
Stevenson postulated that this factor may be a second messenger of the 
anti-inflammatory effect of steroids, and because it was secreted by 
immune cells in response to glucocorticoids, may be a possible 
therapeutic agent for inflammatory disorders without the undesirable 
side-effects of steroids. The physical properties of the active molecule 
indicated that it was actively synthesised in response to steroid, and is a 
peptide of approximate molecular weight, 12 kDa.
Frank and Roth, 1986 also described a factor(s) present in the supernatant 
of bovine monocytes cultured in the presence of hydrocortisone that 
increased the random migration of bovine neutrophils under agarose. 
Production of this factor(s) was inhibited by inhibition of protein 
synthesis and was destroyed by proteolytic enzymes indicating that the 
factor(s) was protein/peptide in nature. These discoveries show 
similarities to the factor described by Stevenson above.
With the discovery of Lipocortin-1 by Flower and Blackwell, 1979, a 
steroid-induced protein with potential anti-inflammatory properties, 
shown to inhibit Phospholipase A2, Stevenson thought that this could be a 
candidate for the migratory stimulating factor he described previously. 
Chettibi et al. 1993 set out to see if the activity associated with PMS was 
due to LC-1 by using anti-LC-1 antibodies in the same capillary-tube 
migration assay performed by Stevenson. They found that the antibodies 
had no effect on the stimulatory activity of PMS. This led to a renewed 
attempt to characterise and purify the active factor(s) present in the 
steroid treated monocyte supernatant (STMS).
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1.3.) Automated cell tracking assay
The parameters being measured in the capiliary-tube migration assay 
were not clear, as the response could be attributed to increased 
stimulation of migration or decreased adhesiveness of the PMNs. Chettibi 
et ah, 1993 attempted to assay STMS in a way which could distinguish 
more clearly these two parameters. They performed an assay developed 
by Dow and Lackie, 1987 which measured the movement of individual 
neutrophils using a computerised tracking assay. Images from a phase 
contrast microscope with xlO magnification were digitised and analysed 
by a BBC microcomputer over a period of 10 minutes. This method 
(Chettibi et al, 1993) showed that in a uniform concentration PMS did 
indeed stimulate the motility of the PMNs, and when compared with 
fMLP showed that the PMS stimulated cells moved in relatively straight 
lines. They also showed that PMS reduced adhesion of PMNs to bovine 
serum albumin (BSA) coated coverslips when compared to control 
monocyte supernatants and culture medium with steroid. Anti-lL -8 
antibodies had no effect on the migration stimulation. PMNs from 
patients under steroid therapy were also more motile than cells from 
control patients. However, the parameters calculated in these assays, 
namely speed and persistence showed no differences between the two, 
despite a clear difference upon visual inspection of the tracks, so it was 
clear that the data processing in this assay was limited in discerning 
different types of cellular locomotion.
A new assay was developed which used a phase contrast microscope at 
x32 magnification. A video camera was attached to a Acorn A5000 
computer with digitiser, and a computer program was written by P. 
Lawrence to measure cell motility and provide accurate data for
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calculation of the parameters of locomotion described by Gail and Boone, 
(1970, 1972), namely speed, diffusion coefficient and persistence.
1.4.) Purification chromatography techniques
The techniques utilised in a purification protocol are very dependent on 
the characteristics of the molecule being dealt with, namely its size, 
charge and hydrophobicity. The material from which it is being purified 
is also crucial, be it biological tissue, bodily fluids, or culture 
supernatants. The initial stage of purification is determined by the volume 
of starting material, as most standard chromatography techniques can 
only deal with volumes up to lO's of ml, so a suitable concentration 
method must be found before starting the purification, in order to allow 
standard chromatography techniques to be utilised. All these things have 
to be considered before deciding on which techniques will be used in 
purification of the active molecule in the starting material.
The purification attempts of Dr. Chettibi indicated that the active 
molecule, present in the starting material, now known as steroid-treated 
monocyte supernatant (STMS), was in fact a relatively small molecule, 
around 1-2 kDa. The charge of the molecule was uncertain as it behaved 
inconsistently throughout various purification attempts, binding to 
MonoQ, an anion exchange support at pH 8 , early in the purification 
protocol, but apparently failing to repeat this at later stages. The 
hydrophobic nature of the molecule was also uncertain, as it appeared at 
early stages to bind partially to a phenyl sepharose column, with activity 
being found in both the bound and unbound eluates. However, the active 
molecule did seem to bind quite consistently to a reversed-phase Sephasil
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C8/C18 column. The activity was however, lost on a regular basis during 
purification, for unknown reasons.
The fact that the starting material was cell culture supernatant with very 
little serum protein present helped the purification, as it contained 
relatively small amounts of contaminants. The active molecule was 
apparently present in very small quantities, making it very important to 
reduce to a minimum the number of steps in the purification protocol, as 
each step usually gives around 75% or less yield, so the quantity of active 
material would be reduced to < 30% after 4 steps. Certain types of 
column were chosen to attempt purification of the active molecule in 
STMS. A Pharmacia Superdex 30 which has a separation range of up to 
10000 MW, was used to separate the active material from large proteins 
and eluted the activity just before the salt.
Due to the requirement to reduce losses of active material during the 
purification, it was important to be able to elute the activity from 
columns in as small a volume as possible, whilst maintaining good 
separation. The HPLC system that was employed was the Pharmacia 
SMART system, which had been specifically designed for micro 
purification. The columns that were available for the SMART system 
were of very small diameter and small bead size giving high quality 
separation and small elution sample size. The system has very small dead 
volumes, which reduces dilution and improves accuracy in the collection 
of samples, and was able to collect samples as small as 5pl. The high 
sensitivity of this system also allowed detection of peaks containing < Ing. 
Concentration of samples after chromatography techniques is often 
required if the activity is spread over several samples. This was achieved 
using a vacuum centrifuge (Warren Scientific), which allowed the 
concentrating of samples from 2-3 ml down to around 20 |il. This method 
of drying samples has the advantage of keeping the sample centrifuged to
45
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the bottom of the tube reducing loss when removing the sample. This is 
very useful when changing from an ion-exchange or reversed-phase 
column to a size exclusion chromatography column, where a the smaller 
the injected sample the better the separation tends to be.
1.5.) Characterisation and purification of the active factor in 
STMS
Stevenson, 1978 made a number of discoveries about the physical 
characteristics of the active molecule present in his culture supernatant 
He showed that the migration stimulating active molecule was soluble, 
destroyed at 9 0 ^0 , and at low and high pH. Size exclusion 
chromatography indicated showed that it co-eluted with Cytochrome C 
which has a molecular weight of 12400. The accuracy of this technique 
and conditions of running only gave a rough indication of the size of the 
molecule (Dr. Stevenson; personal communication). He also showed that 
the production was inhibited by cycloheximide, which implied that 
protein synthesis was required. The activity was also destroyed by 
protease.
These results indicated that the molecule was most likely peptide in 
nature, of size in the region of 3000 - 15000 MW. The quantity present in 
the supernatant was undetermined and the nature of the activity of the 
purified molecule was unknown, i.e. It was unclear if the activity was a 
single molecule, or if it maintained the same level of activity following 
purification.
46
Introduction
1.6.) Characterisation and purification of the active molecule 
in STMS by Dr. S. Chettibi
Dr. Chettibi attempted the purification of the active factor in STMS 
starting material. He approached the problem by trying various ways of 
concentrating the initial starting material to a volume which allowed ease 
of handling during further purification steps. Starting with a 300 ml 
batch of STMS for each purification attempt he utilised ultrafiltration 
techniques, with various molecular weight cut-off filters from Amicon 
and Millipore filtration systems. Unfortunately this technique seemed to 
produce an inconsistency in the activity, i.e. activity was found in the 
retained and eluted portions. The activity also came through the smallest 
available molecular weight cut-off filters of 500 Da. This was therefore 
not an appropriate concentration method.
He then tried using prep grade Bio-Rad Q, an anion exchange matrix. 
Unfortunately the activity would only bind under low salt conditions, and 
so required a ten-fold dilution. This meant that around 3 litres of liquid 
had to be pumped through the MonoQ column which took a considerable 
time. Bacterial/fungal contamination became a major problem. The 
activity eluted from the MonoQ column at around 150 mM sodium 
chloride when a 0-500 mM sodium chloride gradient was used. This 
produced the active factor in a volume of around 10 ml. Subsequent gel 
filtration on a Pharmacia Sephadex G30 showed that the activity eluted in 
the region just before the salt, with another active region associated with 
larger proteins. This indicated that there may have been two active 
factors present in the supernatant, one a large -60  kDa and another, 
perhaps a fragment of the larger of around 1 kDa. The smaller of these 
two molecules was the most active and interesting, and in consequence 
became the subject of further purification attempts.
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The active samples were then applied to a reversed-phase 
chromatography column. The eluted peaks were pooled into glass tubes 
and freeze-dried. They were then re dissolved in 1ml of water and 
assayed at 1/10 in Hank's HEPES v/v. This yielded an activity similar to 
that of starting material. When this sample was applied to Malditof 
(Matrix assisted laser desorption time of flight) mass spectroscopy (Prof. 
Rammage, Edinburgh), it showed a strong peak of mass 1328 (Fig 6). 
Sequencing attempts of this molecule were wholly unsuccessful, and it 
was inferred that if the 1328 molecule was a peptide, it must have a 
blocked N-terminal. Applying this sample to the Pharmacia peptide 
column showed however, that the main UV absorbing peak from the 
reversed-phase column was in fact running as a very small molecule, co­
eluting with the salt fractions at Vt (not shown), with minimal UV 
absorption at the elution point of a molecule of molecular weight, 1328.
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Fig. 6. Mass spectroscopy performed on an active sample from a 
reversed-phase chromatography column
Malditof (Matrix assisted laser desorption time of flight) mass spectroscopy 
(Prof. Rammage, Edinburgh), showing a strong peak of mass 1328.91 in the 
active sample from the reversed-phase chromatography column of Dr. 
Chettibi. The two higher mass peaks correspond to the sodium and potassium 
adducts of the native molecule.
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Materials and Methods
2.1.) M aterials
2.1.1) Interleukin-8 (IL-8) (Genzyme), dissolved in phosphate buffered 
saline (PBS) and stored in 50 [il aliquots at 20 qg/ml in -700c.
2.1.2.) Lysophosphatidic acid (1-oleoyl) (LPA) (Sigma, Chemical Co., 
Dorset ) was made up at concentration of 3.5 mg/ml in ethanol: 
chloroform (1:2 v:v).
2.1.3.) n-formyl-methionyl-leucyl-phenylalanine (fMLP) (Sigma) was 
made up as a 10"^ M stock solution in Dimethyl sulfoxide (DMSO), and 
stored in 100 pi aliquots at -20 ^C.
2.1.4.) Phorbol 12-myristate 13-acetate (PMA) (Sigma) made up at a 
concentration of 1 mg/ml in DMSO.
2.1.5.) 7 -dimethylamino-naph-thalene-1,2 -dicarbonic acid hydrazide 
(DNDH) (Boehringer) was made up at a concentration of 3 mg/ml in 
DMSO.
2.1.6.) Pertussis toxin from Bordetella pertussis (Sigma) was used after 
dilution in PBS, pH 7.4.
2.1.7.) TNFa (Genzyme), was dissolved in phosphate buffered saline 
(PBS), aliquoted into 100 pi samples, and stored at 1 pg per ml at 
-70 o c .
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2.2.) Buffered saline solutions
Several different buffered saline solutions were used throughout this 
study:
2.2.1.) Balanced Salt Solution (BSS)
A two-part mixture was made up to 1 L (at lOx strength)
1. lOg sucrose (Fisons scientific equipment, Loughborough, Poole, 
England)
0.6g Potassium dihydrogen orthophosphate (BDH chemicals, Poole, 
England).
3.58g disodium hydrogen orthophosphate (BDH).
2. 1.86g Calcium chloride (Fisons).
4g Potassium chloride (Fisons).
80 g Sodium chloride (Fisher scientific, UK).
2g Magnesium chloride.6H2O (BDH).
2g Magnesium sulphate (BDH).
Parts were mixed 1:1 (v:v) and made up to Ix concentration by adding 
water.
2.2.2.) Phosphate Buffered Saline (PBS)
8g Sodium Chloride,
0.2g Potassium Chloride,
1.15g Disodium Hydrogen Orthophosphate and
0.2g Potassium Dihydrogen Orthophosphate were dissolved in water, and 
made up to IL before sterile filtering into aliquots.
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2.2.3.) HEPES Water (HO)
5.25g HEPES (Sigma) was dissolved in water, the pH adjusted to 7.4 
using IM HCl, made up to 1 Litre, and dispensed into aliquots before 
autoclaving and storing at 4 ^C.
2.2.4.) HEPES Saline (HS)
2.38g HEPES,
Ig Glucose (BDH),
8g Sodium Chloride and
0.4g Potassium Chloride were dissolved in water, the pH adjusted to 7.4 
using 1 M Hydrochloric acid (HCl) (Prolabo), made up to 1 Litre with 
water, and sterile filtered into aliquots before storing at 4^C.
2.2.5.) Hank s HEPES (HH)
As HS but containing ImM Calcium Chloride and Magnesium Chloride.
2.3.) Antibiotics
A solution of L-Glutamine (29.2 g/L) was made up in water, and sterile 
filtered. A solution of Streptomycin Sulphate (76.2 mg/L) was also made 
up in water. 150 ml (200 mM) Glutamine solution, 100 ml Streptomycin 
Sulphate and 12.5 ml Amphoterisin B were mixed, aliquoted asceptically 
and kept frozen until use.
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2.4.) Ham's F 10 culture medium
20 ml of lOx strength Ham's F-10 culture medium (GIBCO) was added to 
180 ml of HEPES water. 1 ml of 7.5% bicarbonate solution (w/v) was 
added. If serum was required then 20 ml of foetal calf serum was added.
2.5.) Dexamethasone preparation
Dexamethasone (Sigma) was freshly made up at a concentration of 10-2 
M in ethanol and added to the monocyte culture medium at a final 
concentration of 10-6 M dexamethasone and 0.001% ethanol. The control 
culture medium also contained the same concentration of ethanol.
2.6.) Cell preparation and culture
2.6.1.) Preparation of human Neutrophils
Human neutrophils were purified by a modification of the method of 
Haslett et a l ( 1985 ). Whole blood from healthy volunteers was mixed in 
a ratio of 1:10 (v:v) with 5% Dextran MW 500,000 (Sigma) and left at 
370C for erythrocyte sedimentation to occur. The leucocyte-rich huffy 
coat layer was then aspirated and layered over a nyco-prep gradient 
density, Nycoprep 1.077 (Nycomed), and centrifuged at 800 ref for 15 
minutes at room temperature. The resulting pellet consisted of 
polymorphonuclear leucocytes and some contaminating erythrocytes. The 
remaining erythrocytes were removed by hypotonic lysis in distilled 
water for around 20 seconds, and the purified polymorphonuclear 
leucocytes were washed three times (1500 r.p.m. for 5 minutes at room 
temperature) in HH and re suspended in the same buffer at a
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concentration of 106 cells ml"l (Fig. 7). Cells prepared by this method 
were > 9 5 %  neutrophils. Viability was tested by trypan blue exclusion 
and was found to be 98-99%.
2.6.2.) Isolation of human monocytes
Two sources of human monocytes were used.
2.6.2.1) Isolation and culture of human monocytes from whole 
blood
Units of whole blood received from the Royal infirmary in acid-citrate 
dextrose anti-coagulant were mixed 1:10 with 5% dextran of average 
molecular weight, 500,000 in HS for 1 hour which allowed most 
erythrocytes to sediment. The leucocyte-rich plasma was then aspirated 
and layered over Nycoprep (Nycomed) 1.077, centrifuged 800 ref for 20 
minutes at room temperature. The mononuclear leucocyte layer was then 
aspirated. These cells were then washed twice with HEPES saline (300g 4 
min ), which removed most of the contaminating platelets (Fig. 7). They 
were then cultured in HEPES buffered Ham's FIO with 10% Foetal calf 
serum (FS) and antibiotics, for 1 hour, washed twice with HEPES saline 
warmed to 37^0, then cultured for 24 hours in serum-free Hams FIO 
with and without 10“6m  dexamethasone. The conditioned culture medium 
was then centrifuged at 3660 rpm for 20 minutes at room temperature 
and sterile-filtered through a 0.22 pm filter (Millipore). This was the 
starting material for purification.
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2 .6 .2 .2 ) Isolation of human monocytes from leucocyte-rich  
huffy coats
Leucocyte-rich huffy coats were supplied by the Blood transfusion 
service. This was layered over a Nyco-prep gradient density in a 50:50 
ratio (v/v), and centrifuged at 800g for 20 minutes at room temperature. 
The mononuclear leucocyte layer was then aspirated and treated as 
monocytes cultured from whole blood.
Fig. 7
Purification of PMN's / Monocytes from human blood
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2.6.3.) Techniques, solutions and culture medium used in the 
preparation of Bovine aorta endothelial cells:
2.6.3.1.) Saline solution
150 mM Sodium chloride containing antibiotics.
2.6.3.2.) Collagenase solution
150 ml Dulbecco’s modified eagles medium (DMEM) with sodium 
pyruvate, 1.25 mg/ml collagenase.
2.6.3 3.) Bovine endothelial cell culture medium
DMEM with sodium pyruvate containing antibiotics, 10% Foetal calf 
serum and 10% Horse serum.
2.6 3.4.) Trypsin / Versene
Versene was made up essentially as for HS except that EDTA (Sigma) was 
added at a concentration of 0.2g/L before adjusting the pH to 7.5. The 
versene was then dispensed into 20 ml aliquots prior to autoclaving and 
storage at 4^C. Immediately before use.
Immediately before use 0.5 ml of sterile 2.5% solution of trypsin 
(GIBCO) was added to the versene and mixed.
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2.6.3.5.) Preparation of Bovine endothelial cell monolayer
Aortas collected from the local abattoir were flushed through thoroughly 
with saline solution to remove any blood from inside and most of the 
outer fat was cut off. The large end of the artery was then tied off and 
saline solution was injected before returning to the laboratory. The 
remaining fat was then carefully cut away from the outer vessel wall and 
the intercostal arteries were tied off with thread. 20 ml of collagenase 
solution was injected and the artery wrapped in cling-film and incubated 
at 37 oC for 15 mins. After incubation, the aorta was massaged gently to 
displace endothelial cells from the inner wall and the solution containing 
the cells was collected. The cells were washed twice with culture medium 
centrifuging at 300g, 5 oC for 6 minutes. The washed cells were re 
suspended in 20 ml of cell culture medium and grown in 50 cm2 flasks at 
37 oC in a humidified, 5% CO2 to 95% air atmosphere.
2.6.3.6.) Passaging of Endothelial Cell Cultures
When the cultured endothelial cells reached confluency they were 
passaged and recultured to maintain their growth. The culture medium 
was poured off and the cell monolayer washed twice with HS to remove 
all serum from the flask. 3 ml of Versene/trypsin solution was added to 
the culture and incubated for 1 minute at 37 ^C. The versene/trypsin 
solution was then poured off and the cells were left at 37 for 5 
minutes, or until they detached. 5 ml of culture medium containing serum 
was added, and suspension triturated to remove any cells still attached. 
Cells were washed twice, by spinning at 600 g. for 5 minutes at 4 ^C. 
Cells were counted in a haemocytometer and recultured in 50 cm2 culture 
flasks with 5 million cells in 20 ml of culture medium at 37 ^C in
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humidified 5% CO2 to 95% air atmosphere. These flasks gained 
confluency in approximately 5 days. Cells which were not required 
immediately were stored for later use by cryopreservation.
2.6.3.7.) Cryopreservation of endothelial cells
Growth medium was removed, and the cells washed twice with HEPES 
saline. 3ml of Versene/trypsin solution was added to the culture and 
incubated for 1 minute at 37 ®C. Excess trypsin/versene was poured off, 
and cells left for 5 minutes, or until detached. 5 ml of culture medium 
containing serum was added, and suspension triturated to remove any 
cells still attached. Cells were washed twice by centrifuging at 1500 rpm 
for 5 mins. After the second spin the cells were re suspended in 10% 
DMSO, at concentration of around 5 million/ml, and aliquoted into sterile 
cryotubes. Cells were stored at -70 *^ C.
2.6.3.8.) Recovering cryopreserved cells
To recover cryopreserved cells, the cryotube was defrosted in a 37 ^C 
water bath. The cell suspension was then added to 10 ml of DMEM 
culture medium, washed by centrifugation at 1500 rpm for 5 minutes, 
and re suspended in fresh culture medium. Cells were cultured in a 
humidified 5% CO2 (BOC) 95% air atmosphere.
2.6.4.) Trypan blue exclusion
The viability of prepared leukocytes was assayed using Trypan blue 
exclusion. Cells were diluted 1:10 in 0.05% trypan blue and the
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percentage of viable cells was determined by counting the number of cells
excluding the dye, in a haemocytometer. |
. i
2.7.) Neutrophil automated cell tracking assay
2.7.1.) Preparation of migration chambers
.s?;:
A stainless steel slide 75 x 35 x 1 mm with a 18 mm diameter circular 
aperture was heated under flame and a 22 x 22 mm square glass coverslip 
was fixed over the aperture using hot paraffin wax. The chamber was 
then turned over, and the glass surface was coated in Bovine serum 
albumin ( BSA ) by adding 0.5 ml of 0.5% BSA in water (w/v) for 20 
minutes. The coverslip was then washed once with HH and 0.2 ml of 
neutrophil cell suspension at 106 cells/ml was added and left for 10-15
I
minutes, for the neutrophils to adhere. The non-adherent cells were
removed by washing the well with HH, and 0.3 ml of the treatment of 
interest was added to the chamber. A second coverslip was then placed 
over the chamber, and the edges sealed by brushing over with hot 
paraffin wax (Fig. 8).
I"1:
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Fig. 8. Schematic diagram of tracking assay migration chamber
/
2,7.2.) Modified tracking assay
Migration chambers were placed on the stage of an inverted microscope 
within a temperature controlled (37 ^C) transparent box, and locomotion 
observed using a x32 objective optic, by means of a video camera 
connected to a monochrome monitor and an Archimedes A5000 computer 
with a Watford video digitiser, programmed to capture and analyse one 
frame every 5 seconds.
2.7.2.1) Automated cell tracking
The tracking program selected up to 80 cells, in rank order of their 
distance from the screen centre. Selection was based on finding an island 
greater than a threshold area, composed of pixels above threshold 
brightness. The program display was designed to reveal the tracking 
status of each target cell; firstly, the cells were displayed in 16 grey 
shades, each active target cell was outlined in red and the line joining its 
centre to the previous recorded position was plotted. The cells were then 
unplotted, leaving the outlines of the target cells, which were then 
unplotted to leave only the cell tracks. For each frame the computer
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stored the x and y co-ordinates of the centres, the perimeter length and 
the enclosed area of the target cells.
A program running at the required speed was written in C and was 
readily subject to modification and refinement of data processing. Target 
cell searches were carried out synchronously by advancing one pixel for 
each cell, thus giving priority detection to cells that had moved the 
shortest distance, rather than an asynchronous search where each search 
box was completed in turn, thus giving priority detection to cells in rank 
order (P.D. Lawrence, unpublished work). Visual inspection of both 
processes showed that the tendency to assign cells incorrectly increased 
much more rapidly with search-box size for asynchronous than for 
synchronous searches. This clearly reflects the fact that the cells that can 
be assigned with greatest certainty are those that have moved the shortest 
distance. Numerical simulation can be used to confirm the supposition 
that by assigning targets in order of distance moved, the synchronous 
search minimises wrong assignment of the least certain target cells.
2 .7 .2 .2 .) Target cell loss
Target cells were lost to the tracking assay for a variety of reasons. For 
highly motile cells, these include, moving beyond the search box, 
touching the screen edge and touching another cell. In addition some 
stimuli activate a reversible spreading process that causes large parts of 
the cell to become phase-dark, resulting in target loss. Such cells are not 
recovered as targets when they re-brighten. In principle, each of these 
mechanisms should apply to different extents with the different stimuli, 
but analysis of a large body of data did not reveal any significant 
correlation between the rate of target cell loss and either the speed or
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dispersion rates. Neither did the stimuli that appeared to be most active in 
terms of cell shape-change induction give significantly enhanced loss 
rates.
2.8.) Chemotaxis assay
Chemotaxis assays were performed in a modified Boy den chamber. This 
consisted of the cut-off barrel of a 1 ml syringe with a 3 pm pore filter 
glued to the bottom of this upper chamber. 200 pi of the upper chamber 
assay solution (antagonist) containing 1 x 106 /ml of human neutrophils, 
was placed in the upper chamber. This chamber was then placed into the 
lower chamber, which consisted of a 5 ml glass beaker with 4.2 ml of 
agonist (Fig. 9). These were then incubated for 90 minutes at 37 oC. The 
cells were then fixed in 70% ethanol for five minutes. This treatment also 
dissolved the glue allowing the filters to be removed by a fine set of 
forceps. The filters were then washed in distilled water for 3 minutes, 
then the cells were stained using Harris haemotoxylin for 5 minutes. The 
colour was then developed, following a further wash in distilled water for 
3 minutes, using Scott's tap water (equal volumes of 0.7% sodium 
bicarbonate (w/v) (Sigma) and 4% Magnesium sulphate (w/v) ) for 5 
minutes. The filters were then dehydrated by placing in an increasing 
concentration of ethanol 70%, then 95% and finally in 80% ethanol: 20 
butan-l-ol for three minutes each. The filters were made transparent by 
placing them in 100% xylene for 5 minutes, then mounted in Depex on a 
glass slide. The slides were then left on the bench to dry before the 
chemotaxis could be measured.
Measurement of chemotaxis: Analysis of neutrophil chemotaxis was 
performed on an inverted microscope. Two methods were employed for 
this analysis; the measurement of the leading front, and the number of
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cells that had moved half the leading front distance of the positive 
control. The leading front method of analysis measured the distance that 
the two furthest cells had moved into the filter. This was done by 
focusing on the cells sitting on top of the filter and noting the micrometer 
reading on the focus. The microscope was then focused into the filter 
until the last two cells came into focus, and the reading on the micrometer 
was noted. The difference in these two readings gave the leading front 
distance. Five readings were taken for each filter in randomly chosen 
fields, and there were three repeats of each assay. Whilst performing this 
analysis it was noticed that under certain conditions a very small number 
of cells were moving far into the filters and giving an apparently positive 
result i.e. in the positive control many cells moved into the filter but this 
type of analysis only showed a relatively small difference. In order to 
compensate for this, a second method of analysis was employed. The 
distance of the leading front in the positive control was measured and the 
number of cells that had moved half that distance was counted for each of 
the treatments. Again, five randomly chosen fields were analysed for each 
filter. This analysis gave a much more representative result, confirming 
in the data, the obvious differences between the treatments observed 
under the microscope.
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Fig. 10
Chemotaxis modified Bovden chamber
1 ITÜ sy rin ^  barrel
antagonist3|im pore filter 
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2.9.) Chemiluminescent measurement of neutrophil respiratory 
burst
Metabolic activation of neutrophils was assayed by 7-dimethylamino- 
n ap th a len e-1,2-dicarbonic acid hydrazide (D N D H )-enhanced 
chemiluminescence using an LKB 1251 Luminescence Photometer 
(Luminometry; LKB Wallac Oy, Turku, Finland). Neutrophils in HH, at 
a final concentration of 1x10^ cells/mb were stimulated by either fMLP 
or PMA at concentrations of IxlO"^ M, and 10 ng - 1 pg/ml, 
respectively. Data was collected continuously using an Acorn Archimedes 
microcomputer, with software written in C (Appendix II), which 
displayed the results in the form of a line graph, and calculated the area 
under the graph for each assay sample.
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2.10.) Neutrophil adhesion assay
Bovine aorta endothelial cells were cultured on 13 mm diameter glass 
coverslips in a multi-well dish in DMEM with 10% foetal calf and 10% 
horse serum and grown to confluence. Human neutrophils suspended in 
0.1% bovine serum albumin (BSA) in HH (w/v) were labelled with by 
incubating them at 1 x 10^ cells/ml for 1 hour with 20 pCi/ml (51Cr) 
sodium chromate. Free 51Cr was removed by three washes with HH 0.1% 
BSA. 200 |al of neutrophils were mixed with 800 \xl of test substance, 
added to the wells and incubated for 30 minutes at 37 ^ c . Non-adherent 
cells were washed three times with HH 0.1% BSA, and coverslips were 
placed in a Wilj gamma counter. There were three repeats for each 
experiment.
2.11.) Analysis of F-actin content of neutrophils
Purified neutrophils were placed on albumin coated glass coverslips, 
washed to remove non-adherent cells then treated with various stimuli for 
30 minutes at 37 oC. The cells were then fixed using 1% 
paraformaldehyde in serum-free Ham's F-10, for a further 30 minutes, 
and permeabilised with 1% Triton X-100 for 15 minutes at room 
temperature. Cells were gently washed three times with HH and treated 
with 0.1 jig/ml TRITC-labelled phalloidin (Sigma) for 20 minutes at 
room temperature. Cells were washed three times with HH, being left for 
5 mins between washes to allow the unbound phalloidin to diffuse from 
the cells, then the coverslips were mounted onto glass slides in 50% 
glycerol in water (v/v). Results were analysed using an Odyssey confocal 
microscope.
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2.12.) Purification techniques
2.12.1.) Concentration of starting material
Two techniques were used to concentrate the starting material to more 
convenient volumes
2.12.1 .1 .) F reeze drying
Prior to initial purification steps around 600 ml of starting material was 
freeze-dried in an Edward's high vacuum limited speedi-vac ED 150 100 
ml, to a volume of around 20ml. This solution was then centrifuged at 
3660 rpm for 20 minutes to remove denatured protein and precipitated 
salts, before being filter sterilised through a 0.22 jLim filter.
2.12 .1 .2 .) Force Dialysis
The staring material was force dialysed against air, using Visking dialysis 
tubing, size 1; Diameter 8/32"-6.3 mm with molecular weight cut-off of 
12-14000 Da (MEDICELL International Ltd., London). To facilitate 
dialysis of large volumes 2 metres of Visking tubing was used and a glass 
reservoir was topped up at regular intervals (Fig 10).
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Fig. 10. Schematic diagram of vacuum dialysis apparatus
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2.12.2.) Chromatography Techniques
2.12.2.1.) FPLC chromatography
A Pharmacia XK50/.500 column was filled with swollen Bio-gel P2 size 
exclusion chromatography gel matrix (Bio-Rad), and 150 mM sodium 
chloride was used as running buffer. This was run at a flow rate of 1.5 
ml/min. Approximately 40 ml samples were loaded at a time, by 
replacing the buffer supply tube into the sample. A Bio-rad Econo system 
was used for these analyses, detection was at 254 nm and the output was 
on a Bio-rad pen-recorder. Samples were run in 150mM Sodium chloride 
to prevent ionic interactions between molecules in the sample and the gel 
matrix.
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2.12.2.2) SMART System
HPLC purification was performed on the Pharmacia SMART system, 
using mainly Pharmacia chromatography media and columns. The 
SMART HPLC system is used for micro-purification, giving good sample 
recovery efficiency, due to its small void volume (17 |il). It is controlled 
using SMART system software, running on a Compaq Deskpro 
microcomputer with OS2AVarp operating system. Methods for separation 
can be programmed through software control and data collected 
continuously, displayed on-screen and stored for further analysis. Data 
analysis is possible by peak integration, giving areas under elution peaks, 
thus allowing comparison of different separations, and quantitation of 
peaks by comparison to standards.
Absorbance was measured at 214 nm during all chromatography on the 
SMART HPLC system for this study. A 1 mg/ml concentration of a 
standard protein e.g. BSA, gives an absorbance of 1.0 AU, at 280 nm and 
1.0 AUFS. At 214 nm the level of absorbence of proteins is around 15 x 
that of 280 nm absorbence. This wavelength was chosen because of the 
increased sensitivity given, and our lack of knowledge about the molecule 
that we were attempting to purify. If it was peptide in nature, then to 
provide adequate absorbence to allow detection at 280 nm, it would have 
to contain a number of amino acids that absorb well at 280 nm; 
tryptophan and tyrosine.
All reagents used were either of Analytical or HPLC quality.
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2.12.2.2.1) Superdex peptide
Superdex peptide HR 10/30 consists of a composite of cross-linked 
agarose and dextran with bead diameter of 13-15 p.m. It has an exclusion 
limit of 20 kDa, with optimal separation in the range of 0.1 - 7 kDa. The 
bed volume is 24 ml, with a maximum flow rate of 1.2ml/min, pressure 
limit of 1.5 MPa, and pH stability of 1-14.
Injected samples were between 20-250 pi, and flow rates used were 
500 pl/min. Calibration showed that Vo was approximately 10ml and Vt, 
20ml. Fractions of 500 pi were collected from Vo-Vt.
Running buffer consisted of either 1-10 mM Hydrochloric acid in 20% 
(v/v) Acetonitrile (Fisher scientific), or 0.1% (v/v) Trifluoroacetic acid 
(TEA) (Sigma) in 20% acetonitrile. The acidic conditions were to prevent 
ionic interactions between molecules in the samples and the gel matrix. 
Fluates were collected at 500 pl/sample in 0.6 ml eppendorf tubes, and 
stored at -20 °C.
2.12.2.2.2) Ion-Exchange chromatography
Pharmacia Mono Q HR 5/5 is a strong anion exchanger, with a 
composition of hydrophilic resin with charge group -CH2-N+(CH3)3. It 
has pH stability in the range 2-12. A 20mM Tris.Cl buffer was used, and 
samples eluted with a 0-500 mM Sodium chloride gradient, over 15 
minutes.
Buffers: A. 20mM Tris.Cl pH 8.1
B. 20mM Tris.Cl 500 mM NaCl pH 8.15
The differences in pH of the two buffers was to was to correct for UV
absorbence differences between the low and high salt solutions, thus
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providing a level baseline during gradient formation. Eluates were 
collected at 500 pl/sample in 0.6 ml eppendorf tubes, and stored at -20^>C.
2.12.2.2.3.) Reversed-phase chromatography
A Pharmacia Sephasil CIS 4 x 250 mm reversed-phase column was used 
for high performance separation of samples. This is composed of a Silica 
base matrix, with a particle size of 5m, and pore size of 100-200 A. It 
has temperature stability in the range 4-75 >^C, pH stability 2-10, a 
pressure limit of 35 MPa/3500 psi, with recommended pressure ceiling 
for use, and recommended flow rate between 0.5-1.0 ml/min. A 0.1% 
TEA buffer was used, and samples eluted with a 0 - 50% Acetonitrile 
gradient, over 30 minutes. Eluates were collected at 100-250 pl/sample 
in 0.6 ml eppendorf tubes, and stored at -20 ^C.
Buffer A.0.14% TEA (v/v)
B. 0.12% TEA (v/v) 50% acetonitrile (v/v).
The difference in the TEA concentration of buffers corrected any 
differences in the UV absorbence of the two solvents, thus providing a 
level baseline during gradient formation.
2.12.2.3.) Purification of Thymosin |34 from Human Blood  
Buff y coats
Thymosin was purified using the technique of Hannappel and van 
Kampen, 1987.
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Purified human neutrophils from one huffy coat were re suspended in 5 
ml of 0.4% (v/v) Perchloric acid (Sigma), sonicated for 1 min, and 
placed on ice for 30 minutes. The precipitated proteins and cell debris 
were removed by centrifuging at 3660 rpm for 30 mins, at room 
temperature. The perchloric acid was removed by titration with 0.4 M 
Potassium hydroxide (BDH), the reaction being monitored by a pH meter. 
The sample was placed on ice for a further 30 minutes, before the 
insoluble potassium perchlorate was removed by centrifugation at 3660 
rpm for 20 mins. The sample was then prepared for reversed-phase 
HPLC analysis by lowering the pH to 3, using IM Hydrochloric acid, and 
filtered through a 0.22 pm filter.
2.13.) Oxidation of Methionine residue of Thymosin 84
The Thymosin 84 sample purified from neutrophils from a huffy coat, 
section 2.12.2.3., was divided into two equal parts, and both dried using a 
vacuum centrifuge, to approximately 20 pi. The sample to be oxidised 
using the technique of Dr. Pappin, (ICRF, London, personal 
communication), was mixed with an equal volume of Hydrogen peroxide 
(100 volumes) (Sigma), and left for 5 minutes at room temperature. This 
sample, and the unoxidised sample, were then made up to 1 ml in 0.14% 
TFA (Buffer A) and applied to the reversed-phase chromatography 
column for separation of oxidised and non-oxidised thymosin 84.
2.14.) Statistical analysis
Student's ^-test was used to carry out statistical analysis of results.
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3.1.) Development of the automated cell tracking assay data 
analysis
Chettibi et al., (1993) using the tracking assay method developed by Dow 
et al., (1987) showed that the supernatant from monocytes incubated in 
the presence of dexamethasone stimulated the locomotion of human 
neutrophils on albumin-coated glass. In contrast, supernatants from 
untreated monocytes contained factors which possessed the properties of 
known cytokines such as IL-8, which increased neutrophil adhesion and 
spreading, but also potentiated motility (Bignold et al., 1992; Kupper et 
al., 1992). Although the tracks of STMS-treated neutrophils were 
typically extended in comparison with IL-8 controls, of the three assay 
parameters described by Gail and Boone (1970, 1972) in their classic 
analysis of persistent random locomotion, namely speed, persistence and 
augmented diffusion, only speed was significantly enhanced by the STMS 
factor. This suggested a deficiency in the computation which failed to 
demonstrate the dispersive character of locomotion. It was therefore 
undertaken to extensively modify the existing cell tracking assay to 
investigate the contribution of speed and persistence to the dispersive 
character of STMS-induced motion and to obtain qualitative and 
quantitative data to characterise and assay the unknown factor.
3.1.1.) Modified cell tracking program
A modified cell tracking program was written in C by P.D. Lawrence 
and is as described in section 2.7.2.
This program produced files saved at the end of a tracking run that 
consisted of data containing the following information about the cells per
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five second interval: the number of pixels moved by each cell, the area of 
each cell, and the number of cells being measured.
In order to process this data to provide measurements of speed, diffusion 
coefficient, and persistence for the cell population being measured, a 
procedure was written in C language, and incorporated into the cell 
tracking program (Appendix I).
This procedure took the distance travelled by each cell in a five second 
interval, in pixels and converted it into distance in \im. This was done by 
calibrating the number of pixels on the screen to a micrometer on the 
microscope. This allowed calculation of the number of pixels per micron, 
and hence, the number of microns travelled by each cell per measured 
interval.
Plots were then made of mean displacement vs. time, and mean 
displacement squared vs. time. In order to extrapolate the gradient of the 
linear part of the displacement squared vs. time plot and the intersection 
of the line drawn at this point with the time axis a procedure was written 
that allowed the user, using the mouse control, to point on the computer 
screen to the start of this line and draw a line. The gradient of the line 
was calculated and the point of crossing the time axis displayed. This 
provided a convenient way of extrapolating from the plots the diffusion 
coefficient (gradient) and persistence (the intersection with the x-axis) ( 
Fig. 11).
3.1.2.) Speed
The displacement of randomly moving objects determined by the least 
squares approximation in a measured time interval gives an apparent 
speed that approaches the true speed as the measuring interval decreases.
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Fig. 11. Diagram of theoretical cell motility parameters as decribed by Gail 
and Boone, 1970, 1972.
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Slope of the linear portion gives the diffusion coefficient and the point at 
which the extrapolation of this line cuts the time axis has been identified as 
the persistence of locomotion
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However the use of short time intervals reduces the signal to noise ratio 
and a compromise must be sought. In the present case a 5-second time 
interval was chosen because it allowed the assay progress to be assessed 
by eye. It was clear however that the use of a 5-second interval gave 
considerably higher cell speeds than did a 10-second interval (result not 
shown), hence even the 5-second interval must underestimate the true 
speed. Nevertheless for the results displayed in table 1, the average 
distance covered in 5 seconds was very similar for each of the stimuli 
used. Speed was not therefore a sensitive parameter for distinguishing 
different stimuli or for analysing the concentration dependence of a single 
stimulus. It was also of interest that control cells, which were clearly non- 
motile, returned significant speed values as shown in table 1. This 
apparent speed of non-motile cells could be explained by pixel jitter, 
altering the apparent centre of the cells, and convection currents in the 
chambers as the temperature equilibrates.
The average speed over the complete measurement time was expressed in 
pm/min, and used as an indicator of cell motor activation.
3.1.3.) Drift
The non-random component of movement of the whole cell population 
should be zero in the absence of a chemotactic gradient, but for small 
sample sizes where short-term displacement cannot be symmetrical, or 
for fields where other conditions are non-uniform, a component of non- 
random locomotion, called here drift, is always present. Where a non- 
random trend persists over long time periods it could, in principle, mask 
the effects of random or pseudo-random locomotion. Non-random 
movement was calculated by determining the centre of cell density by
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carrying out a vectorial sum of the X and Y displacements of each cell 
centre to determine the average population displacement. This was used to 
calculate drift per frame and thereby the component of speed that could 
be attributed to drift alone. However because target cell loss can reduce 
cell numbers to the point where lack of symmetry produces spurious 
drift, the programme was constructed to display the results corrected for 
the non-random component of locomotion, but also displaying the non­
corrected locomotion. Although there was considerable drift per frame, 
the long-term drift of control cells was negligible. This suggested that the 
short-term effects were self-cancelling and time-lapse video playback 
showed a very clear gyratory locomotion that might underlie such a 
short-term drift phenomenon. When the speed of control cells was 
corrected for drift per frame, it was reduced to more apparently realistic 
levels (table 1). Of the various locomotor stimulants tested, STMS tended 
to give rise to large drift components, although these were variable in 
magnitude. Many of the responses to CMS and IL-8 also appeared to 
contain a large drift component, but this always occurred when the 
number of active target cells fell below around 20. These stimulants 
tended to induce reversible phase-darkening with consequent target-cell 
loss and the apparent drift could be attributed to lack of population 
symmetry which is an inevitable consequence of small sample size.
In order to monitor the drift component of the displacement a procedure 
was written that calculated the average drift of the cell population, and 
direction of drift over the measured time. This allowed the user to note 
any consistency in the direction of drift, perhaps indicating a slope of the 
slide, or microscope stage.
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3.1.4.) Cell displacement
As the first step in calculating diffusion parameters, the mean 
accumulated displacement of cells from their original centres was plotted 
as a function of time, both with drift included and subtracted. The plots 
vary from moderately linear for STMS to parabolic for fMLP (fig. 12). 
A linear plot would indicate that the cells were maintaining their initial 
direction of motion throughout the measuring period. The parabolic 
curve indicates that the cells are changing direction frequently 
throughout.
3.1.5.) Cell-track display
In order to display the dispersive character of neutrophil cell populations 
being assayed, a normalisation procedure was adopted in which the 
starting co-ordinates of each target cell were translated to the origin of an 
x-y plot at the screen centre, and the movement of each individual cell 
represented by a line connecting its centre position at each interval. 
Comparison of the linear tracks produced showed greater elongation 
when stimulated by STMS than by CMS or control culture medium in the 
presence or absence of 10"^M dexamethasone (CM) (Chettibi et ah, 
1993). This method, applied to compare tracks obtained in response to 
CM, STMS, CMS, fMLP, IL-8 and LPA clearly demonstrated that the 
dispersive power of STMS greatly exceeded that of all the other agents 
tested (Fig. 13). The surprising result produced with LPA led to 
investigation of the action of LPA on other neutrophil functions (section
3.12.)
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Fig. 12. Plots of the mean accumulated displacement of 
neutrophils in response to various stimuli.
Adhérant human neutrophils were treated with 400 pi of: (a) Steroid-treated 
monocyte supernatant (STMS); (b) Control monocyte supernatant (CMS); (c) 
tO"8 M n-/ormy/-methionyl-leucyl-phenylalanine (fMLP); (d) 100 ng ml“l 
interleukin-8 (IL-8); (e) 20 pM lysophosphatidic acid (LPA); and (f) Ham's F- 
10 culture medium (CM).
Uncorrected displacement (#  ), drift-corrected displacement (□ ).
î
a
I
g
i
&
Q
15 -
10 —
oo o oo
Time (sec)
2 0 - 1
15 -
oo oo o
Time (sec)
I
î
;
II
a
20-1
15 -
1 0 '
5 -
Time (sec)
2 0 -1
I
1 0 -
■q
o oo oo
Time (sec)
Ii
&
(3
f
It(3
20
15
10
5 -
oo
Time (sec)
20
15
10
5
0
oo oooo o>n
Time (sec)
I
?
f:
Fig. 13. Comparison of tracks obtained in response to various 
neutrophil stimuli.
The starting position of each cell was normalised to the origin of the axes. 
The circle at the origin represents a cell of 10pm diameter. Tracks were 
obtained over an assay time of approximately two minutes. Adherent 
neutrophils were treated with approximately 400 pi of (a), steroid-treated 
monocyte supernatant (STMS) (b). control monocyte supernatant (CMS), (c). 
10-8 M formyl-methyonyl-leucyl-phenyalanine (fMLP). (d). 100 ng/ml 
interleukin 8 (IL-8). (e). 20 pM lysophosphatidic acid (LPA). and serum-free 
Ham's F-10 culture medium (CM).
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3.1.6.) Augmented diffusion
Analysis of cell dispersion by the random walk method as described by 
Gail and Boone (1970, 1972) was based on the plot of the square of 
displacement as a function of time which, for convenience, is called here 
a "diffusion plot". Theoretical models predict a linear diffusion plot for a 
true random walk and a biphasic plot for persistent random locomotion in 
which an initial rising curve becomes linear. In both cases the slope of the 
linear portion gives the diffusion coefficient and the point at which the 
extrapolation of this line cuts the time axis has been identified as the 
persistence of locomotion. They also showed that persistence increases the 
rate of population dispersion and augments the diffusion coefficient by 
the factor (1+p) where p is the persistence time. Their treatment only 
considered the limiting cases where p = 0 or p < t, where t is the elapsed 
time, but they showed that extrapolation of the linear portion of the 
diffusion plot to the time axis gives the persistence time. Thus for random 
locomotion the diffusion coefficient D = S^, where S is the instantaneous 
speed of locomotion. For persistent random locomotion the augmented 
diffusion coefficient (1+p) where p < t.
Figure 14 demonstrates that only STMS-treated cells showed a non-linear 
plot of this type which could be interpreted as persistent random 
locomotion. After STMS, the next most potent dispersing agent lL -8 
showed the characteristics of an agent that stimulated non- persistent 
random locomotion. In contrast, movement stimulated by fMLP showed 
the unexpected quality of constrained diffusion where the diffusion plot 
falls below the extrapolated initial linear portion. This indicates that the 
cells can make large initial excursions from their original positions but 
are tethered by means of strong adhesions and have a low probability of 
productive locomotion. Because drift is, in principle, time-independent
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STMS is obtained as a culture supernatant based on Ham's F-10 medium
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and therefore cumulative, it is quite clear that a high drift component will
give rise to a hyperbolic diffusion plot. For this reason all of the
.diffusion curves were plotted both with drift present and with drift 
removed. The results demonstrate that high drift makes a major 
contribution to the apparent persistence and illustrate that careful analysis 
of the drift component is a prerequisite for interpreting tracking data in 
terms of persistent random locomotion. Nevertheless it is clear that drift 
is not the major contributor to persistence in the majority of STMS assays 
(Fig. 14).
3.2.) Assays for STMS activity
which itself has a stimulatory effect on neutrophil migration speed and a 
minor effect on diffusion coefficients. For this reason all of the 
comparisons given in this study are of locomotor stimulants also Jpresented in Ham's F-10 medium. Table 1 shows the migration 
parameters for the various stimulators. The results illustrated that the 
tracking assays can be used for quantitative estimation of any of the pure 
stimulating agents, giving migration speeds in the range 5-20jam per 
minute. However, the diffusion coefficient is a more sensitive parameter 
varying over the range 0.03-Iqm ^ per second with the lower limit 
strongly dependent on the nature of the medium. Because STMS alone 
gives the higher values, it follows that the diffusion coefficient provides a
large measure of discrimination between this and other activities. Dose 
response curves which show the relationship between speed, persistence 
and augmented diffusion for STMS illustrate that despite the large range
of diffusion coefficients obtained, the errors in this bioassay are also
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Fig. 14. Plots of the square of the mean accumulated displacement 
squared vs. time of neutrophils in response to various stimuli.
The data from fig. 12. were replotted as the square of accumulated 
displacement as a function of time and used to determine the augmented 
diffusion coefficients and the persistence times.
(a) Steroid-treated monocyte supernatant (STMS); (b) Control monocyte 
supernatant (CMS); (c) 10"8 M /î-/ormy/-methionyl-leucyl-phenylalanine 
(fMLP); (d) 100 ng ml“l interleukin-8 (IL-8); (e) 20 pM lysophosphatidic 
acid (LPA); and (f) Ham's F-10 culture medium (CM).
Uncorrected data (#  ), drift-corrected data (□ ).
Straight lines drawn through the linear part of the uncorrected curves and the 
drift corrected cuiwe for STMS gave persistence values of 48 and 47 seconds, 
respectively.
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large and thus limit the precision. Thus the tracking assay provides a 
reasonably quantitative assay of the factor and is relatively insensitive to 
possible contaminating activities.
During the purification of STMS different assay conditions are obtained 
because the sample is no longer present in Ham's F-10 culture medium 
and it is clearly advantageous to use an assay medium that has a minimum 
effect of neutrophil locomotion. The two choices available are balanced
'.,r-salt solution (BSS) or Hank's HEPES. Both media are suitable for the 
assay of STMS and have the great advantage that they do not stimulate the 
locomotion of control cells. Table 1 shows the results when BSS was 
used, however, Hank’s HEPES was used in later purification procedures 
due to ease of preparation and storage.
Figure 15 shows that vacuum dialysis of STMS culture medium followed 
by dilution in BSS gives a preparation which remains highly active both 
in the dispersion assay and in the tilted-stage assay.
:
i
5 I
3.3.) Tilted-stage experiments
Neutrophils moving in response to STMS showed a relatively large drift 
component of locomotion even when cell numbers were sufficiently high 
to ensure a symmetrical population distribution, indicating that the 
residual drift must be due to inherent asymmetry in the system. Because
STMS was known to lower the adhesion of these cells to the surface it
.could increase their sensitivity to convection currents or to a non-level 
stage. It was therefore of considerable practical and theoretical interest to 
see how the cells responded to a gravitational field and this was achieved 
by tilting the whole microscope laterally by 30^. After a brief settling 
period, cells treated with any of the stimulating agents resumed steady
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Fig. 15. The effect of vacuum dialysis on the activity of STMS.
(a) Plot of the square of displacement as a function of time on level surface
(b) Plot of the square of displacement as a function of time on a 30® tilted 
surface, (i) Plot of displacement squared as a function of time. Square of 
uncorrected displacement ( •  ), square of drift-corrected displacement 
(□ )(ii) Plot of mean accumulated displacement as a function of time. 
Uncorrected displacement (#  ); drift-corrected displacement (Û ). (hi), cell 
tracks normalised to the origin of the axes.
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activity. All cells, even the unstimulated controls, showed some tendency 
to move down-slope, but the behaviour of STMS-treated cells was most 
dramatic (Fig. 16).Using the analysis program with automatic drift 
correction, all other stimulants induced random (radial) locomotion with 
an increased drift component. For STMS-treated cells, in contrast, the 
radial component virtually disappeared and movement was dominated by 
non-random movement down-slope. It was highly significant however, 
that although the direction of locomotion was strongly polarised, the rate 
of locomotion was increased by no more than 50%. Such an effect could 
be attributed to the reduction in the random component of locomotion 
because increased track linearity could, in principle, cause a significant 
increase in the apparent speed measured over a 5 second time interval. 
Unattached cells clearly exceeded the maximum tracking speed of around 
lp,m per second, but the rate of target cell loss although increased in tilt 
experiments, was not dramatic and cells that remained as tracking targets 
were clearly seen to be moving from one position of adhesion to another. 
Because the locomotion of cells responding to STMS is highly directional, 
the appropriate analysis is of displacement rather than the square of 
displacement. Clearly the drift correction is no longer appropriate. The 
displacement curves show the characteristic high value for the first 1-2 
giving way to a moderately linear curve typical of tethered random 
locomotion. Comparison of the slope of the sustained linear part of the 
curves give values with greater discrimination between the effects of 
STMS and CMS/fMLP (2.5 and 0.47 / 0.48 \xm per second respectively) 
than obtained in the radial dispersion assay (table 1) with a higher degree 
of confidence in the individual values.
79
Fig. 16. The effect of a gravitational field on neutrophil tracking
Adherent human neutrophils were treated with 400pl of: (a), steroid-treated 
monocyte supernatant (STMS); (b). control monocyte supernatant (CMS); and
(c). lO-^M formyl-methionyl-leucyl-phenylalanine (fMLP). The assay 
chamber was then tilted by 30^ and measurements commenced after a delay 
of 1 minute, (i) Plot of displacement squared as a function of time. Square of 
uncorrected displacement (#  ), square of drift-corrected displacement (O ); 
(ii) plot of the accumulated mean displacement as a function of time. 
Uncorrected displacement (#  ), drift-corrected displacement (□ ); (iii) cell 
tracks normalised to the origin of the axes.
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A caveat to this assay system, that must be pointed out at this stage, is the 
inconsistency in the behaviour of human neutrophils from different 
individuals in our tracking assay. As will be demonstrated later, under 
apparently very similar circumstances, neutrophils from different 
individuals can have very different basal activity which affects the 
tracking parameters.
Blood for neutrophil tracking is normally provided for us by volunteer 
medical students from The Glasgow Royal Infirmary, and is taken under 
similar circumstances each day. However, the variation in neutrophil 
behaviour can be very significant. On some days the cells undergo 
homotypic aggregation to such an extent that assays are impossible. Other 
days the cells stick to the BSA-coated coverslips so strongly that tracking 
becomes impossible due to too many cells per field, whilst other times 
very few cells stick to the coverslip at all. There are also problems with 
basal activity at both extremes, i.e. some samples will have cells that will 
not respond to any stimuli, whilst other cells are activated and motile 
without any stimulation.
3.4.) Dose response of starting material
It was of great interest for purification of this factor to obtain a dose 
response curve of the activity being measured in STMS. This would allow 
us to optimise the conditions of assay during the purification procedure, 
as we would have both highly concentrated and dilute samples during 
different stages. A dose response curve was produced by diluting starting 
material STMS in Ham's F-10 serum-free culture medium (Fig. 17). 
There was a rapid reduction in both the diffusion coefficient and 
persistence of the cell populations as the starting material was diluted to
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Fig. 17. The effect of different dilutions of STMS on the diffusion 
coefficient, persistence and the speed of locomotion of human 
neutrophils.
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1/8 of starting material, similar to the dose response of Stevenson (section
1.2 .6 .) but the reduction in the speed of locomotion was not so dramatic. 
This confirmed that speed was not a good parameter for our active 
factor, but the reduction in diffusion coefficient also indicated that the 
concentration used in assays was very important if the activity was to be 
detected after each purification step.
3.5.) A dhesion of human neutrophils to bovine aorta  
endothelial cells
The adhesion of neutrophils to the endothelium in post-capillary venules 
is a very important stage in the inflammatory process (Anderson and 
Springer, 1987), and is a potential target for anti-inflammatory therapy. 
Initial results of Chettibi et al., 1993, showed that STMS starting material 
decreased the adhesion of human neutrophils to albumin coated 
coverslips, when compared with CMS and Culture medium +/- steroid. It 
was of interest to see if these results could be repeated with a more 
physiologically relevant substrate for adhesion. Bovine aorta endothelial 
cells were used as this substrate. The results show that the adhesion of 
neutrophils to bovine aorta endothelial cells is indeed reduced when 
compared with the controls (Fig. 18).
3.6.) Effect of STMS on the fMLP induced chemotaxis of 
human neutrophils
Preliminary observations of neutrophil chemotaxis using the modified 
Boy den chamber revealed a striking contrast between the response to 
STMS and fMLP. Neutrophils showed massive invasion of the filter when
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Fig. 18. Effect of supernatants from human monocytes cultured 
for 24 hours at 3?0C, with and without 10“^  M dexamethasone, on 
the adhesion of human neutrophils to bovine aorta endothelial 
cell monolayers.
(a) culture medium without dexamethasone; (b) culture medium with IQ-  ^M 
dexamethasone; (c) Control monocyte supernatant (CMS); (d) Steroid-treated 
monocyte supernatant (STMS).
Mean ± s.e.m. (vertical bars) n = 3. P < 0.05 given by
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fMLP was present in the lower chamber, but gave no such response to 
STMS. However when the filters were examined by the leading front 
method it became clear that a few STMS-treated cells were able to invade 
successfully, but in low numbers, in keeping with the predictions for 
persistent locomotion. These observations suggested that a more suitable 
analysis would be to measure total invasion, or to determine the number 
of cells present midway between the leading front and the surface of the 
filter. Figure 19 presents the analysis of chemotactic assays using both the 
leading front and the average invasiveness methods. The results showed 
that STMS was not itself chemotactic, but when present in the upper 
chamber, dramatically inhibited the response to fMLP. In a uniform 
concentration of fMLP (i.e. present in both chambers) there was a similar 
reduction in invasiveness.
3.7.) The contribution to Dispersive locomotion of F-Actin
To investigate the underlying basis of the shape differences and to 
understand the nature of dispersive locomotion, the distribution of 
polymerised actin in the cells was examined. Control non-activated 
neutrophils showed a weak, rather punctate distribution of fluorescence, 
but with no sign of a major polarised focus corresponding to a relatively 
even distribution of cortical actin (Fig. 20 a). The results obtained for 
fMLP were similar to those presented by other workers (Coates et al., 
1992) and are consistent with the interpretation that actin polymerisation 
is much more intense than in control cells and is associated with points of 
adhesive contact that are foci of active locomotion (Fig. 20 b). Cells that 
were highly spread in response to CMS or to TNFa showed an extremely 
punctate distribution of F-actin (Fig. 20 c,d). The pattern of actin staining
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Fig. 19. The inhibition of fMLP-induced chemotaxis of human 
neutrophils by STMS measured using a modified Boyden chamber 
assay.
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(a) upper chamber - culture medium with dexamethasone; lower chamber - 
10"9 M fMLP; (b) upper chamber - STMS; lower chamber - 
10’9 M fMLP; (c) upper chamber - 10-9 M fMLP; lower chamber -10-9 M 
fMLP; (d) upper chamber -culture medium with dexamethasone; lower 
chamber - STMS (e) upper chamber -culture medium with dexamethasone; 
lower chamber -culture medium with dexamethasone O  Number of cells 
which have migrated half of the mean migration distance of positive 
control(A). ^  Cell-front migration distance.
Five randomly selected fields were counted for each filter. Values shown are 
mean ± s.e.m. (vertical bars) P < 0.05 given by against positive control.
Fig. 20. Comparison of F-actin distribution in human neutrophils 
treated with STMS and various neutrophil locomotion stimulators.
Lighter colour indicates higher concentration of F-actin.
(a) culture medium with and without 10-6 M dexamethasone; (b) 10-8 M 
fMLP; (c) CMS; (d) TNFa; (e) STMS. Bar, 2 pm.
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in STMS-treated cells was highly unusual and distinct. Staining was only 
present in the extremes of the bipolar cells and of these two ends, which 
appear to be points of adhesive contact, one was invariably more intensely 
stained than the other (Fig 20 e).
3,8.) Purification of the active factor in STM[S 
3.8.1.) Dose response of starting material compared with that 
of the partially purified factor
The results of Dr. Chettibi in attempting to purify the active factor from 
STMS produced a number of puzzling observations. Firstly, there 
appeared to be two active molecules from the results of gel filtration on 
Sephadex G30, one of which eluted just before the salt from the 
concentrated culture medium, the other a larger molecule which eluted 
along with the larger proteins contained in the supernatant, for example, 
albumin; 66 kDa. Two regions of activity flanking a region in the centre 
that showed no activity indicated this. Secondly, he had shown from 
ultrafiltration that the activity was found to be retained and to go through 
a small molecular weight cut-off filter. This could also be interpreted as 
small and large molecular weight active factors.
However, there was another explanation of these results, which could also 
explain the apparent loss of activity by Dr. Chettibi during previous 
purification attempts. If there was only one active molecule, of low 
molecular weight, bound to a larger protein in the starting material, then 
the puzzling gel filtration and ultrafiltration observations of Dr. Chettibi 
could be explained. However, they could not explain the loss of activity 
during purification. If the dose response curve of the purified small
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Reducing the volume of starting material was a crucial step in the 
purification of the active factor in STMS, as the culture supernatants,
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molecule differed from that of the starting material, then the loss of 
activity could be explained by assays not being performed at the correct
concentrations. The biggest clue to this was on a couple of occasions, 
finding eluates from the reversed-phase column containing a region 
without activity flanked by two regions of activity. This indicated that the 
area in the centre might be active at lower concentration than the flanking 
regions. These observations would also explain anomalies of the Sephadex 
G30 gel filtration samples, and in this study, from P2 gel filtration 
results, in which there was thought to be two active molecules, one of 
relatively high molecular weight, eluting with the protein fractions and 
another eluting at the small molecular weight region associated with a 
pink pigment present in the initial culture medium; vitamin B 12 with
si
%
molecular weight 1351.
Dose response assays were performed on the partially purified factor 
following gel filtration on Bio-gel P2, and also after the next purification 
step, of reversed-phase. These showed a 'bell-shaped' dose response 
curve, one of which is shown in figure 21 , with an increase in diffusion 
coefficient at higher concentrations compared with the control, peaking at 
one concentration showing STMS levels of diffusion coefficient, and
:
falling off at a lower concentration with a lower diffusion coefficient. 
The dilutions represented here are from the pooled samples of 50 ml 
from Bio-gel P2, diluted in HH.
3.8.2) Purification of a molecule of molecular weight 1331 
Da, present in STMS ,1
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Fig. 21. Dose response of active samples from Bio-gel P2.
Samples from bio-gel P2 were pooled into approximately 50 ml aliquots, and 
assayed at various concentrations, being diluted in Hank's HEPES. The first 
dilution, 1/10 takes the concentration of the sample back to 500 ml, that of 
starting material. As can be seen the peak of activity is 1 x 10-4 that of 
starting material indicating an increase in the activity of the sample, possibly 
due to the separation on P2 of the active factor and the putative carrier 
molecule. Shown is a single assay as an example of the dose-response curve.
K, 1 X 103; M, 1 X 106-
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around 300 ml, were of too great a volume to handle using conventional 
chromatography techniques. Dr. Chettibi had taken a number of 
approaches, including ultrafiltration and ion exchange chromatography. 
The results of these approaches were unsatisfactory, as ultrafilters were 
unable to retain all of the activity, with apparently half being retained and 
half going through. In order to get the activity to bind to a MonoQ anion 
exchange column, the sample had to be diluted around ten-fold. This 
meant that 500ml starting material was diluted in water to 5 Litres before 
being applied to the column. The limit of speed of the pump meant that it 
took around 48 hours to complete the 3 Litres, introducing the possibility 
of bacteria or fungal contamination and/or degradation of the active 
molecule.
A different approach was taken initially in this study to facilitate the 
concentration of starting material to a more convenient volume. 
Approximately 500ml of STMS was processed at a time. This was 
concentrated by freeze-drying down to around 50ml. This caused some 
denaturing of protein, and salt precipitation in the sample, which were 
removed by centrifugation at 3660 rpm for 20 minutes followed by 
filtration through a 0.2 jim Millipore filter. This gave a sample of around 
40 ml which was then applied to a 500ml Bio-gel P2 size-exclusion 
chromatography column, separating the active molecule from large 
proteins, and the high concentration of salt from the concentrated culture 
medium. Figure 22 shows a UV trace from this separation procedure. 
The active fractions co-eluted with a region which also contained 
VitaminB12 (cyanocobalamin), a pigmented molecule (pink) (Fig. 23) of 
molecular weight 1351 Da, which is present in the Ham's FIO culture 
medium (indicated by shading).
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Fig. 22. Separation of activity from high molecular weight 
proteins and salt contained in the culture medium
50 ml sample of freeze-dried STMS (500 ml), was applied to a 500 ml bio­
gel P2 size-exclusion chromatography column. A 150 mM sodium chloride 
elution buffer was used to prevent ionic interaction of sample with the gel 
matrix.
A flow rate of 1.5 ml/min was used; Vo was approximately 100 ml, and 
Vt, measured by salt elution, was approximately 350 ml.
UV absorption was measured at 254 nm, and sensitivity was 1.0 Absorption 
units full scale (AUFS).
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Fig. 23. Diagram showing Vitamin B12 (cyanocobalamin).
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From The MERCK index, 10th edition, Merck and Co., Inc., Rahway, N.J., 
U.S.A., of molecular weight 1351, and found in Ham's F-10 culture medium 
in which the monocytes are cultured to produce STMS. The shaded areas 
represent the parts of the molecule removed by high energy Maldetof mass 
spectroscopy, yielding fragments of molecular weight, 1331 (-CN group), 
1188 (-shaded area (1)), and 980 (-shaded areas (1) and (2)).
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The active region from the P2 column was spread over a volume of 60- 
80 ml. The pH was reduced to around 3 using 5M HCl, and the sample 
was applied to a Pharmacia Sephasil C l8 reverse-phase column, using the 
50ml injection superloop. Elution with a 0-50% Acetonitrile gradient 
over 30 minutes separated the activity (shaded area) from the main peak 
of Vitamin B12 (Fig. 24), but also showed that there were a large number 
of other molecules present in the sample. The active samples from the 
reversed-phase column were dried in a vacuum centrifuge in a 1.5 ml 
eppendorf tube, to around 250 |ll. This was applied to the superdex 
column at a flow of 500 pl/min. Vo of the column was found to be 10ml. 
Figure 25 shows the UV trace produced from one such sample. The 
activity was found by tracking assay to be in a region of molecular weight 
1000-2000 Da, and when vacuum-dried was found to have a pink pigment 
present. To further separate the molecules contained in the active region, 
several types of chromatography were attempted, but with limited 
success.
iAnalysis of the active factor following reversed-phase chromatography using Matrix assisted laser desorption time of flight (Malditof) mass 
spectroscopy by the laboratory of Prof. Rammage confirmed that there 
was a molecule of molecular weight 1334 in the sample (Fig. 26), one 
that had previously shown up in samples during Dr. Chettibi's 
purification. Knowledge of the dose response curve of the partially 
purified molecule, indicated that this sample would contain more active 
material, as previously only the periphery of the active molecule had been 
collected. A sequencing attempt was made on this sample, by Dr. 
Cronshaw (Wellmet Protein Characterisation Facility, Edinburgh), 
assuming that there had not been enough material to detect any sequence 
on the previous occasion. Unfortunately no sequence was detected apart 
from an initial Alanine residue, and some faint amino acids (results not
--.2",  T.::  ^-
Fig 24. Active region from P2 (Fig. 22) applied to a Pharmacia 
Sephasil CIS reversed-phase chromatography column.
The pH of the sample was reduced to 3, and applied to the column using the 
Pharmacia superloop, and eluted using a 0-50% buffer B gradient over a 30 
minute period at 500 ml/min, UV absorbance 214 nm, and 0.2 AUFS. 
Buffer A: 0.14% Trifluoroacetic acid 
Buffer B: 0.12% Trifluoroacetic acid, 50% Acetonitrile.
150 pi samples were collected in 0.5 ml eppendorf tubes, dried using a 
vacuum centrifuge, and redissolved in 100 pi of water before being assayed. 
Active fractions ai’e shaded.
H-
Fig. 25. Active fractions from the reversed-phase purification 
(Fig. 24) applied to a Pharmacia superdex peptide column.
A 250 jil injection sample was run at 500 ml/min in lOmM hydrochloric acid, 
20% Acetonitrile buffer to reduce ionic interactions of the sample with the 
gel matrix. Detection was at 0.2 AUFS. Vo was found to be approximately 10 
ml, and Vt approximately 20 ml.
Active fractions are shaded.
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Fig. 26, Matrix assisted laser desorption time of flight (Maldetof) 
mass spectroscopy of the active fraction from superdex peptide 
column (Fig 25)
A major peak of approximately 1335 was detected, and is seen alongside the 
sodium and potassium adducts of the parent molecule (1350.97 and 1366.87, 
respectively). Another peak of 1296.77 was also detected in the sample.
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shown). This indicated that if the molecule was indeed a peptide, it may 
have a blocked N-terminus, or there was still not enough material to 
produce a satisfactory sequence.
Dr. Cronshaw suspected that his sequencing apparatus was not sensitive 
enough to detect the quantities in our sample, so he put us in contact with 
Dr. G. Kemp (Cell and Molecular Biology, University of St. Andrews), 
who had sequencing capabilities with an order of magnitude greater 
detection level. Dr. Kemp attempted sequencing on a number of active 
samples and surrounding peaks, and found a peptide that corresponded to 
a fragment of actin, residues 31-41 (WPSIVGRPRHQ). It was found that 
this was in fact a contamination product as it had mass of 1286, and eluted 
from the reversed-phase column slightly after the activity. Unfortunately, 
in the most active fractions there was very little information from 
conventional sequencing attempts, indicating that if the active molecule 
was indeed a peptide, then it most probably had a modification of the N- 
terminal amino acid that prevented conventional sequencing.
Amelia Jackson, from Kratos, a company who manufacture ‘Maldi V ’ 
mass spectroscopy equipment kindly agreed to analyse our sample on 
their Maldi IV apparatus, which showed the same peak previously seen, 
of 1331 MW (Fig. 27). Increasing the laser power during mass 
spectroscopy allowed them to fragment the ‘peptide’, producing peaks 
that correlate with the amino acids that make up the molecule. This 
yielded some information about the nature of the active molecule. Figure 
28 indicates the fragmentation pattern of the active molecule. Analysis of 
these fragments showed residue fragments of 143, 206.6, 72, 56, and 56. 
These could be interpreted as Phenylalanine (147.1), followed by a 
fragment with two amino acids together 206.6, which is a common 
occurrence in this type of fragmentation (Amelia Jackson, personal 
communication), followed by alanine (71.0), and two glycine residues
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Fig. 27. Matrix assisted laser desorption time of flight (Maldetof) 
mass spectroscopy by Kratos using Maldi V, of an active sample.
A main peak of 1331.3 was detected, with a number of small molecular 
weight peaks.
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Fig. 28. Fragmentation of 1331 MW peak by mass spectroscopy
A min peak of 1331.3 was detected, with a number of small molecular weight 
peaks. Increasing the laser power allowed fragmentation of the parent 
molecule into constituent parts. Subtraction of fragment sizes allows 
calculation of the amino acids present in the peptide molecule.
(a), three peaks are present in this fragmentation, 1332.0, which represents 
the whole molecule, 1188.6, and 980.0
(b). Gating of the mass spectroscope allows only fragments of the 1188 initial 
fragment to show. This produced several further fragments, 979.2, 907.7, 
851.0, 795.0, and 740.1. The lower molecular weight fragments are picked 
out arbitrarily from the baseline by the processing software.
(c). Gating of the 980 fragment produced fragments of sizes, 991.7 
representing the 980.0 fragment, 921.5, 864.7
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R esults_________________________________________________________
(57.0). Unfortunately, there was only partial fragmentation of this 
molecule, so we were unable to determine the full amino acid sequence 
using this technique.
3.8.3.) Identification of molecule with molecular weight 1331 
Da
At this stage we contacted Dr. Darryl Pappin (Imperial Cancer research 
fund (ICRF), London) who performed further mass spectroscopy analysis 
on this molecule. In a short time Dr. Pappin was able to identify this 
molecule as a derivative of vitamin B12, without a CN group 
(acyanocobalamin). The fragments in fact correlated with possible 
fragments from VitB12 (Fig. 23).
To rule out this molecule as the activity Vitamin B12 was assayed and 
found to have no residual activity (results not shown).
3 .8 .4 .) P urification  of Thym osin p4 with an oxidised  
methionine residue with Dispersive activity
This information indicated that the active molecule might be present in 
our assay at very low concentrations. A number of other peaks had 
appeared on mass spectroscopy analysis but had been ignored due to the 
strong presence of the 1331 Da molecule. This led to assaying the samples 
during the early stages of purification at very high dilutions, to determine 
if most of the active fractions were being discarded, through assaying at 
too high a concentration. The purification protocol was also altered. As 
we believed that there may be a large molecule involved in binding the 
active factor, due to the differences in the dose response curves of the 
starting material and purified factor, it seemed possible to remove all the
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unbound small molecules in the starting material by force dialysis; the 
activity being retained, bound to the large molecule. The sample was 
force dialysed in vacuo, followed by dialysis against water, before being 
applied to Mono Q. Active fractions from Mono Q (Fig. 29, shaded area) 
were then applied to the Pharmacia peptide column in a high salt buffer 
(300 mM Sodium chloride) to prevent the interaction of the small active 
molecule with the large carrier molecule. However, this did not occur as 
the activity remained at the excluded molecular size region (Fig. 30). 
This was applied to the reversed-phase column and a small peak was 
found to be active, fraction 18, containing approximately 1.5 pg (when 
peak area is compared to the elution of a 10 |ig sample of thymosin p4), 
in figure 31 a and 33 b, eluting in the same region as previous active 
samples, away from the majority of proteins which eluted late (Fig. 31 a). 
Mass spectroscopy analysis by Dr. Pappin, showed this molecule to have a 
mass of 4980.4, and sequencing of tryptic peptides from this molecule 
using Low-energy mass spectroscopy (Sherman et al., 1995; Hunt et al., 
1986; Wilm and Mann, 1996) yielded six sequences. These were:
Ac-SDKPDMAEIEK Met oxidised to the sulphoxide (+16 Da),
Ac-SDKPDMSEIEKFDK Partial cleavage. Met oxidised, Ac- Acetyl
TETQEK
NPLPSK
ETIEQEK
QAGES-COOH Free acid at C-terminal.
Data base searches revealed the sequences to correlate with the sequence
of Thymosin P4 with oxidised methionine at residue 6 .
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Fig. 29. Anion exchange separation using MonoQ of force- 
dialysed STMS.
STMS was force-dialysed against air to remove small molecules (<10000 
MW), followed by dialysis against water to remove any salt from the sample. 
The sample ( approximately 5 ml) was made to pH 8, by addition of 1 ml of 
100 mM Tris.Cl pH 8, before being filtered through a 0.22 jxm Millipore 
filter and applied to the Pharmacia Mono Q anion exchange column in 20 
mM Tris.Cl pH 8.0.
A 0-500 mM sodium chloride gradient was applied to the column over 15 
minutes, and 500 ml samples were collected in 0.5 ml eppendorf tubes. 
Fractions were then assayed, and active samples were pooled and prepared 
for further purification steps.
Activity was found to be in fractions 7-9.
COui
Figure 30. Size exclusion chromatography, using the Pharmacia 
superdex peptide column
This column was used to attempt separation of the active molecule from the 
putative large carrier protein.
Pooled active samples from the Mono Q anion exchange column (Fig. 20) 
were vacuum centrifuged to 250 pi, and applied to the Pharmacia superdex 
peptide column in 300 mM sodium chloride, 20 mM Tris. Cl pH 8 . The high 
salt concentration was used to dissociate the active molecule from the putative 
larger carrier molecule. Activity however, was found to be in the excluded 
region of the eluted samples (fractions 1-7).
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Fig. 31. Active samples from the superdex peptide column applied 
to the Pharmacia Sephasil CIS reversed-phase chromatography 
column.
Fractions 1-7 from the peptide column were filtered, using a 0.22 pm 
Millipore filter, the pH reduced to 3 using 1 M hydrochloric acid, and 
applied to the Sephasil CIS reversed-phase chromatography column. A 0- 
50% Acetonitrile, in 0.1% TFA gradient was applied over 30 minutes and 
500 pi fractions collected. Samples were vacuum-dried and redissolved in 
water, before being assayed.
(a), shows the programmed gradient, UV trace, and fractions collected from 
the reversed-phase column.
(b). A zoom-in to the active fraction 18. This sample was sent for mass 
spectroscopy analysis.
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3.9.) Sequence and secondary structure analysis of Thymosin 
p4
Thymosin p4 (Tp4) was originally purified as a Thymic hormone present 
in fraction 5 of biologically active thymic extracts (Low et al., 1981). It 
is an intracellular peptides which regulates actin polymerisation by 
sequestering G-actin (Cassimeris et al., 1992). It has a single methionine 
residue, but it is not known whether this is crucial for function. It is also 
found extracellularly in blood plasma and serum (Naylor et al., 1986; 
Hannappel and van Kampen, 1987), and is seen in increased levels in the 
serum of Crohn’s disease and ulcerative colitis (Mutchnick et ah, 1988). 
It has been shown to be an important molecule in cell proliferation 
(Schobitz et al., 1990), differentiation, including immune cells 
(Shimamura et al., 1990) and cell migration; Malinda et al, 1997, showed 
that Thymosin p4 acts as a chemoattractant for Human umbilical vein 
endothelial cells (HUVEC), and significantly accelerated the rate of 
migration into the scratch wounded area of a HUVEC monolayer at a 
concentration of around l|lg/ml.
The oxidised peptide may act as a sign of host cell damage and the 
dispersive response of neutrophils in our assay may be interpreted as an 
anti-inflammatory strategy.
Interestingly, when the group of Dr. Safer (University of Pennsylvania, 
USA) provided us with 1 mg of HPLC purified Tp4 from Bovine spleen, 
we found, by HPLC analysis, that it contained around 10% Thymosin p4 
with the methionine residue oxidised (Tp4ox) (Fig. 32). This led us to 
speculate that Tp4ox may be active in their assay for scratch wound 
repair of HUVEC monolayers, and initial results have indicated that 
Tp4ox is active in this assay at lOOx less concentration than native Tp4 
(A.G. MacLean, personal communication).
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Fig. 32. 10 jLig of Thymosin P4 eluted from the Sephasil reversed- 
phase column.
10 qg from a 1 mg sample of Thymosin 84 (TP4) from Dr. Safer, was 
diluted 1/10 (v/v) in 0.1% TFA and applied to the C18 reversed-phase 
column, and the same gradient applied as used for previous samples. 
Comparison of the peak areas indicated that there was approximately 1.5 jig 
present in our purified TP4 with an oxidised methionine (TP4ox). The 10 jig 
sample has been plotted alongside the Tp4ox and as can be seen, there is a 
shift in the elution from the column caused by the oxidation. The 10 jig of 
HPLC purified TP4 also appears to contain approximately 10% Tp4ox, as 
seen by the small peak in fraction 18.
This 10 jig elution was used as a standard for quantitation of Tp4 present in 
samples eluted from the reversed-phase column.
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Below is the sequence of human, bovine and rat Tp4. As can be seen, 
there is a single methionine residue at position 6 , and a relatively large 
number of charged E, D and K residues, which may help to explain the 
ionic interaction of Tp4 with size-exclusion chromatography media. 
Below the sequence can be seen the secondary structure prediction 
(BLAST), indicating that the molecule probably contains a number of 
alpha-helices, and coil structures. The methionine is positioned at the start 
of the first helix structure, and so its oxidation state may effect the 
secondary structure of the molecule through disruption of this helix.
1 SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES human 1 SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES bovine 1 SDKPDMVEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES rat
10 20 30 40
Tp4 sequence 
Gibrat method Levin method DPM method SOPMA predict Consensus
SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
CCCCCHHHHHHHHHHHHHHHHHHHCCCCCCHHHHHHHHHHCCHHHHHHHHHHHHHHHHHCCCCTHHHCCSCCCCCCHHHHHHHTHHCCTCCHHHHHHHHCCCHCHHHHHTCTCTCTCHHHHHHHHHCCCCCCCCHHHHHHCCCCCCEEEECCCCCCCCCCCHHHHHHHHHHHCCCCCHHHHHHHHCCCCCHHHHHHCCCCCCCCHHHHHHHHCCH
Key:H, G HelixE SheetC coilS BendB bridges
3.10.) Comparison of native Thymosin p4 with the oxidised 
derivative in neutrophil tracking assays
In order to confirm that the active molecule in our assay was indeed 
Thym osin P4 with an oxidised methionine (Tp4ox), and not a 
contaminant present in very small quantities, or not showing up on mass 
spectroscopy, it was necessary to purify Tp4 from a different source, 
unlikely to contain the same contaminants. Initially, using the method of
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Hannappel and van Kampen, 1987, Thymosin p4 (Tp4) was purified 
from human neutrophils of a single huffy coat, which produced around 
20 |Ug of pure Tp4 (Fig 33). Analysis by Maldi mass spectroscopy, 
indicated that both oxidised and unoxidised were present (Dr. Pappin, 
personal communication), and tracking assays indicated that TP4ox was 
indeed active, having the same shape dose response curve, whilst the Tp4 
with non-oxidised methionine at residue 6 having a lesser activity at 
higher concentrations (Fig 34). This left us with strong evidence that 
Tp4ox was responsible for the dispersive locomotion of STMS. However, 
because the source of this Tp4 was an immune cell, and purification was 
on the same reversed-phase column as the STMS sample, it was clear that 
another source of Tp4 was required, for definitive proof that there was 
not a contaminating molecule causing the activity.
Three different approaches were taken simultaneously. We received 1 mg 
of Bovine pancreatic Tp4 from Daniel Safer. At the same time. Dr. 
Pappin attempted to synthesise de novo T(34. This has proved to be a 
difficult task, as initially there was a very low yield, and more recently 
there has been a problem of modifications to the N-terminal serine 
residue (Darryl Pappin, personal communication).
Another approach was to utilise the fact that there is a shift in Tp4 elution 
from the reversed-phase column when it is oxidised. 50% of the 
unoxidised Tp4 from the neutrophil buffy-coat preparation was oxidised 
and eluted from the reverse-phase column giving a sample of oxidised 
Tp4 which was very unlikely to contain any contaminants, unless they too 
underwent the same shift in elution from the column following oxidation 
(Fig. 35). Assays of this sample have confirmed that Tp4 with an oxidised 
methionine at residue 6 causes dispersive locomotion in the tracking assay 
(Fig. 34). Three assays have been plotted together for non-oxidised 
thymosin p4 demonstrating the problem of inconsistency of the assay.
92
Figure 33. Purified Thymosin P4 from human neutrophils.
The sample purified as described in section 2.12.2.3., was applied to the 
reversed-phase column and eluted as previously. This yielded 20 pg, using 
the area under the peak to compare with the standard 10 pg Tp4 (Fig. 32). 
Fractions 1/2, 4,5, and 7 were sent for mass spectroscopy analysis. Fraction 7 
was found to contain Tp4, whilst, fractions 4/5 contained TB4ox.

Fig. 34. Comparisons of the diffusion coefficient of neutrophils 
treated with various concentrations of Thymosin p4, both 
oxidised and non-oxidised.
A 60 pg/ml sample was made for each of the thymosin (34 samples to be 
tested. This allowed direct comparison between the oxidised thymosin (34 
(Tp4ox) purified from STMS (60jLig/ml) and the thymosin (34 from human 
neutrophils. Graph (a) shows the results for thymosin with an oxidised 
methionine residue, purified from STMS®, oxidised human neutrophil 
thymosin B4 tSa, and hydrogen peroxide oxidised thymosin (34 from human 
neutrophils S  (b) non-oxidised thymosin from human neutrophils EË3, non­
oxidised thymosin p4 from bovine spleen S .
Average diffusion coefficients for the peak of Tp4ox activity were 0.54 ± 
0.18, compared with 0.1 ± 0.04 for non-oxidised thymosin p4 (Tp4) at the 
same concentrations, p < 0.05; n = 4.
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Fig. 35. Oxidation of human neutrophil Thymosin p4 with 
hydrogen peroxide and its elution from a reverse-phase 
chromatography column.
50% of a sample of Thymosin P4 from human neutrophils was oxidised using 
the method described in section 2.13. and applied to the Sephasil C l8 
reversed-phase column. Elution was as previously. The non-oxidised sample 
was also applied separately. Fraction 6 contains the (50%) unoxidised sample, 
which elutes as previously, and fraction 4 contains the Tp4ox. As can be seen 
there is a shift in the elution of Tp4ox, which should separate it from any 
contaminants from the neutrophil preparation.
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with a large variation in baseline activity, as explained earlier in this 
chapter.
3.11.) Comparison of levels of oxidised Thym osin (34 in 
cultured monocyte supernatants with and without steroid.
Parallel purification of cultured monocyte supernatants either in the 
presence (STMS) or absence (CMS) of dexamethasone, has revealed that 
T|34ox is present only in STMS cultures. Two human huffy coat 
monocytes were cultured in the presence or absence of 10"^ M 
Dexamethasone. This provided approximately 100 ml of both CMS and 
STMS. These samples were processed through the same purification 
protocol used to purify the active T|34ox previously. Figure 36 shows the 
final reversed-phase analysis of the two samples plotted together. As can 
be seen, there is a peak associated with the STMS sample that is not 
present in the CMS sample. Quantitation of these observations, showing 
the comparative amounts of T^4 and T|34ox, using a technique such as, 
Enzyme-linked immunosorbent assay (ELISA), awaits the production of 
an antibody specific to T|34ox.
3 .1 2 .)  The L y so p h o sp h a tid ic  a c id -in d u ced  M o tility , 
polarisation and inhibited metabolic burst of Neutrophils.
It has been shown in other laboratories that whilst lysophosphatidic acid 
has a receptor present on different cell types, none is apparently present 
on human neutrophils. During investigations into the effects of different 
activators of neutrophil locomotion, LPA was assayed at biologically
93
Fig. 36. Parallel purification of Thymosin p4 from STMS and
CMS.
100 ml of STMS and CMS were processed to purify Thymosin P4, as 
previously. They were force-dialysed, applied to monoQ, superdex peptide 
and sephasil C l8. The top UV trace shows the STMS sample, with the peak in 
tubes 3-5 corresponding to Tp4ox. The middle line is that of CMS with little 
difference between that and the baseline (no sample applied), at the bottom.
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active concentrations in the cell tracking assay. LPA was found to induce 
random locomotion with a speed similar to that of STMS and fMLP (table 
1). This indicated that LPA was indeed having an effect on neutrophil 
function. Visual inspection of the cells under phase contrast microscope 
indicated that LPA was inducing alterations in cell morphology, with the 
cells polarising under the influence of LPA.
These observations led us to investigate the effect of LPA on polarisation 
or shape change, as well as and the fMLP and PMA-induced metabolic 
burst.
3.12.1) Polarisation of Human neutrophils in response to 
Lysophosphatidic acid
Addition of LPA to neutrophils induced very rapid shape changes and the 
effect was dose-dependent, in terms of the numbers of cells that became 
polarised. (Figs 37 a-e). Virtually 100% of cells polarised in response to 
20  pM concentration of the lipid and appeared to be similar in form to 
cells polarised in response to 1 x 10"^ M fMLP (Fig 37f). Higher LPA 
concentrations did not increase cell area, but many of the cells showed 
well defined spike-like projections (Fig. 37e).
Tracking analysis showed that LPA increased the speed of locomotion and 
gave a linear plot of the square of displacement against time, 
characteristic of locomotion with negligible persistence (Fig 14 e), and 
stimulation of locomotion by low concentrations of LPA correlated very 
well with the observed effects on shape change (table 2). Higher 
concentrations of LPA rendered the cells non-motile, but motility could 
be restored by the addition of albumin (table 2) indicating that the carrier 
solvent i.e. ethanol:chloroform was not responsible.
94
Table 2. The effect of different concentrations of LPA on the 
speed of locomotion of human neutrophils.
Treatments Cell speed (|xm min-1)
PBS 2.5 ± 0.4
0.2 liM LPA 8.23 + 0.36*
2 nM LPA 11.6 + 0 .2*
20 nM LPA 13.5 ±0.6*
100 HM LPA 8.2 ±0.18*
100 HM LPA + 0.1% ALB 16.2 ± 2*
PB S+0.1% ALB 5.3 ± 0.3*
10-8 M fMLP 15.4+ 1.5*
PBS, phosphate buffered saline. LPA, lysophosphatidic acid. ALB bovine 
serum albumin.
Mean ± s.e.m., n=3. p< 0.01 given by *
Fig. 37. The effect of lysophosphatidic acid (LPA) on the shape of 
human neutrophils.
Cells were fixed with 2.5% gluteraldehyde after 20 min incubation at 37^C in 
the presence and absence of LPA. (a) control cells in PBS, (b) cells treated 
with 0.2 pM LPA, (c) cells treated with 2 pM LPA, (d) cells treated with 20 
pM LPA, (e) cells treated with 100 pM LPA and (f) cells treated with lO-^M 
fMLP.
Photographs represent cell appearance under phase contrast microscopy using 
x32 objective.
Bars = 20 pm.
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3.12.2.) Effect of LPA on the fMLP-induced metabolic burst 
of human neutrophils
The majority of agents that increase the polarisation and motility of 
human neutrophils can either enhance or inhibit the metabolic burst of the 
cells. The ability of LPA therefore both to induce the metabolic burst 
directly and to modulate the effect of other agents was investigated. Using 
DNDH-enhanced chemiluminescence, LPA was shown ineffective in 
stimulating the metabolic burst at concentrations below 20pM, although it 
did have a weak stimulatory effect at higher concentrations (100-200 
pM). In contrast, LPA was a powerful inhibitor of the fMLP-induced 
metabolic burst with a clear dose-dependent response and showed half­
maximum activity at a concentration around 10 pM. (Fig. 38). The 
actions of fMLP on neutrophils are known to be mediated through 
pertussis toxin sensitive heterotrimeric G proteins of the class Gi, and the 
effects of LPA in many cell types are inhibited by pertussis toxin (van 
Corven et al., 1993). These results indicate that the actions of both fMLP 
and LPA may share a common G-protein based mechanism. The results 
in figure 39 gave strong support for this model and showed that LPA 
inhibited the effect of fMLP by the same proportion when it was added as 
the sole inhibitor or when used together with a concentration of pertussis 
toxin (PTx) capable of inhibiting the response by 50%.
3.12.3.) Effect of LPA on the PMA-induced metabolic burst of 
human neutrophils
The results of these experiments showed two distinct effects of LPA. At 
low LPA concentrations there was a significant activation of the
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Fig. 38. The effect of different concentrations of LPA on the 
fMLP-induced metabolic burst of human neutrophils.
The metabolic burst was measured by DNDH-enhanced chemiluminescence, 
10"^ M fMLP was added to 10^ cells m pl of control and LPA-treated 
neutrophils.
Mean ± S.E.M., n=4. 
p < 0.05 given by
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Fig. 39. The inhibitory effect of LPA on the fMLP-induced 
metabolic burst of pertussis toxin-treated human neutrophils.
1 X 10^ cells ml"l were incubated for 1 hour in the presence and absence of 
lOOng ml"l pertussis toxin (PTx). LPA was used at a final concentration of 
20 |im and fMLP at 10"^ M.
a). fMLP at 10"6 M b). fMLP + PTx. c). fMLP + LPA, and d). fMLP + PTx 
+ LPA
Mean ± S.E.M., n=3. 
p < 0.05 given by
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metabolic burst induced by PM A, but at higher concentrations, LPA 
became a dose-dependent inhibitor of the action of PM A, causing half 
maximum inhibition at a concentration of around 10 |iM (Fig 40). These 
assays were carried out with a concentration of PMA that was sub- 
maximal in terms of both peak light emission and total light emission, but 
the degree of inhibition given by a single concentration of LPA was not 
very sensitive to the PMA concentration. Thus, for 10 ng/ml PMA, 20 
[iM LPA gave 40% inhibition and for 1 jlg/ml PMA the same 
concentration of LPA gave 39.5% inhibition where the response varied 
two-fold, suggesting that LPA was not acting by competing directly with 
PMA. The time course of the inhibited response differed from lower 
concentrations of PMA because, although the peak time was delayed, as in 
lower PMA concentrations, the total duration was not altered.
3.12.4.) The effect of pertussis toxin on LPA inhibition of the 
PMA-stimulated metabolic burst.
To further investigate the involvement of the heterotrimeric inhibitory G 
protein in LPA-induced inhibition of the metabolic burst, human 
neutrophils were pre-incubated with a concentration of PTx which was 
highly effective in inhibiting the response to fMLP. This treatment had 
no effect whatsoever on the response to PMA (Fig. 41). When control 
cells and pertussis toxin-treated cells were stimulated by PMA in the 
presence of LPA, the response curves were virtually identical showing 
that the powerful inhibitory effect of LPA was neither inhibited nor 
enhanced by pertussis toxin, thus ruling out the involvement of pertussis 
toxin-sensitive G proteins in the response of the cells to PMA or the 
inhibition of this response by LPA.
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Fig. 40. The effect of different concentrations on the PMA- 
induced metabolic burst of human neutrophils.
The metabolic burst was measured by DNDH-enhanced chemiluminescence, 
lOOng ml“l PMA was added to 1 x 10^ cells ml"l of control and LPA-treated 
neutrophils.
Mean ± S.E.M., n=4. 
p < 0.05 given by
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Fig. 41. The inhibition of the PMA-induced metabolic burst of 
pertussis toxin-treated neutrophils by LPA.
1 X 106 cells ml"l were incubated for 1 hour in the presence and absence of 
lOOng ml"l pertussis toxin (PTx). LPA was used at a final concentration of 
20 pm and PMA at lOOng ml~l-
a). PMA b). PMA + PTx c). PMA + LPA d). PMA + PTx + LPA 
Mean ± S.E.M,, n=3. 
p < 0.05 given by
AS
:-8l
■
iI
!;ï:
______   ■ _ _
R esu lts_________________________________________________________
3.12,5.) Effect of LPA on Degranulation of Human neutrophils
Some molecules have been shown to inhibit the metabolic burst of 
neutrophils simply by quenching the superoxide ions, preventing them 
reacting with the DNDH, and emitting light for the luminometer to 
detect. To rule out this false positive result for the inhibition of the 
metabolic burst by LPA, the fMLP-induced degranulation of neutrophils 
was assayed. There are a number of marker enzymes released 
simultaneously with the superoxide ions when neutrophils are treated with 
fMLP. Examples of these molecules are: myeloperoxidase, elastase, and 
collagenase, which can be assayed using a number of different techniques. 
Andrew MacLean, (unpublished result), assayed the effect of LPA on the 
degranulation of human neutrophils using myeloperoxidase and elastase as 
markers. He found that LPA significantly inhibited the fMLP-induced 
degranulation of human neutrophils. These results rule out any possibility 
of LPA quenching the DNDH-enhanced chemiluminescence results.
The primary aim of the investigations carried out in this work was to was 
to purify the active factor in the steroid-treated monocyte supernatant 
(STMS) responsible for dispersive motility in the automated cell tracking 
assay. This active molecule was also found to have other effects on 
neutrophil cell function, namely, alterations in F-actin distribution, cell 
shape, and inhibition of fMLP-induced chemotaxis. The purification of 
Thymosin |34 with an oxidised methionine residue, and subsequent 
confirmation that it causes dispersive motility raises many interesting 
questions that will require further investigation.
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Discussion
4.1.) Dispersive locomotion of neutrophils in response to a 
steroid-induced factor
4.1.1.) Development of the automated cell tracking assay
The effect of steroid-induced factors on neutrophil migration is primarily 
of interest in elucidating anti-inflammatory mechanisms. Glucocorticoids 
down-regulate the synthesis of many pro-inflammatory mediators (Lew 
et ah, 1988; Almawi et al., 1991; Standiford et al., 1992), but some of 
their actions can be interpreted in terms of up-regulation of anti­
inflammatory mediators (Flower, 1990; Goulding et ah, 1990; Wong et 
ah, 1991). However since the initial discovery of the STMS effect, there 
has been some difficulty in interpreting a neutrophil migration- 
stimulating activity as an anti-inflammatory effect. The parameters being 
measured in the initial assay (Stevenson, 1978) were not clear. The 
contribution to the dispersion of the cell pellet, from the end of the 
capillary-tube, of lowered adhesion or increased cell motility were not 
apparent in the assay results. This led Chettibi et ah, 1993 to utilise a 
computerised neutrophil cell tracking assay developed by Dow et ah, 
1987, running on a BBC Microcomputer. This assay indicated that cells 
treated with STMS had an increased speed of locomotion when compared 
with controls and IL-8 , but the apparent differences in cell tracks 
between the samples were not being converted into differences in the 
persistence and diffusion coefficient.
The work described in this thesis started with the development of a 
procedure written in the C programming language to process the raw 
data from the cell tracking program written by P.D. Lawrence. The new 
system of neutrophil tracking was very successful in differentiating the
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obvious differences in the cell motility between different treatments that 
stimulated neutrophil locomotion.
The quality of locomotion induced by STMS now provides information to 
resolve this difficulty. Dispersive locomotion would tend to prevent cells 
collecting at a focus and this might become important in terminating 
inflammatory responses. STMS-stimulated neutrophil locomotion has a 
non-exploratory character, in marked contrast to that induced by fMLP 
where we find intense activity coupled with strong adhesion which is an 
ideal pre-requisite for finding junctions between endothelial cells. The 
type of locomotion induced by STMS coupled with, or perhaps 
determined by the low adhesion state of the cells is more suitable for 
leaving than for finding a specific site. Thus STMS activity might be one 
of the factors that decreases the pool of marginating neutrophils in 
response to steroids, and inhibits transmigration between endothelial 
cells.
The spectacular dispersion of cells in response to STMS presents a 
dramatic contrast with their response to other agents such as fMLP and 
IL-8 which are equally potent stimulators of the locomotor activity. 
However the response conforms to the pattern predicted by Gail and 
Boone (1970,1972) for persistent random locomotion. Their original 
mathematical treatment has since been extended by a number of workers. 
Dunn (1983) and Dunn and Brown (1987) have presented highly 
sophisticated analyses and have argued that motor activity at the cellular 
level can never be truly random. Analysis of persistent random 
locomotion provides a simple model in which augmented diffusion can be 
attributed to the single parameter, the persistence. In the present study, a 
population of cells is engaged in random locomotion where each cell 
slowly changes speed and direction and these parameters eventually 
become unpredictable with respect to their initial values. For this
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situation, persistence is best described as the half-life ( t i /2 ) for 
randomisation of the locomotion of all of the cells with respect to their 
values at the to, the starting time.
The surprising finding of the present work is that locomotion of cells in 
response to the majority of stimuli tested is not persistent. This is 
particularly intriguing for responses to fMLP where the results show 
very clear constrained diffusion which is very similar to that described 
by Sheetz et al., (1989) of the random movement of colloidal gold 
labelled cell surface proteins. Tranquillo et ah, (1988) have shown that 
the chemotactic locomotion of neutrophils in a gradient of fMLP is 
persistent, but it is clear from inspection of the diffusion equations that 
any form of non-random locomotion must show persistence. These 
results also contrast with those presented by Dow et ah, (1987) where 
neutrophils moving in response to fMLP under the same conditions 
presented here showed highly variable persistence.
4,2.) Tilted-stage experiments
In the modified assay, variability has been greatly reduced and the 
contrast between responses to fMLP, lL -8 and STMS can be attributed to 
differences in persistence rather than speed. The contrast in response to 
these factors was even more sharply defined when cell locomotion was 
studied in the tilt assay which was designed to increase the response to 
changes in cell-substrate adhesion. This makes the response to STMS 
highly directional and dispersion gives way to displacement as the 
appropriate form of analysis (Sheetz et ah, 1989). The results in fig. 12 
show that for all stimulants the displacement in the first 1-2 frames is 
high and continues at this level in the presence of STMS, but falls rapidly
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in the presence of CMS and fMLP. The sustained slope of the 
displacement curve is clearly a sensitive and easily measured parameter 
which can be obtained in the first 30 seconds of analysis, in comparison 
with the diffusion coefficient which relies heavily on the late data to 
establish the form of the curve. These results indicate that tilt probably 
increases the true speed of locomotion of STMS treated cells by 1.5-2 
fold, but the locomotion remains that of cells moving from one point of 
adhesion to another, rather than free floating.
It is possible to speculate on the underlying mechanism for persistence. 
Electron microscope studies (Young et ah, 1997, enclosed) confirm the 
visual observation that cells treated with STMS tend to be bipolar rather 
than multipolar as found with IL-8 and fMLP. The saltatory type of 
locomotion indicates that adhesion at one pole is broken only when a 
competing adhesion is established at another pole and that there is no 
indication of rolling locomotion as observed when the cells make initial 
contact with vascular endothelium (for review see Bevilacqua and Nelson,
1993) We have now shown that placing the cells in a gravitational field 
polarises the locomotion in response to STMS much more strongly than 
that induced by other stimuli. This can be interpreted in terms of the 
tendency of the non-adhering pole to align down-slope where highly 
adherent, multipolar cells would be much less affected. Again this 
explanation reveals a paradox. If the direction of locomotion is so readily 
polarised by an external force, the inherent determinant of direction must 
be very weak. We do not consider that there can be a significant 
contribution from mechanical inertia for cells moving at relatively low 
speeds under conditions where low Reynolds number hydrodynamics 
apply. It therefore seems most probable that persistence for these cells 
must be a consequence of bipolar shape and a natural tendency of a new 
adhesion to generate a molecular motor complex whose orientation is
101
Discussion
determined by the geometry of the encounter of the cell surface with the 
substrate. Our results also indicate that for fMLP, one of the major 
mechanisms for sensing a gradient must involve differential adhesion 
strengths for contact sites aligned along the gradient.
4.3.) D ispersive locom otion, inhibition of chem otaxis and 
adhesion as the potential anti-inflammatory effect of STMS
The original assay for STMS activity, as noted at the time, did not 
distinguish between the consequences of reduced adhesiveness and 
increased motility and it is generally accepted that the steps involved in 
adhesion of neutrophils to endothelium are a key target for anti­
inflammatory agents (Gahmberg et ah, 1992; Cronstein, 1994). STMS 
released into the blood stream by monocytes in response to 
glucocorticoids would present itself to neutrophils as a uniform 
concentration and could therefore modify neutrophil behaviour in very 
much the way that we observe in our assays. Thus the cells should 
undergo some of the classic signs of activation, including polarisation and 
increased motility (Coates et ah, 1992; Fernandez et al., 1995; 
Ehrengruber et al., 1996) however they would also undergo a dramatic 
decrease in adhesiveness with the expected consequence that they would 
not be able to adhere under conditions of even modest shear stress.
The evidence presented in this study shows that the response to STMS 
contrasts sharply to the effects of the pro-inflammatory, chemotactic 
species exemplified by IL-8 , fMLP and lipid derived inflammatory 
mediators.
The mechanisms of neutrophil chemotaxis are still not clearly 
understood, but the quantitative features have been well described.
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Chemotactic locomotion of human neutrophils in a gradient of fMLP for
, y E
example, is characterised by persistent locomotion up-gradient in which 
the cells adopt a largely bipolar morphology (Tranquillo and Moghe,
1994). This bears superficial resemblance to the behaviour induced by a 
uniform concentration of STMS. However the activity of the cells in a
uniform concentration of chemotactic agent is characterised by very 
active exploratory motion, with pseudopodia forming at apparently 
random positions on the cell periphery and acting in conflict with one 
another. Each pseudopodium has high locomotory activity, but also high
apparent adhesiveness to the substrate and the consequence for each cell is 
seen as high apparent locomotory activity as measured by the speed ,
I?
with very low persistence. A simple interpretation of this behaviour is
that it underlies the mechanisms of gradient sensing and that pseudopodia
that reach up-gradient will be reinforced by the effects of the gradient
and dominate over down-gradient pseudopodia. The observations suggest
that adhesive effects may be more important than pure locomotory effects
in determining the outcome of the conflict
.The role of actin polymerisation in activated neutrophils has been the 
subject of intensive study (Coates et ah, 1992). The results in this study 
indicate that pseudopodia are the sites of high concentrations of F-actin 
and the observations of motile activity indicate that this actin will be in a 
state of constant reorganisation. The accepted mechanisms for 
pseudopodium driven locomotion require some form of actin cycling 
between the leading edge and a juxtanuclear location behind it (Stossel, 
1988). For a highly directed chemotactic response virtually all of the 
actin could be concentrated into this one active area. The results 
presented here and in Young et ah, 1997, show no such extreme 
bipolarity in response to uniform concentrations of chemotactic agents on 
protein coated glass and neither is the morphology in cells treated, and
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then fixed, in suspension. However, STMS-treated neutrophils are highly 
bipolar and furthermore appear to have a major concentration of F-actin 
at one pole and a secondary, minor concentration at the opposite pole. 
These cells do not have the overall degree of activity of cells responding 
to a chemotactic agent, but appear to be more highly motile because the 
locomotion is more persistent. The mechanism of locomotion is obscure 
because the cells appear to be weakly tethered to the glass by one 'tail' 
whilst the other moves freely until the cell appears to attach to, and move 
to, a distant site. The obscurity lies in the fact that because the cell 
appears to have a single site of adhesion, and is freely motile, there is no 
obvious reason why movement should continue in the previously 
determined direction. It is also not clear what role actin may play in this 
type of locomotion. There are two extreme models; the looping model 
and the tumbling model. In the looping model the tail of the cell would be 
the major point of adhesion whilst the head would make exploratory 
movements and then adhere, causing the tail to detach and move close to 
the head. In the tumbling model each end would act in turn as an adhesion 
point and the corollary is that the polymerised actin would have to pass 
from one pole of the cell to the other. Here the speed of locomotion 
would be governed by the rate at which loss of actin from the trailing 
pole allowed the leading adhesion to dominate over the trailing adhesion. 
In this model the directed flow of actin to the distant pole would underlie 
directional persistence.
The effect of STMS on chemotactic responses also sheds 
considerable light on its possible mode of action. STMS is not itself a 
chemotactic agent, but is a powerful inhibitor of the chemotactic response 
to fMLP. It appears to short-circuit chemotactic responses by inducing a 
highly polarised structure without any aspect of gradient sensing, but 
unlike other polarising stimuli, it causes a dramatic decrease in
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adhesiveness to protein coated-glass (Chettibi et aL, 1993), bovine aorta 
endothelial cells, and Human umbilical endothelial cells (Young et ah, 
1997, enclosed). Observations of the morphology of the cells and of the 
internal organisation give some indication why this should be. The 
surface of STMS-treated neutrophils, seen in scanning EM is readily 
distinguished from that induced by chemotactic agents by its extreme 
smoothness (Young et ah, 1997, enclosed). There is evidence that some 
forms of adhesion, for example that mediated by L-selectin is greatly 
increased by the clustering of the lectin on microvilli (von Andrian et al., 
1995). Following this example we propose that neutrophil adhesion may 
depend on the presence of surface projections, the lack of which in 
STMS-treated cells could explain the lowered levels of adhesion 
observed.
4.4.) Thym osin p4 as an anti-inflam m atory m ediator of 
G lucocorticoids
4.4.1.) Oxidation as a modulator of Inflammation
Methionine is the most readily oxidised amino acid, and a number of 
peptides and proteins have been described whose conformation, and or, 
function is altered by the oxidation of one or more methionine residues. 
Examples of altered conformation caused by methionine oxidation are: 
interferon a -2 B , where a single methionine oxidation altered 
conformation, and immuno-reactivity to a monoclonal antibody, although 
no change in function was observed (Gitlin et al., 1996). There is reduced 
activity in human parathyroid hormone following oxidation of one of 
two, and both methionine residues (Nabuchi et ah, 1995).
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The oxidative state of a number of molecules has been implicated in 
inflammation, as a signal of cellular damage. Oxidation of methionine 
residues inactivates bacterially derived chemotactic peptides like fMLP, 
whilst oxidation of pro-inflammatory lipid mediators gives rise to a 
broad spectrum of products, some with pro-inflammatory and some with 
anti-inflammatory effects (lira et al., 1997; Girona et al., 1997). 
Oxidation of a single methionine residue inactivates a l  anti-trypsin (the 
major inhibitor of neutrophil elastase) (Hall and Roberts, 1992; Cox and 
Billingsley, 1984) and the significance of this is underlined by the poor 
prognosis for insult induced lung damage for individuals with low a l  
anti-trypsin levels. The oxidation of the methionine in thymosin p4 has 
also been shown to reduce its actin binding in in vitro studies (Huff et al.,
1995).
The oxidation state of host inflammatory mediators may be a useful 
signal to leucocytes that the inflammatory response is causing damage to 
host tissue and reduce the avidity of that response. The oxidation of a 
uniquely eukaryotic peptide. Thymosin p4, makes it an ideal candidate as 
a signal to reactive oxygen producing phagocytic cells that the 
inflammatory response is causing host cell damage, and the inflammatory 
response needs to be reduced.
4.4.2.) Potential anti-inflammatory mechanisms of Tp4ox
The finding that Thymosin p4 with an oxidised methionine residue 
(Tp4ox) is produced by monocytes cultured in the presence of anti­
inflammatory glucocorticoids and is responsible for the dispersive 
locomotion induced by STMS implies that it may have a role as a
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mediator of the anti-inflammatory effects of glucocorticoids. A number 
of potentially anti-inflammatory functions have so far been ascribed to 
Tp4ox, in this study and also by Andrew MacLean, 1997.
4.4.2.1.) Dispersive locomotion
The type of locomotion induced by Tp4ox coupled with, or perhaps 
determined by the low adhesion state of the cells is a potential anti­
inflammatory mechanism, in that, persistence of the cells in a uniform 
concentration of agonist is more suitable for leaving than for finding a 
specific site. The release of Tp4ox at a site of inflammation by 
macrophages could have the effect of causing the neutrophil to leave the 
immediate area of inflammation. This can best be described in terms of 
the original assay for STMS by Stevenson, 1978, the capillary-tube 
migration assay (Fig. 5), in which neutrophils were seen to migrate away 
from the end of the capillary-tube in response to STMS. This type of 
behaviour is mimicked, to some degree, by the response of neutrophils in 
the cell tracking assay track displays (Fig 13), where the normalised cell 
tracks for STMS disperse away from the centre of the axes, whilst the 
tracks for CMS, and other neutrophil motility activating factors remain 
close to the centre due to the low persistence of the cells.
4.4.2.2.) Adhesion
The results presented in this study show the inhibition, by STMS of 
adhesion of human neutrophils to bovine aorta endothelial cells (Fig. 18). 
Previous work by Chettibi et al., 1993, showed that STMS inhibited the
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adhesion of neutrophils to bovine serum albumin-coated coverslips, and 
further work has been carried out by MacLean, 1997, in this laboratory, 
showing the same inhibitory effect of STMS, and HPLC purified active 
samples, using human umbilical vein endothelial cells (HUVEC) activated 
with IL-1 as the adhesive substrate. The adhesion of leucocytes to 
vascular endothelium is a crucial stage in their recruitment to an 
inflammatory site, and any disruption to this process has dramatic effects 
on the ability of leucocytes to combat infectious agents, seen in leucocyte 
adhesion deficiency (LAD) (Anderson and Springer, 1987). However, in 
inflammatory disorders were there is excessive leucocyte infiltration into 
tissue without apparent insult, a mediator that reduces adhesion of 
leucocytes to the endothelium would be of great therapeutic benefit. The 
mechanism by which glucocorticoids reduce the number of marginating 
neutrophils is thought to be by inhibition of their adhesion to vascular 
endothelium. Part of this reduction of adhesion is probably due to the 
decrease in the surface expression of endothelial adhesion molecules 
ICAM -1 and L-selectin on endothelial cells(Cronstein et al., 1992). 
Release of Tp4ox by blood monocytes in patients under glucocorticoid 
therapy could also account for a decrease in the number of marginating 
neutrophils.
4.4.2.3.) Chemotaxis
The mechanism by which neutrophils are able to detect and move up a 
chemotactic gradient is unknown. There are two main models proposed, 
and a third is a hybrid of the first two. The temporal model involves the 
cells being able to remember the concentration of agonist at a particular 
time, move to another site, and compare the levels, deciding to move
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towards the higher concentration. The mechanism by which a cell 
'remembers' is unknown. The spatial model proposes that a cell is able to 
detect a small change in concentration across the length of its cell by 
differences in the number of agonist receptors occupied, choosing to 
move in the direction with more occupied receptors. However the 
neutrophil detects a chemotactic gradient and moves towards a site of 
inflammation, it is a fundamental function of the cell in vivo, and  
inhibiting this would be potentially of great therapeutic benefit. STMS 
starting material is a potent inhibitor of the fMLP-induced chemotaxis of 
neutrophils in the modified Boy den chamber assay (section 3.6). It 
remains to be tested if Tp4ox is an inhibitor of this particular function of 
neutrophils.
4.4.2.4.) Degranulatioii
Although no inhibitory effect on the fMLP or PMA-induced release of 
superoxide ions by human neutrophils has been found, using partially- 
purified HPLC samples or neutrophil huffy coat T^4ox (results not 
shown), MacLean, 1997, has found a significant inhibitory effect of 
partially-purified HPLC samples, active in our cell tracking assays, on the 
fMLP-induced de granulation of human neutrophils. It remains to be seen 
if T(34ox present in these active samples was the mediator responsible for 
this inhibitory effect, but would be consistent with its potential anti­
inflammatory role, preventing the release of enzymes, such as, elastase 
and collagenase.
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4.5.) Parallel purification of Tp4ox from STMS and CMS
The results of parallel purification of thymosin p4 from STMS and CMS 
(section 3.11) show that there is more Tp4ox present in STMS than CMS, 
and indeed the UV trace for CMS at the elution point of Tp4ox is 
indistinguishable from the baseline trace. This would appear to confirm 
the glucocorticoid induction of secretion of Tp4 by steroid-treated 
monocytes. It is not clear whether TP4 is actively secreted by the 
monocytes, or released by cell damage caused by the glucocorticoid 
presence. Stevenson, 1978, however, showed that at the concentration of 
steroid being used in the culture of monocytes used here, no significant 
cell damage occurred. This would imply that the cells are actively 
secreting Tp4ox into the culture medium.
The result of the parallel purification of STMS and CMS does not give a 
clear cut answer to the question of the relative quantity of Tp4ox being 
released by the cells under both culture conditions as the signal to noise 
ratio in the samples is low, and will therefore require a repeat of this 
procedure using a greater starting volume for each.
4.6.) Oxidation of Thymosin and its release by glucocorticoid  
treated monocytes
The mechanism by which the monocyte could oxidise and release 
thymosin p4 is unclear. The vast majority of secreted proteins leave the 
cell by the classic ER/golgi/ route and they pass to the PM by either the 
constitutive or the regulated secretion pathways. An increasing number 
apparent exceptions are now being identified where the polypeptide does 
not possess an ER translocation signal. These polypeptides appear to be
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translated on cytoplasmic ribosomes and then pass directly through the 
PM by an unspecified mechanism. Examples of this are lipocortin 1, a 
cytosolic protein which also has an extracellular pool and has been 
implicated in modification of neutrophil behaviour. This polypeptide 
lacks an ER signal yet is efficiently exported from monocytes / 
macrophages (Comera and Russomarie, 1995). Interestingly, although 
there is a large cytosolic pool of lipocortin 1, and the synthesis appears to 
be steroid regulated, the export also appears to be steroid regulated 
(Comera and Russo-marie, 1995; Philip et ah, 1997; Mizuno et al., 1997). 
This molecule shares another feature with thymosin (34 in that it has an 
N-terminal acetyl group. The hypothesis has been proposed that proteins 
which have this post-translational modification are by and large those 
with a long residence time in the cytosol; the implication being that the 
acetylase enzyme is non-specific and slow acting.
lL-1 is also exported directly through the PM, although in this case the 
export appears to be coupled with proteolytic cleavage catalysed by lL-1 
cbnverting enzyme (ICE).
From this it can be concluded that a number of proteins which could be 
involved in signalling can be secreted directly from the cytosol. 
Furthermore a number of these show the characteristic feature associated 
with long residence time in the cytosol. This sub-class also share the 
interesting feature in that all have been proposed to interact with actin. 
The secretion of lipocortin-1 by a steroid dependent mechanism and the 
acetylated N-terminal shows apparent similarities to the release of T(34ox 
by steroid-treated monocytes.
There are two possible sites at which T|34ox could act as an anti­
inflammatory signal.
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Release of T(34 in its native state by monocytes at an inflammatory site 
and subsequent oxidation by reactive oxygen species produced by 
neutrophils could signal these cells, via a specific receptor for the 
oxidised derivative, to 'switch o ff their inflammatory responses and 
leave the site by the dispersion mechanism described above. Diffusion of 
Tp4ox from the site could then affect the adhesion of marginating, and 
chemotaxis of migrating neutrophils, preventing them from successfully 
reaching the inflammatory site.
The second site of action is in the bloodstream. Release of Tp4ox by 
blood monocytes could reduce the number of vascular endothelium- 
adherent neutrophils, as seen in patients under glucocorticoid therapy.
4.7.) Lysophosphatidic acid: An induces neutrophil locomotion 
and inhibits their fMLP and PMA-induced metabolic burst
The study into the effects of LPA as a mediator of neutrophil function 
came from our initial neutrophil tracking assays, in which we compared 
the motility induced by a number of neutrophil locomotion stimulators. 
LPA has been previously reported to have no effect on intracellular 
calcium concentration in human neutrophils (Jalink et al., 1990), but little 
work had been carried out on its effect on other neutrophil functions and 
responses, and since LPA is released at physiological concentrations by 
thrombin-activated platelets, 1-1.5 pM (i.e. 0.5-2.5 pg/ml) (Eichholtz et 
al., 1993)., it seemed reasonable that it would have some effect on 
immune cells infiltrating into a wound site.
In the present studies, LPA affected neutrophil shape change and 
activated motility. In addition this lipid was a powerful inhibitor of the
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production of oxygen species (the metabolic burst) by human neutrophils 
in response to fMLP and PMA.
4.7.1.) Intracellular mechanism of LPA effects on human 
neutrophils
LPA has been reported to affect various cell functions through the 
activation of a family of membrane-bound G proteins, some of which are 
pertussis toxin-sensitive and some pertussis toxin insensitive (van Corven 
et ah, 1993). The results in this study show an apparently simple 
mechanism for the action of fMLP consistent with the involvement of 
heterotrimeric inhibitory G protein (Gi). Thus LPA antagonises the 
effect of fMLP by lowering the activation of Gi whilst pertussis toxin 
achieves the same effect by the ADP-ribosylation of G^a subunit(Kumagia
et ah, 1993). When the two agents were used in conjunction, the residual 
activity present when the action of fMLP was partially inhibited by LPA 
and further reduced by the presence of pertussis toxin was consistent with 
the action of a common mechanism.
An obvious consideration when interpreting these results is to consider 
the possibility that LPA is in some way reducing the detected metabolic 
burst by a quenching mechanism as seen with some other molecules tested 
in a chemiluminescence assay. To rule this out as a possibility the fMLP- 
induced degranulation of human neutrophils was assayed and similar 
inhibition was observed by LPA (Dr. A.G. MacLean, personal 
communication). These types of assay are not open to the same artefact 
possibilities as chemiluminescence, so it safe to conclude from these 
results that the observed inhibition of the metabolic burst of human 
neutrophils by LPA was through a cellular process.
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Since both LPA and PTx alone can produce total inhibition of the fMLP- 
mediated response, it is difficult to design experiments in which 
alternative pathways of inhibition could be identified. In contrast the 
inhibition of PMA-simulated metabolic burst by LPA shows an effect that 
cannot be attributed to the same heterotrimeric inhibitory G proteins 
because the action of PMA occurs at a later point in the pathway and 
LPA-induced inhibition of the PMA-stimulated metabolic burst in both 
pertussis toxin-treated and untreated cells was identical.
An alternative explanation follows very readily from consideration of the 
involvement of the small cytosolic GTP-binding proteins in the regulation 
mechanism of NADPH-oxidase activity. Recently a number of cytosolic 
GTP-binding proteins (G(9x) have been reported to be involved in the 
regulation of the metabolic burst enzyme, NADPH-oxidase ( review see 
Morel et al., 1991). These include, Rac 2 a member of the Ras super 
family of GTP-binding proteins (Knaus et al., 1991), p61P^^ox and 
p4 '7phox^ which were identified by their absence in patients with chronic 
granulomatous disease and the Ô 1 which was identified as the small 
GTP-binding protein and the GDP-dissociation inhibitor rhoGDl
(Abo et al., 1991). In vivo experiments showed that LPA was among the 
phospholipids able to inhibit rhoGAP (Tsai et al., 1989) and recent work 
has shown that LPA was able to stimulate the rho family of small GTP- 
binding proteins that are involved in the regulation of actin stress fibres 
and the assembly of focal adhesions in fibroblasts (Ridley and Hall, 1992; 
Ridley et al., 1992).
Although the regulation of small GTP-binding proteins by LPA in human 
neutrophils has not been reported elsewhere, the present results provide 
good evidence for the action of LPA via the small GTP-binding protein. 
The mechanism of the effect of LPA on neutrophil shape change.
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locomotion and inhibition of the metabolic burst in this study could be 
mediated through its effects on these small GTP-binding proteins. Clearly 
any action at the penultimate stage in the signal transduction pathway 
obscures any upstream effects and it is therefore not clear if LPA inhibits 
the action of fMLP by acting both at an early stage to block the trimeric 
G proteins and at a late stage to block the action of the small GTP-binding 
protein. The alternative model is that the action of LPA on the same 
GTP-binding protein is modulated via the trimeric GTP-binding protein. 
Obviously, further experiments are required to address the direct 
involvement of these small cytosolic GTP-binding proteins in the 
regulation of the neutrophil activation and their regulation by LPA.
4.7.2.) Role of LPA as an inflammatory mediator
These results imply that LPA could have a modulatory effect on 
neutrophils following an injury. Released by platelets during blood 
clotting, its proliferative effects on a number of cell types, including 
fibroblasts, could aid in tissue repair. It will be of interest to see if LPA 
exerts any chemotactic stimulus on fibroblasts encouraging them to 
migrate towards the damaged site and speed up the repair of tissue. The 
stimulatory effect of LPA on the migration of neutrophils, in this study, 
does not have an obvious function in vivo. It remains to be seen if LPA is 
chemotactic for neutrophils in vitro, which could provide a role in 
attracting the cells to a site of possible infection. The inhibitory effect of 
LPA on degranulation and the metabolic burst seems to conflict with this 
role, in that, a factor with a pro-inflammatory function to activate the 
motility and attract neutrophils from the bloodstream then inhibits their 
main anti-microbial functions. The possible role that LPA has in 
inflammation remains to be clarified by further investigation.
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Program written in C, to run on an Acorn Archimedes 
microcomputer; to display results from tracking assay
Calculates average cell displacement, speed, drift and direction of drift of cell 
population.
Displays graphs of: Average speed vs time. Displacement vs time, and 
displacement squared vs time.
Allow the user to draw a line, using the mouse control, that corresponds to 
the linear part of the displacement squared graph; outputing the parameters of 
cell locomotion, namely, diffusion coefficient and persistence.
#include "track.h"
#include <bbc.h>
#include <sprite.h>
#include <time.h>
#include <math.h>
extern celldata cellarray[FRAMES][MAXCELLS]; 
extern int interval;
FILE *frle;
void cell_pos_speed( int frame,char ^mame, int numactive )
{int fr, cell; 
int no_readings; 
int totaLno„readings = 0; 
int x_start = 48; 
int y„start = 388; 
int xjncrem ent = 428; 
int x_startl = x„start + x_increment; 
int x_start2 = x_start +  2 * x_increment; 
double sp_dr_x = 0; 
double sp_dr„y = 0; 
double drift_speed = 0; 
double sp„drift„x = 0; 
double sp_drift_y = 0; 
double x_drift = 0, y_drift = 0; 
double drift_angle = 0; 
double x_dr = 0; 
double y_dr = 0; 
double drift = 0; 
double tot_drift = 0; 
double mean_x_dr = 0; 
double mean_y_dr = 0 ; 
int x_step; 
int X ,y,buttons; 
double xO, y0, x l, y l; 
double diffusion; 
double paths = 0;
double sum_xvals = 0, sum_^vals = 0; 
double total_sum_speed = 0; 
double frame_mean = 0; 
double d_paths; 
double dy_val = 0; 
double sum_speed = 0; 
double mean = 0; 
double y_val = 0; 
double init_area = 0; 
double final_area = 0;
*>:r
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double sum_area = 0;
int d2y_co = 0; 
int dd2y_co = 0; 
int d2time = 0; 
int dy_co = 0; 
int ddy_co = 0; 
char path [80];
bbc_gcol ( 0 , 7 ) ;  
bbc_move( x_start, y_start); 
bbc_draw( x_start + 400, y_start ); 
bbc_move( x„start, y„start); 
bbc_draw( x_start, y_start + 600 ); 
bbc_move( x_stait, y_start + 300 ); 
bbc_draw( x_start + 10, y_start + 300); 
bbc„move( x_start, y_start + 600 ); 
bbc_draw( x„start +10, y_start + 600 ); 
bbc_move( x_start + 200, y_start); 
bbc_draw( x_start + 200, y_start +10); 
bbc_move( x_start + 400, y_start); 
bbc_draw( x_start + 400, y_start +10); 
bbc_move( x„startl, y_start); 
bbc_draw( x„startl + 400, y_start ); 
bbc„move( x_startl, y_start); 
bbc_draw( x_startl, y„start + 400 ); 
bbc_move( x„startl, y_start + 200 ); 
bbc_draw( x_startl + 10, y_start + 200); 
bbc_move( x_startl + 200, y„start ); 
bbc_draw( x„startl + 200, y_start + 1 0 ) ;  
bbc_move( x_startl, y_stait + 400 ); 
bbc_draw( x_startl + 10, y_start + 400 ); 
bbc__move( x_start2, y„start); 
bbc_draw( x_start2 + 400, y_start ); 
bbc_move( x„start2, y_start); 
bbc_draw( x„start2, y_start + 400 ); 
bbc_move( x_start2, y_start + 200 ); 
bbc_draw( x„start2 +10, y_start + 200); 
bbc_move( x_start2 + 200, y_start); 
bbc_move( x_start2, y_start + 400 ); 
bbc_draw( x_start2 + 10, y_start + 400); 
paths = 0; no_readings = 0;x_drift = 0; y„drift = 0; 
for( cell = 0; cell < numactive; cell++ )
{if( c e lla iT a y  [ fr a m e  - l ] [ c e l l ] .v a l i d  )
{no_readings++;
paths += (double)0.36  ^ (double)sqrt( fsqr( (double)cellai'ray[frame -1][cell].centre.x - 
(double)cellarray[0][cell].centre.x) + (double)fsqr(cellarray[frame -l][cell].centre.y 
- (double) cellarray [0] [cell]. centre, y) ) ;
}}diffusion = sqr (paths / no„readings); 
strcpy( path, "$.comma." ); 
strcat( path, name ); 
file = fopen( path, "w" ); 
for( fr = 1 ; fr < frame ; fr++ ){no_readings = 0; sum_xvals = 0; sum_yvals = 0;sp_drift_x = 0; sp„drift_y = 0;sp_dr_x = 0; 
sp„dr_y = 0;
for( cell = 0; cell < numactive; cell++ )
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if( cellarray [fr] [cell], valid )
{no„readings++;
sum_xvals += ((double)cellarray[fr][cell].centre.x - (double)cellarray[0][cell].centre.x); 
sum_yvals += ((double)cellarray[fr][cell].centre.y - (double)cellarray[0][cell].centre.y); 
x_drift = sum_xvals/no_readings; 
y„drift = sum_yvals/no_readings;
sp_drift_x += ((double)cellarray[fr] [cell].centre.x - (double)cellarray[fr-1 ] [cell] .centre.x); 
sp_drift_y += ((double)cellarray[fr][cell].centre.y - (double)cellarray[fr-l][cell],centre.y);
}sp_dr„x = sp_drift_x/no_readings; 
sp_dr_y = sp_drift_y/no_readings;
drift_speed = (double) sqrt(fsqr(sp_dr_x) + (double)fsqr(sp_dr_y)) ; 
tot_drift = ((double)sqrt(fsqr(x_drift) + (double)fsqr(y_drift))) 0.36; 
x_dr += x_drift; 
y_dr += y^drift;
sum„speed = 0, paths = 0, d_paths = 0; no„readings = 0; sum_area = 0; 
for( cell = 0; cell < numactive; cell++ ) 
if( cellarray [fr] [cell], valid )
{no_readings++;
sum_speed += (( sqrt ( fsqr (( (double)cellarray[fr][cell].centre.x
- (double)cellarray[fr -1 ] [cell].centre.x))
+ (doiible)fsqr( cellarray [fr] [cell].centre.y
- (double)cellarray[fr -1 ][cell].centre.y)))
4.32 ) - (double)(drift_speed 4.32);
/* convert pixels per 5 seconds to microns per minute 'V 
paths += ( 0.36 =1= (double) sqrt( fsqr( cellarray [fr] [cell].centre.x
- (double)cellarray[0] [cell] .centre.x )
+ (double)fsqr( cellarray [fr] [cell] .centie.y
- (double)cellarray[0] [cell].centre.y )))
- tot_drift;
d_paths += 0.36 * (double)sqrt( fsqr( cellarray [fr] [cell].centre.x
- (double)cellarray[0] [cell] .centre.x )
+ (double)fsqr( cellarray [fr] [cell].centre.y
- (double)cellarray[0][cell].centre.y )); 
sum_area += ( cellarray [fr] [cell].area);}if(fr == 1) init_area = 0.36 0.36 (sum_area/no_readings);
if(fr == frame -1) final_area = 0.36 0.36 * ( sum_area/no_readings);
total_no_readings += no_readings;
total_sum_speed += sum„speed;
frame_mean = sum_speed / no_readings;
mean = (total_sum_speed / total_no_readings);
y_val = fsqr(paths / no_readings);
dy_val = fsqr(d_paths / no_readings);
x_step = (2 interval fr/(frame/40 + 1));
bbc_gcol(0, 7);
bbc_circle(x_start + x_step, y„start + 2.8 * y„val, 6); 
bbc_gcol(3, 1);
bbc_rectangle(x_start + x_step, y_start + 2.8 * dy_val, 8,8); 
bbc_gcol(0, 2);
bbc„circle( x_start2 + x_step, y_start + 4 * no_readings,6); 
bbc_gcol(0, 6);
bbc_circle( x_startl + x_step, y_start + 20 paths / no_readings,6); 
bbc_gcol(0, 3);
bbc_rectangle( x_staitl + x„step, y„start + 20 * d_paths / no_readings ,8,8); 
bbc„gcol(0, 5);
bbc_circle( x_startl + x_step, y_start + 20 tot„drift ,6); 
bbc_gcol(0, 3);
bbc_circle( x„start2 + x_step, y_start + 15 * frame_mean,6 );
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/'I' comma separated file */
d2y_co = y_val;
dd2y_co = dy_val;
d2time = interval fr;
dy_co = 10 paths / no_readings ;
ddy_co =10 * d_paths / no_readings ;
fprintf(file, "%d,", d2time );
fprintfÿile, "%4.2f,", (float)dy_co/10 );
fprintf(file, "%4.2f,\n", (float)ddy_co/10 );
/*fprintf(file, "%d,", ditime ); 
fprintf(file, "%d,", d2y_co ); 
fprintf(file, "%d,", dd2y_co ); 
fprintf(file, "%d,\n", d2time );*/
}fclose( file ); 
mean_x_dr = x_dr/frame; 
mean_y_dr = y_dr/frame;
drift =(double)( sqrt(fsqr(x_dr * 0.36) + (double)fsqr(y_dr 0.36) ))/frame;
drift_angle = atani (mean_y„dr , mean_x_dr );
text_colour(2);
tab( 4, 23); printf( "Diff. coeft" );
tab( 4, 24); printf( "Persistance"
tab( 57, 28); printf( "Frames");text_colour( 2 );
tab( 57, 24); printf( "Cells");
text„colour( 2 );
tab( 57, 27); printf( "Area");
text„colour(2);
tab( 57, 23); printf( "Speed");
text„colour(2);
tab( 32, 24); printf( "Drift" );
text_colour(2);
tab( 32, 23); printf( "Distance");
text_colour(7);
tab(17, 23 );
printfC’??? ");
tab(17,24);
printfC'??? ");
/='= print mean speed corrected for jitter of 2-3 in y-axis ''V 
text__colour(3);
tab(65, 23); printf( "%3.1f", (mean ) );
printf( "pm/min");
text_colour(7);
tab(4, 1); printf( "200pm<");
text_colour(2);
tab (65, 24);
printf( "%d-%d ", numactive, no_readings);
text_colour(7);
tab(65, 27);
printf( "%3.1f", init_area);
printf( "pm<-");
printf( " % 3.1 f", final_aiea ) ;
printf( "pm<");
text_colour(5);
tab( 42, 24);
printf( "%2.2f", drift);
printf( "pm at ");
printf( "%1.0f", (drift_angle * 360)76.28);printf( "oo");
text_colour(6);
tab( 42, 23); printf( "%4.2f", paths/no_readings ); 
printf( "pm" );
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pauseQ;
mouse( &x, &y, &buttons ); 
xO = x; yO = y; 
mouse( &x, &y, &buttons ); 
bbc_move(xO, yO); 
bbc„draw( x, y ); 
x l = x; y l = y; 
do {mouse( &x, &y, &buttons ); 
if( X != x l I y != y l){bbc_gcol(3,6); 
bbc_move(xO, yO); 
bbc_draw (x l,y l ); 
bbc_move(xO, yO); 
bbc_draw( x, y ); 
xl = x; y l =y; 
i f ( x O ! = x l )
{text„colour(6); 
tab( 17, 23); printf( " "); tab( 17, 23);
printf( "%2.3f’,(y0 - yl)/( 4 * (xO - xl))); 
printf( "pm^sec.");
if(yO !=yl  )(tab( 17, 24); printf( " "); tab(17, 24 );
if(frame > 40)
printf( "%4.2f", (xO - x„start - (xO - x l) (yO - y_start) /(yO - yl))); 
printf( "sec.");}else {printf( "% 4.2f, (xO - x_stait - (xO - x l) * (yO - y„start) /(yO - yl))/2); 
printf( "sec.");
1 1
I whiie( buttons ); 
bbc_gcol(0, 7);
'void scatter_list( int frame, int numactive )
int paths = 0; 
int no_readings = 0; 
int cell;
bbc_gcol( 0, 7 ); 
if( 60 / interval >= frame ) return; 
for( cell = 0; cell < numactive; cell++ ) 
if( cellarray [60 / interval] [cell], valid )
{no_readings++; 
paths += 0.36 *
(double)sqrt( sqr( cellarray [60/interval] [cell].centre .x  - 
(double)cellarray [0] [cell]. centre.x)
+ (double)sqr( cellarray [60/interval] [cell].centre.y - (double)cellarray [0] [cell] .centre.y)
); }
I
I
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}
void scatter( int frame, int numactive, char *name, char ^details, char "*'date ) 
{char path [80]; 
clrscrO; 
cursor_off(); 
pointerO; 
text„colour(7); 
tab ( 58, 7); 
printf( "25pm/min." ); 
tab (48,7 );
/* text_colour(6); 
printf( "100pm<" ); 
text„colour(7); 
tab(31,7); 
printf( "20pm"); 
text_colour(7); 
tab( 65, 28 ); 
printf( "%d", frame ); 
printf( '"^ ’"); 
printf( "%d", interval); 
printf( "sec."); 
tab( 15, 20 ); 
if( frame <40)
{printf( "%d", interval 20 ); 
printf( "sec."); 
tab( 42, 20 );
printf( "%d", interval * 20 ); 
printf( "sec."); 
tab(69, 20 );
printf( "%d", interval * 20 ); 
printf( "sec.");
}if( frame >40){printf( "%d", interval =*= 40 ); 
printf( "sec."); 
tab( 42, 20 );
printf( "%d", interval * 40 ); 
printf( "sec."); 
tab( 69, 20 );
printf( "%d", interval 40 ); 
printf( "sec.");
}tab( 4, 30 );
text_colour(2); printf( "Details " ); 
text_colour(7); printf( "%s", details ); 
text„colour(2); tab( 4, 28 ); printf( "Title "); 
text_colour(7); printf( "%s", name ); 
tab( 20, 28 );
text„colour(5); printf( "%s", date ); 
text_colour(2);
scatter_list( frame, numactive ); 
celLpos_speed( frame, name, numactive);
/"'strcpy( path, "$.plot." ); 
strcat( path, name ), 
sprite_screensave( path, 0 );"^ 7 
pauseO;}
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300, y_increment = -300;
void graphs( int frame, int numactive, char ^mame, char ^details, char "'date ) 
char path [80];
int x„start = 200, y_start = 800, x_increment = 
int length =100;
int x_startl, y_startl, paths, distance; 
int cell, fr;
int x_drift, y_drift, sum_xvals, sum_yvals; 
int no_readings; 
int X, y, buttons; 
clrscrO;
/* Loop through every second frame "V 
for( fr = 0; fr< frame; fr = fr + 2)(plot a series of 12 axes */ 
x_startl = x_start + fr/2%4 x„increment; 
y_startl = y„start + fr/8%3 y_increment; 
bbc_gcol( 0, 7 );
bbc_move( x„staitl - length, y_startl ); 
bbc„draw( x_startl + length, y_startl ); 
bbc_move( x_startl, y_startl - length ); 
bbc_draw( x_startl, y_startl + length ); 
calculate population drift for each frame */ 
no_readings = 0, sum„xvals = 0, sum_yvals 
for( cell = 0; cell < numactive; cell++ ) 
if( cellarray [fr] [cell] .valid )
{no_readings++;
sum_xvals += (cellarray [fr][cell].centre.x 
sum_yvals += (cellairay[fr][cell].centre.y 
1x_drift = sum„xvals/no_readings; 
y_drift = sum__y val s/no_readings ;
calculate the mean population displacement, distance, and plot as circle radius distance "7 
no__readings = 0, paths = 0; 
for( cell = 0; cell < numactive; cell++ ) 
if( cellaiTay[fr][cell].valid )
no_readings++;
paths += (double)sqrt( sqr( cellarray [fr] [cell].centre.x - (double)cellarray [0] [cell] .centre.x 
- x_drift) +
(double) sqr( cellarray [fr] [cell].centre.y - (double)cellarray [0] [cell] .centre.y -
y_drift) );
1distance = paths/no_readings; 
bbc_gcol( 0, 7);
bbc_circle (x_staitl , y_startl , distance * 3);
/* calculate the position of the cell centres and plot as circles radius 2 "'Z 
for( cell = 0; cell < numactive; cell++ ) 
if( cellarray [fr] [cell], valid )
{bbc_gcol( 0,4); "7 
bbc_gcol( 0, fr%7 + 1 ); 
bbc„circlefill
( ( (double)cellarray [fr] [cell] .centre.x
- (double)cellarray[0][cell].centie.x - (double)x„drift) "= 3 + x_startl,
( cellarray[fr][cell].centre.y
- cellairay [0] [cell] .centre.y - y_drift) * 3 + y_startl, 2 );
0, distance = 0;
cellarray [0] [cell]. centre.x) ; 
cellarray [0] [cell]. centre.y) ;
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if((fr/2 + l)%12== 0)
{pauseO;
strcpy( path, "$.TRACK.jygraph." ); 
strcat( path, name ), 
sprite_screensave( path, 0 ); 
clrscrO;
}do{
mouse( &x, &y, &buttons );
}while( buttons );
1pauseQ;
}
void tracks( int frame, int numactive, char "'name, char "'details, char "'date )
{char path [80];
int x_start = 600, y_start = 500; 
int cell, fr; 
int x,y,buttons; 
clrscrQ;
bbc„gcol( 0 ,7 ) ;
bbc„move( x_start - 400, y_start ); 
bbc_draw( x„start + 400, y_stait ); 
bbc_gcol(0,7);
bbc_circle( x_start, y„start ,60); 
bbc_move( x_start, y_start - 400 ); 
bbc_draw( x_start, y_start + 400 ); 
for( cell = 0; cell < numactive; cell++ ){for( fr = 1 ; fr < frame; fr++ ) 
if( cellarray [fr] [cell], valid ){bbc_gcol( 0, cell % 7 + 1 ); 
bbc_move(
(( cellarray[fr - 1][cell].centre.x) 5 - (cellarray[0][cell].centre.x) * 5 + x__start), 
(( cellarray [fr - l][cell].cenhe.y) "' 5 - (cellarray [0] [cell].centre.y) "' 5 + y_start)); 
bbc_draw(
(( cellarray [fr] [cell].centre.x ) "' 5 - (cellarray [0] [cell], centre.x) "' 5 + x_start),
(( cellarray [fr] [cell].centre, y ) * 5 - (cellarray [0] [cell].centre.y) "' 5 + y_start));
}pauseQ;
do
{mouse( &x, &y, &buttons ); 
strcpy( path, "$.trak." ); 
strcat( path, name ), 
sprite_screensave( path, 0 );
} while( buttons );
1pauseQ;
}void trackdata( int frame, int numactive, char "'name, char "'details, char "'date )
{FILE "'file; 
int trakx_co = 0; 
int traky„co = 0; 
char path [80];
int x_stait = 600, y„start = 500; 
int cell, fr;
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clrscrO;
bbc_gcol( 0 ,7 ) ;
bbc_move( x_start - 400, y_start ); 
bbc_draw( x_start + 400, y_start ); 
bbc_move( x„start, y_start - 400 ); 
bbc_draw( x_start, y_start + 400 ); 
strcpyC path, "$.trakdata." ); 
strcat( path, name ); 
file = fopen( path, "w" );
for( fr = 1 ; fr < frame; fr++ )
{trakx_co = 0; traky_co = 0;
for( cell = 0; cell < numactive; cell++ )
if( cellarray [fr] [cell], valid )
{bbc_gcol( 0, cell%7 + 1 ); 
bbc_move(
(( cellarray [fr - 1] [cell].centre.x) * 5 - (cellarray [0] [cell].centre.x) 5 + x_start),
(( cellarray [fr - l][cell].centi'e.y) * 5 - (cellarray [0] [cell]. centre .y) * 5 + y_start)); 
bbc_draw(
(( cellarray [fr] [cell] .centre.x ) * 5  - (cellarray [0] [cell].centre.x) 5 + x_start),
(( cellarray[fr][cell].centre.y ) * 5 - (cellarray[0][cell].centre.y) 5 + y_start)); 
trakx_co = (cellarray[fr][cell].centre.x ) - (cellarray[0][cell].centre.x); 
traky_co = (cellarray[fr][cell].centre.y ) - (cellarray[0][cell].centre.y); 
fpriiitf(file, "%d,", trakx_co ); 
lprintf(file, "%d,", traky„co );
}else
{fprintf(file, " ," ); 
fprintf(file, " ,' );
}fprintf(file, "\n" );
} fclose( file );
pauseO;
}
void histograms( int frame, int numactive, chai" "'name, char "'details, char "'date )
/"' Takes cell displacements - drift grouped in predetermined band width listed in counter and 
finds
the number of cells whose displacments fall in that band width ie size [counter] "'/
{char path [80];
int x_start = 40, y_start = 720, x_increment = 360, y_increment = -360;
int length = 320, x_staitl, y_startl ;
int cell, fr;
int size[100];
int counter;
int x_drift, y_drift, sum_xvals, sum_yvals; 
int no_readings; 
int X, y, buttons; 
clrscrO;
for( fr = 0; fr < frame; fr = fr + 2)
{x_startl = x_start + fr/2%3 * x_increment; 
y_startl = y_start + fr/6%3 "' y_increment; 
bbc_gcol( 0, 7 ); 
bbc_move( x_startl, y_startl ); 
bbc_draw( x_startl + length, y_startl );
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bbc__move( x_staitl, y_startl ); 
bbc_draw( x_staitl, y„startl + length ); 
for(counter = 0; counter <100; counter++)
{size[counter] = 0;
sum_xvals = 0; sum_yvals = 0; 
for( cell = 0; cell < numactive; cell++ ) 
if( cellarray [fr] [cell], valid )
{no_readings++;
sum_xvals += (cellarray[fr][cell].centre.x - cellairay[0][cell].centre.x); 
sum_yvals += (cellarray[fr][cell].centre.y - cellarray[0][cell].centre.y);
)x_drift = sum_xvals/no_readings; 
y_drift = sum_yvals/no„readings; 
for( cell = 0; cell < numactive; cell++ ) 
if( cellarray [fr] [cell], valid )
{counter = (double)sqrt( sqr( cellarray [fr] [ceil].centre.x
- (double)cellarray[0] [cell] .centre.x
- (double)x_drift ) + (double)sqr( cellarray [fr] [cell] .centre.y
- (double)cellarray[0] [cell] .centre.y - (double)y_drift )/4 ); 
size[counter]= (size[counter] + 1);
1bbc_gcol( 0, 6);
for(counter = 0; counter <60; counter++) 
bbc_rectanglefill(x_startl + 4 counter, y„startl, 4, 20 * size [counter]);
}if((fr/2+ l)%9 == 0){pauseO;
strcpy( path, "$.jyhist." ); 
strcat( path, name ), 
sprite_screensave( path, 0 ); 
clrscrO;}do{
mouse( &x, &y, &buttons );
} while( buttons );
}pauseO;
}void root( int frame, int numactive )
{int x_start = 200, y_start = TOO;
int cell, fr, no_readings, x_drift, y_drift;
int time_span, paths;
int sum_xvals = 0, sum„yvals = 0;
int xO, yO, x l, y l;
int X, y, buttons;
clrscrO;
bbc_gcol( 0 ,7 ) ;
bbc_move( x_start - 200, y_start ); 
bbc_draw( x_start + 800, y_start ); 
bbc_move( x_start, y_start ); 
bbc_draw( x_start, y_start + 800 ); 
bbc_gcoi( 0 , 6 ) ;  
for( fr = 1 ; fr < frame; fr++ )
{
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time„span = FACTOR / interval; 
no_readings = 0; sum_xvals = 0; sum__yvals = 0; 
for( cell = 0; cell < numactive; cell++ ) 
if( cellarray [fr] [cell], valid)
{no„readings++;
sum„xvals += (cellarray[fr][cell].centre.x - cellarray[ff -1][cell].centre.x); 
sum_yvals += (cellarray[fr][cell].centre.y - cellarray[fr-1][cell].centre.y);
1x__drift = sum_xvals/no_readings; 
y_drift = sum„yvals/no_readings; 
paths = 0, no_readings = 0; 
for( cell = 0; cell < numactive; cell++ ) 
if( cellarray [fr] [cell] .valid ){no„readings++; 
paths += time_span *
(double)sqrt( sqr( cellarray[fr][cell].centre.x
- (double)cellarray[0] [cell] .centre.x - x_drift)
+ (double)sqr( cellarray [fr] [cell].centre.y
- (double)cellarray[0] [cell] .centre.y - y_drift) );
}bbc_circle(x_start + 400/fr, y_start + 100000/(sqr(paths/no_readings)), 4);
}pauseO; 
bbc_gcol(3, 7); 
mouse( &x, &y, &buttons ); 
xO = x; yO = y; 
mouse( &x, &y, &buttons ); 
bbc_move(xO, yO); 
bbc„draw( x, y ); 
x l = x; y l = y; 
do(
mouse( &x, &y, &buttons ); 
if( X != x l II y != yl){bbc_move(xO, yO); 
bbc_draw( x l, y l ); 
bbc_move(xO, yO); 
bbc_draw( x, y ); 
xl = x; y l = y; 
if( xO != xl ){tab(18, 20); 
printf( " ");
tab( 18, 20);
printf( "%d", 10000 * (yO - yl)/(xO - xl)/100);
}if(yO !=yl  ){tab(18, 21); 
printf( " ");
tab(18, 21);
printf( "%d", xO - x_start - (xO - x l) (yO - y„start) /(yO ~ yl));
}
}
} while( buttons ); 
pauseO;
}
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void ratio_plot( int frame, int numactive )
{float mean_speed = 0, mean_ratio = 0; 
int y_start = 200, x_start = 200; 
float ratio = 0, speed = 0; 
int cell, fr;
for(fr = 1; fr < frame; fr++ ){
speed = 0; ratio = 0;
for( cell = 0; cell < numactive; cell++ )
if( cellarray [fr] [cell], valid ){speed += (float)(sqrt(fsqr(ceilarray[fr][cell].centre.x - cellarray[&-1 ][cell].centre.x) + 
fsqr(cellarray[fr] [cell].centre.y - cellarray [fr-1 ] [cell]. centre.y )))/5 ; 
ratio += (float)cellarray [fr] [cell] .area/cellarray [fr] [cell] .perimeter;
}/"'printfCarea %d, perimeter %d\n",cellarray[fr][cell].area,cellarray[fr][cell].perimeter);
printfC ratio %4.2f, sp %4.2f\n",ratio,speed);"'/
bbc_gcol( 0 ,7 ) ;
bbc_move( 200,200 );
bbc_draw( 200,1000 );
bbc_move( 200,200 );
bbc„draw( 1000,200 );
bbc_gcol( 0, cell%7 + 1 );
bbc_circlefill(x_start + ( 100*ratio ), y_start + (100 speed),2 ); 
pauseO;
}}void display( int frame, int numactive, char "'name, char "'details, char "'date )
{int quit = 0; 
int choice; 
int X, y , buttons;
do{
clrscrO;
cursor_off();
pointerO;
tab( 5 ,2 ) ;  
text_colour( 7 ); 
printf( "1: Scatter." ); 
tab( 5 ,4  );
printf( "2: Square-root." ); 
tab( 5, 6 );
printf( "3: Graphs." ); 
tab( 5, 8 );
printf( "4: Histograms." ); 
tab( 5 ,10);  
printf( "5: Tracks" ); 
tab( 5 ,12);
printf( "6: Trackdata" ); 
tab( 5,14 ); 
printf( "7: Ratio" ); 
tab( 5, 16 ); 
printf( "8: Quit" ); 
do{
■ . V .. :
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mouse( &x, &y, &buttons );
} while( buttons );
do{
choice = keypressedO; 
if( choice != -1 ) 
choice -= 'O’; 
else 
choice = 0;
mouse( &x, &y, &buttons ); 
if( buttons == 4 ) 
choice = 15 - y / 64;
} while( choice == 0 );
switch( choice )
{case 1 :
scatter( frame, numactive, name, details, date ); 
break;
case 2 :
root( frame, numactive); 
break;
case 3 :
graphs( frame, numactive, name, details, date ); 
break;
case 4 :
histograms( frame, numactive, name, details, date ); 
break;
case 5 :
tracks( frame, numactive, name, details, date ); 
break; 
case 6 :
trackdata( frame, numactive, name, details, date ); 
break; 
case 7 :
ratio_plot( frame, numactive ); 
break; 
case 8 : 
quit = 1 ; 
break;
}} while( quit —  0 );}
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Program written in C, to run on an Acorn Archimedes 
microcomputer; to collect data from the LKB Luminometer
Program plots the results on screen, and calculates the area under the curve 
for each sample.
#include<stdlib.h>
#include<stdio.h>
#include<bbc.h>
#include<math.h>
#include<ctype.h>
#include<os.h>
#include<string.h>
#include<time. h>
#define maxtubes 15 
#define maxloops 180 
typedef struct
float tot_area; 
float reading; 
float time_sec; 
float area;
} tube_data;
global variables "7 
tube_data tube_array [maxloops] [maxtubes] ; 
char name[20], details[200], date[20]; 
int no_loops = 0; 
float scaler = 1.0; 
int no_tubes = 0; 
int stim = 0; 
int main(void); 
int plot_results(int Ip, int tb); 
int store„results(int no_loops); 
void display_results(void); 
void stop„luminometer(void); 
int rescale(int Ip, int tb);
emulate *fx a,x and define some basic routines 
definitions of fx() function calls: 
fx( 2, 1 )- gets characters from RS423 port. 
fx( 2, 0 )-gets chaiacters from the keyboard, 
fx( 3, -selects output stream direction: 
fx( 3, 0 )-printer, screen 
fx( 3, 1 )-printer, screen, RS423 
fx( 3, 2 )-printer 
fx( 3, 3 )-printer, RS423 
fx( 3, 4 )- screen
fx( 3, 5 )- screen, RS423
fx( 3, 6 )-
fx( 3, 7 )- RS423
fx( 7, 3 )- receiving RS423 baud rate of 300(luminometer) 
fx( 8, 3 )- transmit RS423 baud rate of 300(luminometer) 
fx( 229, 1 )-sets escape key to produce ascii character &1B or 27 
fx( 229,0 Presets escape key to interupt program"7
void fx( int a, int x ){inty;
os_byte( a, &x, &y );
}
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int keypressedO {return bbc_inkey( 0 );
}void mouse( int *x, int "'y, int "'buttons ) 
{ os_regset regs; 
os_swi( Oxlc, &regs );
"'x = regs.r[0];
"'y = regs.r[l];
"'buttons = regs.r[2];}
void pauseO 
{int flag = 0; 
int X, y, buttons;
do{
mouse( &x, &y, &buttons );
} while( buttons );
do{
if( keypressedO != -1 ) dag = 1; mouse( &x, &y, &buttons ); 
if( buttons ) flag = 1 ;
} while( Iflag );
void cat() 
os_cli( "cat $.LUMIN.result" );
}void pointer( void ){int X = 1, y ;
os_byte( 0x6a, &x, &y );}
/"' asks user for number of tubes to be measured"'/ 
void tube„entry(){int flag = 1; 
no_tubes = 0; 
fx( 2, 0 ); 
while( flag == 1 ){bbc„tab( 20, 20);
printf( "Enter the number of tubes to be assayed (l-25)\n" );
bbc„tab(20, 22);
printfC ");
bbc_tab(20, 22);
scanf( "%d", &no_tubes );
if( no_tubes > 0 && no_tubes < 25 ){flag = 0;}
}return;
}
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asks user which simulant of metabolic burst is being used "V 
void loop_entry(){int timerun = 0; 
int flag = 1 ; 
fx(2,0);
while( flag == 1 )
{bbc„tab( 20, 25 ); 
printfC ");
bbc_tab( 20, 24 );
printfCEnter the time for run in minutes ( 1 - 1 0 0  )"); 
bbc_tab( 20, 25 ); 
scanfC %d", &timerun );
no„loops = ( timerun * 60 ) / (( no_tubes 2 ) + 15); 
if( timerun > 0 && timerun < 100 ){flag = 0;
}
}return;
} enters luminometer to auto-mode"'/ 
void auto_operation(){int num = 0; 
int bitmask =127; 
int inchar; 
int in_char; 
bbc„cls(); 
bbc_tab( 20, 18);
printfC To enter luminometer to automode:"); 
bbc_tab( 20, 20 );
printfC 1. Switch off luminometer."); 
bbc_tab( 20, 22 );
printf("2. Restart luminometer whilst holding down"); 
bbc_tab( 22, 24 );
printfC preset and store buttons simultaneously.");
bbc_tab( 20, 26 );
printfC3. Press return");
bbc_tab( 20, 28 );
printf("4. TYPE ' contrlQSPl ’");
pauseO;
fx( 156,16 );
fx (21 ,0 ) ;
fx( 5, 1 );
bbc_cls();
bbc_mode(3);
bbc„vdu(3);
bbc_vdu(28);
bbc„vdu(4);
bbc_vdu(22);
bbc_vdu(76);
bbc_vdu(5);
bbc_cursor(l);
fx( 7, 3 );fx( 8, 3 );
fx( 6, 0 );
fx( 3, 5 );
fx( 2, 0 );fx( 229, 1 );
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in_char = getchar(); printf("%c", in_char ); 
fx( 2, 1 );
while( inchar != 33){in_char= getcharQ; 
inchar = in_char &bitmask; 
printf("%c'',inchar ); 
if ( in_char == 10)(num++;} 
if ( num ==3){inchar = 33;}
}fx( 229, 0 ); 
fx( 3, 0 ); 
fx( 2, 0 ); 
bbc_mode(21); 
return;
draws the axes of the graphs for plotting results"'/ 
void experimentO
int colour_plot[18] = { 67, 75, 76, 19, 27, 119,
19, 56, 95, 78, 60, 123,
23 ,7 ,31 ,30 ,44 ,  107 };
int i;
int ctr = 0; 
int y_val = 0; 
bbc_cursor(0); 
bbc_gcol( 0, 47); 
bbc_move(10, 100); 
bbc_draw(10, 900); 
bbc_move(10,100); 
bbc_draw(900,100); 
for( i = 1 ; i < 9; i++ )
{bbc_gcol( 0, 47); 
bbc_move( 100"'i, 90); 
bbc_draw( 100"'i, 100); 
bbc_move( 0, 100 + 100"'i); 
bbc_draw( 10,100 + 100"'i);}bbc_colour( 77 ); 
bbc_tab( 30, 2 );
printf( "LKB LUMINOMETER"); 
y_val = 6;
for( ctr = 0; ctr < no_tubes; ctr++ ){y_val++; 
bbc_colour(50); 
bbc_gcol(0, colour_plot[ctr]); 
bbc_tab( 44, y_val ); 
printf(" tube num %d", ctr + 1 );
}/"' takes the results from the luminometer and converts 
them into decimal values"'/ 
void input_results()
{ int flag = 0;
int tb = 0; int Ip = 0;
float sum_reading = 0;
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int tubenum = 0; 
int tube[4] = 0; 
int reading [8] = 0; 
int num; 
int in„char; 
int inchar; 
int bitmask =127; 
float time_elapsed = 0; 
int ctr = 0;
for(tb= 0; tb<no_tubes; tb++){tube„array[0][tb].tot„area = 0;
}fx( 3, 6 );
fx( 2, 1 );fx( 7, 3 );
fx( 15, 0 );fx( 229,1 );bbc_cursor(0);
bbc_tab( 0, 4 );
while(bbc_adval(-2) == 0 )
{}time„elapsed = 0; 
while (inchar != 89){fx ( 2, 1 );
in_char = getchar();
for( Ip = 0; Ip < nojoops; lp++ )
bbc_tab( 43, 6 + no_tubes ); 
printfC’ ");
time„elapsed = time_elapsed + 2 + no_mbes; 
for( tb = 0; tb < no_tubes; tb++ ){fx( 2, 0 );
if ( keypressedO == ’s')
{nojoops = Ip; 
stop_luminometer() ; 
store_results (nojoops) ;
1fx( 3, 6 ); 
fx( 2, 1 );
num = 0;tubenura = 0; 
in_char = getchar(); 
inchar = in_char &bitmask; 
while( inchar != 13 ){tube[num] = inchar - 48; 
in_char = getchaif); 
inchar = in_char &bitmask; 
num++;}tubenum = (tube[2] * 10) + tube[3]; 
num = 0; tube[num] = 0; 
in_char = getchaiO; 
inchar = in_char &bitmask; 
while( inchar != 13)
{reading[num] = inchar - 48; 
in_char = getcharQ;
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inchar = in_char &bitmask; 
num++;}sum_reading = 0;if( reading[l] == -16 && reading[2] == -16 && reading[3] == -16 ){sum_reading = (float)reading[4] + (float)reading[6]/10 +
(float)reading[7]/100 + (float)reading[8]/1000; 
flag = 1 ;}if ( reading[l] == -16 && reading[2] == -16 && reading[3] != -16 )
{sum_reading = ((float)reading[3] "= 10) + (float)reading[4] +
(float)(reading[6] /10.0) + (float)(reading[7] /100.0);}if( reading} 1] == -16 && reading[2] != -16 && reading[3] != -16)
sum„reading = ((float)reading[2] * 100.0) + (float)(reading[3] * 10.0) + 
(float)reading[4] + (float)(reading[6] /10.0);
}if( reading} 1] —  -16 && reading[2] == -16 && reading[3] == -16 && reading[5] != 46 
&& flag!=l)
{for (ctr = 1000; ctr == 1; ctr / 10){sum_reading += (float)(reading[4] * 1000) +
(float) (reading [5] 100) +
(float)(reading[6] * 10) +
(float)(reading[7] * 1);
}flag = 0;}time_elapsed = time_elapsed + 1 ; 
tube_aiTay[lp][tb].reading = sum_reading; 
tube„array[lp][tb].time„sec = time_elapsed; 
if(sum_reading > 1000){rescale( Ip, tb);} 
plot_results(lp, tb);
}}fx(3,0);
fx( 2, 0 ); 
fx( 7, 7 ); 
fx( 8, 7 );
store_results (nojoops); 
exit(l);}return;
}
/"'plots the data from the luminometer*/ 
int plot„results(int Ip, int tb)
float time__dash = 0; 
float dash = 0; 
int y_val;
float x_start = 10.0; 
float y_start = 100.0;
int colour„plot[18] = { 67, 75, 76, 19, 27, 119,
19, 56, 95,78,60,123,
23 ,7 ,31 ,30 ,44 ,  107 };
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float triang_ai'ea = 0; 
float rectang_area = 0; fx( 3,0 ); 
fx( 2, 0 ); 
bbc„colour(57); 
bbc_tab( 1,2 );
printfC'Loop %d of % d  ", lp+1, no joops ); 
b bc jab ( 1,4);
printfC-------------");bbc_coiour( colour_plot[tb] ); 
y_val = 7 + tb - 1; 
b bcjab ( 43, y_val ); 
printfC
y_val = 7 + tb; 
b bcjab ( 43, y„val ); 
printf(">");
bbc„gcol(0,colour„plot[tb]);
dash = (( y_start + tube_array[Ip][tb].reading / scaler ) - (y„start + tube„array[lp- 
l][tb],reading / scaler )) / 2.0;
time_dash = ( tube_array[lp][tb].time_sec - tube_array[Ip-1 ] [tb].time_sec ) / 2; 
if( Ip > 0 ){if( tb%2 == 0 )
{bbc__move( x_start + tube_array[lp-l][tb].time_sec, 
y_start + tube_array [Ip-l][tb].reading / scaler ); 
bbc_draw( x_start + tnbe__array[Ip] [tb] .time_sec, 
y_start + tube_array [Ip] [tb] .reading / scaler );}else{bbc_move( x_start + tube_array[lp-l][tb].time_sec, 
y_start + tnbe_array [Ip-1 ] [tb]. reading / scaler ); 
bbc_draw( x„start + tube„array[lp-l][tb].time_sec + time_dash, 
y_start + (tube_array [Ip-l][tb] .reading / scaler) + dash ); 
bbc_gcol(0, 63 );
bbc_move( x_start + tube_array[lp-l][tb].time_sec + time„dash, 
y_start + (tube„array[lp-l][tb],reading / scaler) + dash ); 
bbc„draw( x_start + tube_array[lp][tb].time_sec, 
y„start + tube_array[lp][tb] .reading / scaler ); 
bbc_gcol( 0, colour„plot[tb] );
}triang_area = 0.5 * (( tube_array[lp][tb].time_sec - tube„array[lp-l][tb].time_sec ) *
( tube_array [Ip] [tb] .reading - tube_ai'ray [Ip-l][tb] .reading )); 
rectang_area = ( tube„array[lp][tb].time_sec - tube_array[lp-l][tb].time_sec ) * 
tube_array [Ip-1 ] [tb] .reading; 
tube_airay [Ip] [tb]. area = triang_area + rectang_aiea; 
tube_array[0][tb].tot_area += tube_array[lp][tb].area; 
bbc_rectanglefill( 900, 780 - tb*32,tube_array[0][tb].tot„area/500 , 15 ); 
return nojoops;I
/^creates file called lumi_prog which contains the program to run the luminometer*/ 
void lumi_prog( )
FILE *fp; fx( 2,0 );
fx( 3,4 );
fp = fopen( "LumLprog", "w" ); 
fputs( "50 CONTMIX \n", fp );
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fprintf(fp, "90 LOOP %d \n", no joops );
fputs( "100 FIRSTIN \n", fp );
fprintf( fp, "110 LOOP %d\n", no jubes );
fputs( "120 PRPOS\n",fp);
fputs( "125 PRC\n" ,fp);
fputs( "140 NEXT\n" ,fp);
fputs( "150 ENDLOOP \n", fp );
fputs( "160 WAITO\n",fp);
fputs( "170 ENDLOOP \n", fp );
fputs( "280 OFFMIX \n", fp );
fputs( "300 OUT\n",fp) ;
fputs( "RUN\n", fp );
fclose(fp);}
/* writes the program from lumi_prog through the rs423 port*/ 
void send Jo Ju m i(  )
{int in_char; 
int ctr;
FILE *fp;
fp = fopen( "LumLprog", "r” );fx(7,3);fx( 8, 3 );
fx( 2, 1 );
fx( 3, 5 );
in_char = fgetc( fp ); 
while ( in_char != EOF )
{printf("%c", in_char); 
in_char = fgetc( fp );
1fclose(fp); fx( 2, 0);
fx(3,0);
b bcjab ( 20,43 ); 
printf(" wait ");
for ( ctr = 0 ; ctr < 4000000; ctr++){} 
return;}
/* request date details and filename from user and then create file called filename 
with the dsta*/ 
int store_results(int nojoops){FILE *file; 
chai'path[80];
fx( 3, 0 );
fx( 2, 0 ); 
fx( 229, 0 ); 
bbc_cls(); 
bbc_mode(21); 
do{
b bcjab ( 2, 2 ); 
printf( "Enter date:- " ); 
gets( date ); 
b bc jab ( 2 ,4 ) ;  
printf( "Enter details:- " ); 
gets( details );
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b b c jab  ( 2,6 );
printf( "ENTER FILE NAME " ); 
gets( name);
StrcpyC path, "$.LUMIN.result." ); 
strcat( path, name ); 
file = fopen( path, "w" );
if( file == NULL ) printfC "CANNOT OPEN FILE" );
}while( file == NULL ); 
fwrite( name, sizeof( char ), 20, file ); 
fwriteC details, sizeof( char ), 160, file ); 
fwrite( date, sizeof( char ), 20, file ); 
fwriteC &no__loops, sizeof( int), 1, file ); 
fwriteC &no_tubes, sizeof( int ), 1, file );
fwriteC tube_array, sizeof( tube_data ), maxloops maxtubes , file ); 
fcloseC file ); 
display_results(); 
return nojoops;}
/* loads file entered by user and displays results*/ 
void ioad(){int ch = 0; 
char path[80];
FILE * file;
int error;
bbc_mode(21);
bb cjab ( 2, 4 );
printfC "Avaliable filesAn" );
cat();
printfC" &d",ch); 
do{
printfC "\nEnter name of desired file: " ); 
gets( name );
StrcpyC path, "$.LUMIN.result." );
strcatC path, name );
file = fopenC path, "r" );
error = 0;
if( file == NULL )
{printfC "Cannot open fileAn" ); 
error = 1 ;}}while( error == 1 ); 
fread( name, sizeof( char ), 20, file ); 
fread( details, sizeof( char ), 160, file ); 
fread( date, sizeof( char ), 20, file ); 
freadC &noJoops, sizeof( int ), 1, file ); 
fread( &noJubes, sizeof( int ), 1, file );
fread( tube„array,sizeof( tube_data ), maxloops maxtubes, file );
display_results();
fcloseC file );
pauseQ;
return;
}/* displays results*/ 
void display_results(void){FILE *%;
int time„dash = 0;
int dash = 0;
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int x_start =10; 
int y„stait = 100;
int colour_plot[18] = { 67, 75, 76, 19, 27, 119,
19, 56, 95, 78, 60, 123,
23,7 ,31,30,  44, 107 };
int tb = 0;
int Ip = 0;int incr =10;
int num = 0;
inty_vai = 8;
char path[80];
bbc_cls();
experimentO;
fx( 2, 0 );
fx( 3, 0 );fx(7,7);
fx( 8, 7 );
fx ( 5, 0 );
bbc_tab( 2 ,4 ) ;
printf("File: %s", name);
bbc_tab( 24,4);
printfC Details: %s", details);
StrcpyC path, "$.LUMIN.csv.");
StrcatC path, name);
fp = fopenC path, "w" );
forC Ip = 0; Ip < nojoops; lp++ )
forC tb= 0; tb < nojubes; tb++ ){fprintfCfp, " %f, " ,tube__array [Ip] [tb]. time„sec ) ; 
fprintfCfp, "%f," ,tube_aiTay [ip] [tb] .reading ) ; 
ifC tube_array[Ip][tb].reading > 1000){rescaleC Ip, tb);} 
bbc_gcolCO,colour_plot[tb]);
bbc_rectanglefillC 900, 780 - tb*16,tube_array[0][tb].tot„area/500 , 10 ); 
dash = CC y_start + tube_array[lp][tb] .reading / scaler )
- C y_start + tube_array [Ip-l][tb] .reading / scaler )) / 2; 
time_dash = C tube_array[lp][tb].time_sec - tube_array[lp-l][tb].time_sec ) / 2; 
ifC Ip > 0 ){ifC tb%2 == 0 ){bbc_moveC x_start + tube„array[lp-l][tb].time_sec, 
y„stait + mbe_array [Ip-l][tb].reading / scaler ); 
bbc_drawC x_start + tube_array[Ip] [tb] .time__sec, 
y„start + tube_array [Ip] [tb].reading / scaler );
}else
{bbc_moveC x_start + tube„array[lp-l][tb].time_sec, 
y_start + tube_array [Ip-l][tb] .reading / scaler ); 
bbc„drawC x_start + tube_array[lp-l][tb].time_sec + time_dash, 
y_start + Ctube_array [Ip-l][tb] .reading / scaler) + dash ); 
bbc_gcolC 0 ,63);bbc_moveC x_start + tube_array[lp-l][tb].time_sec + time_dash, 
y_start + Ctube_array [Ip-1 ] [tb] .reading / scaler) + dash ); 
bbc_drawC x_start + tube_array[lp][tb].time_sec, 
y_stait + tube„array [Ip] [tb] .reading / scaler );}}1fprintfC fp, "\n");
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}num = 0; 
printf("\n");
for( tb= 0; tb < nojubes; tb++ )
{num++;
bbcjab ( incr+40, y_val + num + 10);
printf("Total area for tube %d: %4.0f\n",tb + I,tube„array[0][tb].tot_area);
Ifclose(fp); 
fx( 2, 0 ); 
fx( 5, 0 ) 
fx( 3, 0 ) fx( 7, 7 ) fx( 8, 8 ) 
pauseO; 
main(); 
return;}
int rescaie(int Ip, int tb)
{int x_start =10; 
int y_start =100; 
int ctr = 0;
scaler = abs(tube_array[lp-l][tb].reading/1000)+l; 
for( ctr = 0; ctr < Ip; ctr++ ){for( tb = 0; tb < no_tubes; tb++ ){experimentO; 
if( ctr > 0 ){bbc_move( x_start + tube_array[lp-l][tb].time_sec, 
y„stait + tube_array [ip-l][tb] .reading / scaler ); 
bbc_draw( x_start + tube_array[lp][tb].time„sec, 
y_start + tube_array [Ip] [tb].reading / scaler );
}}}return nojoops;]
/* sends the character for escape to the luminometer*/ 
void stop Juminometer(void)
{f x ( 2 1 , l ) ;  fx(21,2); 
fx (21 ,3 ) ;  
fx(156, 16); fx( 229,1 ); fx( 7, 3 ); fx( 8,3);  fx( 5, 2 ); bbc_vdu(2); 
bbc_vduq( 1, 16); 
bbc_vdu(3); 
fx( 3, 0 ); 
fx( 2, 0 ); fx( 229,0); 
return;
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}
/* The programme menu */
int main(void)
{int quit = 0; 
int choice; 
int X , y, buttons; 
bbc„mode( 21); 
do{ 
bbc_cls(); 
pointer(); 
bbc_tab( 5 ,0 );
printf( ” LKB LUMINOMETER MENU" );
bbc_tab( 5 ,2 ) ;
printf( "1: RUN" );
bbc_tab( 5, 4 );
printf("2:LOADFILE");
bbc_tab( 5 ,6 ) ;
printf( "3: DISPLAY RESULTS" ); 
bbc_tab( 5 ,8 ) ;
printf( "4: AUTO OPERATION" ); 
bbc_tab( 5, 10);
printf( "5: STOP LUMINOMETER" ); 
bbc_tab( 5 ,12) ;  
printf( "6 : QUIT" ); 
do{
mouse( &x, &y, &buttons );
}while( buttons ); 
do{
choice = keypressedO; 
if( choice != -1 ) 
choice -= 'O'; 
else
choice = 0;
mouse( &x, &y, &buttons ); 
if( buttons =  4 )  
choice = 1 5 -  y / 64 ;
}while( choice == 0 ); 
switch ( choice )
{case 1 : 
bbc_cls(); 
tube_entry(); 
loop_entryO; 
lumLprogO; 
send„to„lumi(); 
bbc_cls(); experimentO; 
input_results(); 
break;
case 2 : 
bbc_cls(); 
bbc„tab( 20 ,8);  
loadQ; 
break;
case 3 : 
bbc_cls();
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display_results();
pauseO; break; 
case 4 : 
bbc_cls(); 
auto_operation(); 
break; 
case 5 : 
bbc_cls();
stop„luminometer() ; 
break; 
case 6 : 
bbc_cls(); 
exit(l); 
fx( 2, 0 );}}while( quit == 0 );
}
/'"Header File'"/
/"' Functions from screen '"/
void pIot( point p);
void move( point p );
void draw ( point p );
void graphics„colour( int c );
void gcol( int c );
void mode( int m );
void cursor„off( void );
void clrscr( void );
void text_coiour( int );
void tab( int x, int y );
chai’ get( void );
int keypressed( void );
void palette( char a, char b, char c, char d );
void settextwindow( void );
void clearwindow( void );
/'" Functions from basic 
int MAX( int a, int b ); 
int MIN( int a, intb ); 
int sqr( int ); 
float fsqr( float ); 
void pause( void );
